INCYTE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited, in thousands, except number of shares)


	For the Six Months Ended June 30, 2020
									Total
	Common		Additional		Accumulated Other		Accumulated		Stockholders’
	Stock		Paid-in Capital		Comprehensive Loss		Deficit		Equity
Balances at January 1, 2020	$	216	$	4,044,490	$	(15,542)	$	(1,430,758)	$	2,598,406
Issuance of 772,538 shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units		1		14,618		—		—		14,619
Issuance of 1,957 shares of Common Stock for services rendered		—		145		—		—		145
Stock compensation		—		42,758		—		—		42,758
Other comprehensive income		—		—		2,435		—		2,435
Net loss		—		—		—		(720,642)		(720,642)
Balances at March 31, 2020	$	217	$	4,102,011	$	(13,107)	$	(2,151,400)	$	1,937,721
Issuance of 936,688 shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and 175,615 shares of Common Stock under the ESPP		1		69,193		—		—		69,194
Issuance of 1,403 shares of Common Stock for services rendered		—		139		—		—		139
Issuance of 3,187 shares of Common Stock upon conversion of Convertible Senior Notes due 2020		—		162		—		—		162
Stock compensation		—		46,406		—		—		46,406
Other comprehensive income		—		—		684		—		684
Net income		—		—		—		290,298		290,298
Balances at June 30, 2020	$	218	$	4,217,911	$	(12,423)	$	(1,861,102)	$	2,344,604


	For the Six Months Ended June 30, 2019
									Total
	Common		Additional		Accumulated Other		Accumulated		Stockholders’
	Stock		Paid-in Capital		Comprehensive Loss		Deficit		Equity
Balances at January 1, 2019	$	213	$	3,813,678	$	(10,165)	$	(1,877,759)	$	1,925,967
Issuance of 1,044,745 shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units		1		15,480		—		—		15,481
Issuance of 1,200 shares of Common Stock for services rendered		—		104		—		—		104
Stock compensation		—		40,690		—		—		40,690
Adoption of ASU No. 2016-02		—		—		—		95		95
Other comprehensive income		—		—		918		—		918
Net income		—		—		—		102,312		102,312
Balances at March 31, 2019	$	214	$	3,869,952	$	(9,247)	$	(1,775,352)	$	2,085,567
Issuance of 400,292 shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and 143,379 shares of Common Stock under the ESPP		1		15,190		—		—		15,191
Issuance of 1,444 shares of Common Stock for services rendered		—		123		—		—		123
Stock compensation		—		40,710		—		—		40,710
Other comprehensive income		—		—		282		—		282
Net income		—		—		—		105,318		105,318
Balances at June 30, 2019	$	215	$	3,925,975	$	(8,965)	$	(1,670,034)	$	2,247,191

See accompanying notes.

6

Table of Contents

INCYTE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)


	Six Months Ended
	June 30,
	2020		2019
Cash flows from operating activities:
Net income (loss)	$	(430,344)	$	207,630
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		25,692		27,326
Stock-based compensation		88,816		81,207
Other, net		8,567		227
Unrealized gain on long term investments		(24,142)		(16,364)
Change in fair value of acquisition-related contingent consideration		12,681		13,279
Changes in operating assets and liabilities:
Accounts receivable		(119,724)		4,918
Prepaid expenses and other assets		(11,663)		8,354
Inventory		(9,384)		(2,288)
Accounts payable		7,262		(32,243)
Accrued and other liabilities		38,204		16,577
Net cash (used in) provided by operating activities		(414,035)		308,623
Cash flows from investing activities:
Purchase of long term investments		(95,468)		—
Sale of long term investment		4,536		—
Capital expenditures		(83,125)		(65,561)
Purchases of marketable securities		(287,419)		(103,970)
Sale and maturities of marketable securities		309,658		99,821
Net cash used in investing activities		(151,818)		(69,710)
Cash flows from financing activities:
Proceeds from issuance of common stock under stock plans		83,813		30,672
Payment of finance lease liabilities		(387)		(409)
Payment of contingent consideration		(24,520)		(16,766)
Net cash provided by financing activities		58,906		13,497
Effect of exchange rates on cash, cash equivalents, restricted cash and investments		2,553		(158)
Net (decrease) increase in cash, cash equivalents, restricted cash and investments		(504,394)		252,252
Cash, cash equivalents, restricted cash and investments at beginning of period		1,833,707		1,164,986
Cash, cash equivalents, restricted cash and investments at end of period	$	1,329,313	$	1,417,238
Supplemental Schedule of Cash Flow Information
Interest paid	$	119	$	119
Income taxes paid	$	24,165	$	6,439
Reclassification to common stock and additional paid in capital in connection with conversions of 1.25% convertible senior notes due 2020	$	162	$	—
Unpaid purchases of property and equipment	$	14,817	$	—
Leased assets obtained in exchange for new operating lease liabilities	$	8,720	$	2,358
Leased assets obtained in exchange for new finance lease liabilities	$	529	$	29,740

~~(unaudited)~~

Nine Months Ended

September 30,

2017

2016

Cash flows from operating activities:

Net income (loss)

$
(163,513)

$
95,349

Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:

Depreciation and amortization

39,319

40,859

In-process research and development impairment

12,000

—

Stock-based compensation

99,287

68,598

Expense related to senior note conversions

54,881

—

Other, net

216

325

Unrealized loss (gain) on long term investments

2,343

(20,497)

Change in fair value of acquisition-related contingent consideration

(1,914)

10,283

Changes in operating assets and liabilities:

Accounts receivable

(49,587)

(6,712)

Prepaid expenses and other assets

(32,051)

(13,323)

Inventory

4,741

4,439

Accounts payable

(5,666)

25,683

Accrued and other liabilities

36,223

15,018

Deferred revenue—collaborative agreements

—

(9,644)

Net cash (used in) provided by operating activities

(3,721)

210,378

Cash flows from investing activities:

Acquisition of business, net of cash acquired

—

(142,965)

Purchase of long term investments

(123,891)

—

Capital expenditures

(85,770)

(104,405)

Purchases of marketable securities

(131,919)

(26,921)

Sale and maturities of marketable securities

134,604

77,815

Net cash used in investing activities

(206,976)

(196,476)

Cash flows from financing activities:

Restricted investments, net

(40)

13,976

Proceeds from issuance of common stock under stock plans

58,554

32,468

Proceeds from issuance of common stock, net

649,387

—

Cash paid in connection with senior note conversions

(8,934)

—

Direct financing arrangements repayments

—

(445)

Payment of contingent consideration

(12,521)

(1,226)

Net cash provided by financing activities

686,446

44,773

Effect of exchange rates on cash and cash equivalents

(46)

(15)

Net increase in cash and cash equivalents

475,703

58,660

Cash and cash equivalents at beginning of period

652,343

521,439

Cash and cash equivalents at end of period

$
1,128,046

$
580,099

Supplemental Schedule of Cash Flow Information

Interest paid

$
180

$
3,892

Income taxes paid

$
6,187

$
717

Reclassification to common stock and additional paid in capital in connection with conversions of 0.375% convertible senior notes due 2018

$
351,041

$
5

Reclassification to common stock and additional paid in capital in connection with conversions of 1.25% convertible senior notes due 2020

$
330,011

$
4

Unpaid purchases of property and equipment

$
10,774

$
6,989

See accompanying notes.

67

Table of Contents

INCYTE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~June 30, ~~2017~~2020

(Unaudited)

1. Organization and business

Incyte Corporation (including its subsidiaries, “Incyte,” “we,” “us,” or “our”) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products JAKAFI® (ruxolitinib), ICLUSIG® (ponatinib) and ~~ICLUSIG® (ponatinib)~~PEMAZYRE® (pemigatinib). Our operations are treated as ~~one~~1 operating segment.

2. Summary of significant accounting policies

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of ~~September~~June 30, ~~2017~~2020, the condensed consolidated statements of operations, comprehensive income (loss), and stockholders’ equity for the three and six months ended June 30, 2020 and 2019, and the condensed consolidated statements of ~~operations, and comprehensive income (loss) for the three and nine months ended September 30, 2017 and 2016, and the condensed consolidated statement of~~ cash flows for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 and ~~2016~~2019 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, ~~2016~~2019 has been derived from our audited consolidated financial statements.

On June 1, 2016, we acquired (the “Acquisition”), pursuant to a Share Purchase Agreement dated as of May 9, 2016 (the “Share Purchase Agreement”), all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.à.r.l., since renamed Incyte Biosciences Luxembourg S.à.r.l., the parent company of certain European subsidiaries of ARIAD Pharmaceuticals, Inc. (“ARIAD”). Refer to Note 3 for further information regarding the Acquisition.

Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.

Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2019.

Principles of Consolidation. The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.

~~Acquisitions.~~ Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs are expensed as incurred. The operating results of the acquired business are reflected in our consolidated financial statements after the date of acquisition. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use.

7

~~Table of Contents~~

Foreign Currency Translation. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in ~~interest and~~ other income (expense), net, in the condensed consolidated statements of operations. ~~To date, both the translation gains or losses in other comprehensive income (loss) and the transaction gains or losses in foreign exchange gain (loss) have been immaterial.~~

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Concentrations of Credit Risk. Cash, cash equivalents, marketable securities, and trade receivables ~~and restricted investments~~ are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in

8

Table of Contents

debt securities and, by policy, limit the amount of credit exposure to any ~~one~~1 issuer and to any ~~one~~1 type of investment, other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales ~~of JAKAFI, ICLUSIG~~ and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, or trade receivables ~~or restricted investments~~ to date and do not require collateral on receivables.

Current Expected Credit Losses. Effective January 1, 2020, financial assets measured at amortized cost are assessed for future expected credit losses under guidance within ASC 326, Financial Instruments – Credit Losses, to determine if application of an expected credit losses reserve is necessary. On a quarterly basis, receivables that resulted from revenue transactions within the scope of ASC 606 and recognized on an amortized cost basis are reviewed on a customer-level basis to analyze expectations of future collections based upon past history of collections, payment, aging of receivables and viability of the customer to continue payment, as well as estimates of future economic conditions. Receivables generally consist of two types: receivables from collaborative agreements, including milestones, reimbursements for agreed-upon activities and sales royalties; and receivables from customer product sales. Collaborative agreement receivables are closely monitored relationships with select, reputable industry peers. Collection of receivables is assessed within each collaborative partnership on a quarterly basis, including evaluation of each entity’s credit quality, financial health and past history of payment. Customer product sales receivables are independently evaluated on a monthly basis, on which unusual items or aged receivables are closely monitored for signs of credit deterioration, or indications of payment refusal. Customer product sales are with specialty pharmaceutical distributors, wholesalers, and certain public and private institutions, some of which whose financial obligations are funded by various government agencies. These receivables are assessed for signs of credit deterioration and in the Company’s sales history and future expectations of economic conditions, there are minimal instances of bad debts or uncollected receivables.

Cash and Cash Equivalents. Cash and cash equivalents are held in banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.

Marketable Securities—Available-for-Sale. Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders’ equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in ~~“Interest and~~ other income ~~net.”~~(expense), net on the condensed consolidated statements of operations. The cost of securities sold is based on the specific identification method.

Accounts Receivable. As of ~~September~~June 30, ~~2017~~2020 and December 31, ~~2016,~~2019, we had noan immaterial allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.

Inventory. Inventories are determined at the lower of cost and net realizable value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.

We began capitalizing PEMAZYRE inventory after FDA approval in April 2020 as the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to FDA approval have been recorded as research and development expense in our statements of operations. As a result, cost of product revenues for the next 48 months will reflect a lower average per unit cost of materials.

JAKAFI,ICLUSIG and PEMAZYRE raw materials and work-in-process inventory isare not subject to expiration and the shelf life of finished goods inventory is 36 ~~months from the start of manufacturing of the finished goods. ICLUSIG raw materials and work-in-process inventory is not subject to expiration and finished goods inventory has a shelf life of 24~~ months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.

The ICLUSIG inventories were recorded at fair value less costs to sell in connection with the Acquisition, which resulted in a higher cost of ICLUSIG product revenues over a one year period from the acquisition date.

89

Table of Contents

Variable Interest Entities. We perform an initial and ~~on-going~~ongoing evaluation of the entities with which we have variable interests, such as equity ownership, in order toidentify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (“VIE” or “VIEs”). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE’s economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE. As of ~~September~~June 30, ~~2017,~~2020, there were no0 entities in which we held a variable interest which we determined to be VIEs.

Long Term Investments. Our long term investments consist of equity investments in common stock of ~~publicly held~~publicly-held companies with whom we have entered into collaboration and license agreements. The investments in companies over which we have significant influence, but not controlling interest, are accounted for using the equity method (fair value option). The investments in companies over which we do not have significant influence are accounted for as available-for-sale securities. We classify all of our equity investments in common stock of ~~publicly held~~publicly-held companies ~~with whom we have entered into collaboration and license agreements~~ as long term investments ~~given we intend to hold these~~on our condensed consolidated balance sheets. Our equity investments ~~for the foreseeable future.~~

~~Equity Method Investments.~~ ~~In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, the investment is~~are accounted for ~~either (i) under the equity method of accounting or (ii)~~ at fair value ~~by electing the~~using readily determinable pricing available on a securities exchange on our condensed consolidated balance sheets. All changes in fair value ~~option under U.S. GAAP.~~ are reported in the condensed consolidated statements of operations as an unrealized gain (loss) on long term investments.

In assessing whether we exercise significant influence over any of the companies in which we hold equity investments, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. ~~Under the~~Currently, none of our equity ~~method of accounting,~~investments in publicly-held companies are considered relationships in which we record within our results of operations our share of income or loss of the investee company. Under the fair value option, our investment is carried at fair value on our condensed consolidated balance sheets as a long term investment and all changes in fair value are ~~reported in our condensed consolidated statements of operations as an unrealized gain (loss) on long term investments.~~able to assert control.

Property and ~~Equipment.~~Equipment, net. Property and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.

~~Management continually reviews~~Lease Accounting. Accounting Standard Codification (“ASC”) 842, Leases, was adopted for the ~~estimated useful lives~~fiscal year beginning on January 1, 2019. All leases with a lease term greater than 12 months, regardless of technologically sensitive equipment and believes that those estimates appropriately reflect the current useful life of our assets. In the event that a currently unknown significantly advanced technology became commercially available, we would re-evaluate the value and estimated useful lives of our existing equipment, possibly having a material impactlease type classification, are recorded as an obligation on the ~~financial statements.~~

~~Lease Accounting.~~ ~~We account for~~balance sheet with a corresponding right-of-use asset. Both finance and operating leases by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date we gain possession of leased property. We include tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses to determine the straight-line rent expense over the expected life of the lease.

~~Capital~~ leases are reflected as ~~a liability at~~liabilities on the ~~inception~~commencement date of the lease based on the present value of the ~~minimum~~ lease payments ~~or, if lower,~~to be made over the ~~fair value~~lease term. Current operating lease liabilities are reflected in accrued and other current liabilities and noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheet. Right-of-use assets are valued at the initial measurement of the ~~property. Assets under capital leases~~lease liability, plus any initial direct costs or rent prepayments, minus lease incentives and any deferred lease payments. Operating lease right-of-use assets are recorded in property and equipment, net on the condensed consolidated balance ~~sheets~~sheet and ~~depreciated~~lease cost is recognized on a straight-line basis. For finance leases, expense is recognized as separate amortization and interest expense, with higher interest expense in the earlier periods of a ~~manner similar to other property~~lease. Leases with an initial term of 12 months or less are not recorded on the balance sheet and ~~equipment.~~we recognize lease expense for these leases on a straight-line basis over the term of the lease. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit.

Other Intangible Assets, net. Other intangible assets, net consist of licensed intellectual property rights acquired in business combinations, which are reported at acquisition date fair value, less accumulated amortization. Intangible assets with finite lives are amortized over their estimated useful lives using the straight-line method.

~~In-Process Research and Development.~~ ~~The fair value of in-process research and development (“IPR&D”) acquired through business combinations is capitalized as an indefinite-lived intangible asset until the completion or~~

9

~~Table of Contents~~

~~abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and amortized.~~

Impairment of Long-Lived Assets. Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.

~~Indefinite-lived intangible assets, including IPR&D, are tested for impairment annually as~~10

Table of October 1 or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value. Due to the discontinuation of the OPTIC-2L study described in Note 3 below, we considered our indefinite-lived IPR&D asset to be impaired and recorded a $12.0 million impairment charge in research and development expense on the condensed consolidated statements of operations during the three and nine months ended September 30, 2017. Contents

Goodwill. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at the reporting unit level at least annually as of October 1 or when a triggering event occurs that could indicate a potential impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets are below their carrying amounts. A reporting unit is the same as, or one level below, an operating segment. Our operations are currently comprised of a single, entity wide reporting unit. We completed our most recent annual impairment assessment as of October 1, ~~2016~~2019 and determined that the carrying value of our ~~reporting unit~~goodwill was not impaired.

Income Taxes. We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized.The primary factors used to assess the likelihood of realization are our recent history of cumulative earnings or losses, expected reversals of taxable temporary timing differences, forecasts of future taxable income and available tax planning strategies that could be implemented to realize the deferred tax assets. Upon evaluating and weighting both positive and negative evidence, we concluded that we should continue to maintain the valuation allowance on the majority of our deferred tax assets as of June 30, 2020.

~~In addition, we follow~~We recognize the ~~guidance~~tax benefit from an uncertain tax position only if it is more-likely-than-not that the position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We adjust the level of the liability to ~~accounting for uncertainty~~reflect any subsequent changes in ~~income taxes. This guidance creates a single model to address uncertainty in~~the relevant facts surrounding the uncertain positions. Any interest and penalties on uncertain tax positions are included within the tax provision.

The Coronavirus Aid, Relief, and ~~clarifies~~Economic Security (CARES) Act was signed into law in March 2020 to provide an estimated $2.2 trillion designed to stimulate the U.S. economy during the COVID-19 pandemic. The Act includes tax relief, government loans, grants and investments for entities in affected industries, which has related accounting and financial reporting impacts. Disclosure for certain income ~~taxes by prescribing the minimum recognition threshold a~~ tax ~~position is~~accounting measures are required ~~to meet before it is recognized~~ in the period of enactment and disclosure for government loans, investments, grants, and revenue recognition are required in future periods as federal agencies establish rules and procedures to implement the CARES Act. During the six months ended June 30, 2020, we have delayed certain payroll tax and estimated income tax payments that we are deferring to future periods. However, we do not expect the CARES Act to have a material impact on our overall financial ~~statements.~~results, our income tax provision or our liquidity. We have further described the expected impact and risks of COVID-19 on our business in the overview to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Item 1A. Risk Factors.

Financing Costs Related to Long-term Debt. Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the ~~consolidated balance sheets.~~

~~Grant Accounting.~~ Grant amounts received from government agencies for operations are deferred and are amortized into income over the service period of the grant. Grant amounts received for purchases of capital assets are deferred and amortized into interest and other income, net over the useful life of the related capital assets. Such amounts are recorded in other liabilities on the condensed consolidated balance sheets.

Net Income (Loss) Per Share. Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock, restricted stock units, performance stock units and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.

Accumulated Other Comprehensive Income (Loss). Accumulated other comprehensive income (loss) consists of unrealized gains or losses on marketable securities that are classified as available-for-sale, ~~a long-term investment classified as available-for-sale,~~ foreign currency translation gains or losses and defined benefit pension obligations.

Revenue Recognition. Revenue-generating contracts are assessed under ASC 606, Revenue from contracts with customers, to identify distinct performance obligations, determine the transaction price of the contract and allocate the transaction price to each of the distinct performance obligations. Revenue is recognized when we have satisfied a

1011

Table of Contents

~~Revenue Recognition.~~ ~~Revenues are recognized when (1) persuasive evidence~~performance obligation through transferring control of ~~an arrangement exists, (2) delivery~~the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. We determine at contract inception whether we will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has ~~occurred or services have been rendered, (3)~~a present right to payment, (ii) the ~~price is fixed or determinable~~customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance withrewards of ownership and (v) the ~~arrangement. We assess whether~~customer has accepted the ~~fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment.~~asset. We assess collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

Product Revenues

Our product revenues consist of U.S. sales of JAKAFI and PEMAZYRE and European sales of ICLUSIG. Product revenues are recognized once we ~~meet all four~~satisfy the performance obligation at a point in time under the revenue recognition criteria as described above. ~~In November 2011, we began shipping~~We sell JAKAFI and PEMAZYRE to our customers in the U.S., which include specialty pharmacies and wholesalers. ~~In June 2016, we acquired the right to and began shipping~~We sell ICLUSIG to our customers in the European Union and certain other jurisdictions, ~~(Note 3),~~ which include retail pharmacies, hospital pharmacies and distributors.

We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. Product shipping and handling costs are included in cost of product revenues.

Customer Credits: Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.

Rebates and Discounts: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program in the U.S. and mandated discounts in Europe in markets where government-sponsored healthcare systems are the primary payers for healthcare. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launches. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

Chargebacks: Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel. If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

Medicare Part D Coverage Gap: Medicare Part D prescription drug benefit mandates manufacturers to fund ~~50%~~70% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

Additionally, beginning in January 2020, the amount of spending required by eligible patients in the Medicare Part D insurance coverage gap increased 30% due to the expiration of a provision in the Patient

1112

Table of Contents

Protection and Affordable Care Act, which now results in a change in the True Out of Pocket (TrOOP) calculation methodology. The methodological change has resulted in an increase in required spending by patients and, in turn, an increase in manufacturers’ contributions on behalf of patients in the Medicare Part D insurance coverage gap.

Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.

Product Royalty Revenues

Royalty revenues on commercial sales for ruxolitinib (marketed as ~~JAKAVI®~~JAKAVI® outside the United States) by Novartis Pharmaceutical International Ltd. (“Novartis”) are based on net sales of licensed products in licensed territories as provided by Novartis. Royalty revenues on commercial sales for baricitinib (marketed as OLUMIANT) by Eli Lilly and Company (“Lilly”) are based on net sales of licensed products in licensed territories as provided by Lilly. Royalty revenues on commercial sales for capmatinib (marketed as TABRECTA®) by Novartis are based on net sales of licensed products in the licensed territories as provided by Novartis. We recognize royalty revenues in the period the sales occur.

~~Cost of Product~~Milestone and Contract Revenues

Cost of product revenues includes all JAKAFI related product costs as well as ICLUSIG related product costs. The ICLUSIG inventories were recorded at fair value less costs to sell in connection with the Acquisition, which resulted in a higher cost of ICLUSIG product revenues over a one year period from the acquisition date. In addition, cost of product revenues include low single digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States. Subsequent to the Acquisition on June 1, 2016, cost of product revenues also includes the amortization of our licensed intellectual property for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years.

~~Contract and License Revenues~~

Under agreements involving multiple deliverables, services and/or rights to use assets that we entered into prior to January 1, 2011, the multiple elements are divided into separate units of accounting when certain criteria are met, including whether the delivered items have stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. When separate units of accounting exist, consideration is allocated among the separate elements based on their respective fair values. The determination of fair value of each element is based on objective evidence from historical sales of the individual elements by us to other customers. If such evidence of fair value for each undelivered element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value for each undelivered element does exist or until all elements of the arrangement are delivered. When elements are specifically tied to a separate earnings process, revenue is recognized when the specific performance obligation tied to the element is completed. When revenues for an element are not specifically tied to a separate earnings process, they are recognized ratably over the term of the agreement. We assess whether a substantive milestone exists at the inception of our agreements. For all milestones within our arrangements that are considered substantive, we recognize revenue upon the achievement of the associated milestone. If a milestone is not considered substantive, we would recognize the applicable milestone payment over the remaining period of performance under the arrangement. As of September 30, 2017, all remaining potential milestones under our collaborative arrangements are considered substantive.

On January 1, 2011, updated guidance on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements we may enter into on or after January 1, 2011. This updated guidance (i) relates to whether multiple deliverables exist, how the deliverables in a revenue arrangement should be separated and how the consideration should be allocated; (ii) requires companies to allocate revenues in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (iii) eliminates the use of the residual method and requires companies to allocate revenues using the relative selling price method. During the three and nine months ended September 30, 2017 and 2016, we did not enter into any agreements that are subject to this updated guidance. If we enter into an agreement with multiple deliverables after January 1, 2011 or amend existing agreements, this updated guidance could have a material effect on our financial statements.

12

~~Table of Contents~~

Our ~~collaborations~~license agreements, which fall within the scope of ASC 606, Revenue from Contracts with Customers, include distinct drug compound out-licensing, collection of upfront payments, milestones or royalty revenues from a counterparty, and provision of commercially available products to suppliers. Our agreements often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization ~~events. These three categories~~events outside of our control, such as regulatory approval of a compound, first patient dosing or achievement of sales-based thresholds. For such cases, we believe that revenue related to these events should not be recognized until the milestone ~~events reflect~~has been achieved.

Some contracts form collaborative arrangements of various types with third-parties. We assess whether the ~~three stages~~nature of the ~~life-cycle~~arrangement is within the scope of ~~our drugs, which~~ASC 808, Collaborative Arrangements, in conjunction with the revenue recognition guidance in ASC 606 to determine the nature of the performance obligations and associated transaction prices. A collaborative relationship may exist when we ~~describe~~participate in ~~more detail~~an activity or process with another party, such as performance of research and development services or the exchange of intellectual property for use in clinical trials, when both parties share in the ~~following paragraphs.~~risks and rewards that result from the activity and participate and govern contract activities through a joint steering committee.

The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the U.S. Food and Drug Administration (the “FDA”) requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate’s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (“IND”), which must be reviewed by the FDA.

The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (“NDA”) or biologics license application (“BLA”) to the FDA for review and FDA approval of the NDA or BLA.

Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.

13

Table of Contents

Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase I, Phase II or Phase III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.

Cost of Product Revenues

Cost of product revenues includes all JAKAFI, ICLUSIG and PEMAZYRE related product costs. In addition, cost of product revenues include low single-digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States and the amortization of our licensed intellectual property for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years from the date of acquisition on June 1, 2016 of all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.à.r.l. (since renamed Incyte Biosciences Luxembourg S.à.r.l.) from ARIAD Pharmaceuticals, Inc. (“ARIAD”). Cost of product revenues also includes employee personnel costs, including stock compensation, for those employees dedicated to the production of our commercial products.

Research and Development Costs. Our policy is to expense research and development costs as ~~incurred.~~ incurred, including amounts funded by research and development collaborations. Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense. If a collaboration is a cost-sharing arrangement in which both we and our collaborator perform development work and share costs, we also recognize, as research and development expense in the period when our collaborator incurs development expenses, our portion of the co-development expenses that we are obligated to reimburse.

We often contract with clinical research organizations (“CROs”) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract.

These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment

13

~~Table of Contents~~

as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees

14

Table of Contents

are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period.

Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred.

Stock Compensation. Share-based payment transactions with employees, which include stock options, restricted stock units (“RSUs”) and performance shares (“PSUs”), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates. The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting. The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method. The fair value of RSUs that are subject to cliff vesting are recognized as compensation expense over the requisite service period using the ~~straight line~~straight-line attribution method, and the fair value of RSUs that are subject to graded vesting are recognized as compensation expense over the requisite service period using the accelerated attribution method. The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, which we assess as of the end of each reporting period. Once a performance condition is considered probable, we record compensation expense based on the portion of the service period elapsed to date with respect to that award, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining requisite service ~~period.~~period using the straight-line attribution method for PSUs that are subject to cliff vesting and using the accelerated attribution method for PSUs that are subject to graded vesting.

Long Term Incentive Plans. We ~~recorded $34.9 million~~have long term incentive plans which provide eligible employees with the opportunity to receive performance and ~~$99.3 million~~service-based incentive compensation, which may be comprised of cash, stock ~~compensation expense on our condensed consolidated statements~~options, restricted stock units and/or performance shares. The payment of ~~operations for~~cash and the ~~three~~grant or vesting of equity may be contingent upon the achievement of pre-determined regulatory, sales and nine months ended September 30, 2017, respectively. We recorded $26.5 million and $68.6 million of stock compensation expense on our condensed consolidated statements of operations for the three and nine months ended September 30, 2016, respectively.internal performance milestones.

Acquisition-Related Contingent Consideration. Acquisition-related contingent consideration ~~which~~ consists of our future royalty ~~and certain potential milestone~~ obligations on future net sales of ICLUSIG to Takeda Pharmaceutical Company Limited, which acquired ARIAD is(“Takeda”). Acquisition-related contingent consideration was recorded on the acquisition date of June 1, 2016 at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations.

Collaboration loss sharing. Under collaboration and license agreements with shared commercialization efforts, we record our share of the losses from the co-commercialization efforts in collaboration loss sharing on the condensed consolidated statement of operations. For the three and six months ended June 30, 2020, collaboration loss sharing represents our 50% share of the United States loss for commercialization of tafasitamab under our agreement with MorphoSys.

Recent Accounting Pronouncements

In ~~May 2014,~~June 2016, the Financial Accounting Standards Board (“FASB”) issued ~~Accounting Standards Update (“ASU”)~~ASU No. ~~2014-09, “Revenue from Contracts with Customers”, which will replace numerous requirements in U.S. GAAP, including industry-specific requirements.~~2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” This guidance ~~provides a five step model~~applies to all entities and impacts how entities account for credit losses for financial assets measured at amortized cost and available for sale debt securities. ASU 2016-13 requires financial assets measured at amortized cost to be ~~applied~~presented at the net amount expected to ~~all contracts with customers, with~~be collected. The measurement of expected credit losses is based on relevant information about past events,

15

Table of Contents

including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate expected credit losses over the lifetime of the asset. For available-for-sale debt securities, entities will be required to recognize an ~~underlying principle~~allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize ~~revenue~~any improvements in estimated credit losses on its available-for-sale debt securities immediately in earnings.

Upon adoption, we assessed each financial asset measured at amortized cost and each available-for-sale debt security held for the impact of the guidance as of January 1, 2020 and noted an insignificant impact due to ~~depict~~ the ~~transfer of goods or services~~minimal credit risk associated with our financial assets subject to ~~customers at an amount~~ASC 326. As such, it was concluded that a reserve for credit losses was de minimis on the ~~entity expects~~adoption date. Financial assets will continue to be ~~entitled~~assessed on a quarterly basis in future periods.

In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to ~~in exchange~~the Disclosure Requirements for ~~those goods or services. ASC No. 2014-09 requires extensive quantitative~~Fair Value Measurement,” which eliminates the required disclosure of the amount of and ~~qualitative disclosures covering~~reason for transfers between Level 1 and Level 2 of the ~~nature, amount, timing~~fair value hierarchy. The guidance also eliminates the required disclosure of the entity’s valuation process for Level 3 fair value measurements, however public entities are required to disclose the range and ~~uncertainty of revenue and cash flows arising from customer contracts, including disclosures on~~weighted average used to develop significant ~~judgments made when applying the guidance.~~unobservable inputs for Level 3 fair value measurements. This guidance is effective for ~~annual reporting periods~~fiscal years beginning after December 15, ~~2017~~2019. We adopted this guidance for the period beginning January 1, 2020 and ~~interim periods therein. An entity can elect~~enhanced our disclosures in Note 4 to ~~apply~~ the ~~guidance under one of the following two methods: (i) retrospectively~~condensed consolidated financial statements to ~~each prior reporting period presented – referred to as the full retrospective method or (ii) retrospectively~~comply with the ~~cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings – referred to as the modified retrospective method.~~

14

~~Table of Contents~~

We have substantially completed an initial impact assessment of the potential changes from adopting ASU 2014-09. The impact assessment consisted of a review of a representative sample of contracts, discussions with key stakeholders, and a cataloging of potential impacts on our financial statements, accounting policies, financial controls, and operations. We currently do not anticipate a material impact on our revenue recognition practices for product and royalty revenues. We do anticipate that the adoption of ASU 2014-09 will have primarily two impacts on our contract revenues generated by our collaborative research and license agreements:

(i)Changes in the model for distinct licenses of functional intellectual property which may result in a timing difference of revenue recognition. Whereas revenue from these arrangements was previously recognized over a period of time pursuant to revenue recognition guidance that was in place for our arrangements at the time such arrangements commenced, revenue from these arrangements may now be recognized at point in time under the new guidance.

(ii)Assessments of milestone payments, which are linked to events that are in our control, will result in variable consideration that may be recognized at an earlier point in time under the new guidance, when it is probable that the milestone will be achieved without a significant future reversal of cumulative revenue expected.

We have not yet completed our final review of the impact of this guidance including the new disclosure requirements, as we are continuing to evaluate the impacts of adoption and the implementation approach to be used. We plan to adopt the new standard effective January 1, 2018 and are considering adopting using the modified retrospective method. We continue to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact our current conclusions.standard.

In ~~February 2016,~~August 2018, the FASB issued ASU No. ~~2016-02, “Leases,~~2018-14, “Compensation – Retirement Benefits – Defined Benefit Plans – General,” ~~that requires lessees~~an update to ~~recognize assets~~Subtopic ASC 715-20. The guidance amended year-end disclosure requirements related to defined benefit pension plans, and ~~liabilities on the balance sheet~~does not affect interim disclosures. The guidance is effective for ~~most leases including operating leases. Lessees now classify leases as either finance or operating leases~~fiscal years ending after December 15, 2020 and ~~lessors classify all leases as sales-type, direct financing or operating leases.~~is permitted for early adoption. The statement of operations presentation and expense recognition for lessees for finance leases is similar to that of capital leases under Accounting Standards Codification (“ASC”) 840 with separate interest and amortization expense with higher periodic expense in the earlier periods of a lease. For operating leases, the statement of operations presentation and expense recognition is similar to that of operating leases under ASC 840 with single lease cost recognized on a straight-line basis. This guidancestandard is to be applied ~~using~~on a ~~modified~~ retrospective ~~approach at the beginning of the earliest comparative period presented~~basis. Incyte sponsors defined benefit plans for employees located in ~~the financial statements and is effective for annual periods beginning after December 15, 2018 and interim periods therein. Early adoption is permitted.~~Europe. We are currently analyzing the impact of ASU No. ~~2016-02 and, at this time, are unable to determine~~2018-14 on the ~~impact of the new standard on our~~ condensed consolidated financial statements.

In ~~October 2016,~~August 2018, the FASB issued ASU No. ~~2016-16, “Intra-Entity Transfers of Assets~~2018-15, “Intangibles – Goodwill and Other ~~Than Inventory,~~– Internal-Use Software,” ~~which requires companies~~an update to account for the income tax effects of intercompany sales and transfers of assets other than inventory in the period in which the transfer occurs. The new standard is effective for public business entities for annual periods beginning after December 15, 2017 (i.e. 2018 for a calendar-year entity).Subtopic ASC 350-40. The guidance ~~will be applied~~directs accounting for ~~the annual period beginning January 1, 2018 using a modified retrospective approach with a cumulative catch-up adjustment~~service contracts for cloud computing arrangements to ~~opening retained earnings.~~

~~We have elected~~follow guidance within ASC 350-40 to ~~early adopt ASU No. 2016-16 as~~determine capitalization of ~~the first quarter of 2017, which requires us to reflect any adjustments as of January 1, 2017, the beginning of the annual period that includes the interim period of adoption.~~implementation costs. The primary impact of adoption was the recognition of a deferred tax asset of $34.9 million related to the excess of the tax basis over the consolidated book value basis in the intellectual property rights that were licensed from the U.S. parent company to our wholly-owned subsidiary in Switzerland during 2015 and a $2.1 million reversal of long-term prepaid taxes. Under previous guidance companies were prohibited from recognizing an increase in tax basis and any income taxes incurred as a result of a sale or transfer of assets to companies that are part of a consolidated reporting entity. Given the full valuation allowance placed on the additional $34.9 million of deferred tax assets, the recognition upon adoption only required a $2.1 million adjustment to our retained earnings as of January 1, 2017 due to the adjustment of the prepaid tax asset.

15

~~Table of Contents~~

In November 2016, the FASB issued ASU No. 2016-18, “Restricted Cash,” which requires entities to show the changes in total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions on the balance sheet. The reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard is effective ~~for public business entities~~ for fiscal years beginning after December 15, ~~2017~~2019 and may be applied on either a retrospective or prospective basis. We adopted this guidance for the period beginning January 1, 2020 on a prospective basis. New contracts for development of internal-use software were assessed and no qualifying contracts were identified during the period. We will continue to assess contracts and will disclose material, qualifying contracts if identified in future periods.

In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.” The guidance clarifies the interactions between Topic 808 and Topic 606, including clarifications on revenue recognition, unit of account, and reporting disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 retrospectively to the date of our initial application of ASC 606, and noted that in assessment of our collaborative agreements, there was no material financial statement impact. Our collaborative arrangements and their associated accounting conclusions are described in detail within Note 9 to the condensed consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods ~~therein and is to be applied retrospectively.~~therein. Early adoption is ~~permitted.~~permitted for any annual periods for which financial statements have not been issued and interim periods therein. We are currently analyzing the impact of ASU No. ~~2016-18~~2019-12 on ~~our~~the condensed consolidated financial statements.

~~In January 2017,~~16

Table of Contents

3. Revenues

As discussed in Note 2, revenues are recognized under guidance within ASC 606 and ASC 808. The following table presents our disaggregated revenue for the FASB issued ASU No. 2017-04, “Intangibles–Goodwill and Other,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Under the new standard, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The new standard is effective for public business entities that are SEC filers for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The standard is to be applied on a prospective basis. We are currently analyzing the impact of ASU No. 2017-04periods presented (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
JAKAFI revenues, net	$	473,706	$	409,506	$	933,185	$	785,117
ICLUSIG revenues, net		22,798		24,391		50,046		45,029
PEMAZYRE revenues, net		3,786		—		3,786		—
Total product revenues, net		500,290		433,897		987,017		830,146
JAKAVI product royalty revenues		66,217		56,895		122,550		102,466
OLUMIANT product royalty revenues		25,830		19,140		51,277		35,177
TABRECTA product royalty revenues		706		—		706		—
Total product royalty revenues		92,753		76,035		174,533		137,643
Milestone and contract revenues		95,000		20,000		95,000		60,000
Total revenues	$	688,043	$	529,932	$	1,256,550	$	1,027,789

For further information on our revenue-generating contracts,refer to Note 9 to the condensed consolidated financial statements.

In March 2017, the FASB issued ASU No. 2017-07, “Compensation–Retirement Benefits,” which requires the presentation of the service cost component of the net periodic benefit cost in the same income statement line as other employee compensation costs arising from services rendered during the period. In addition, only the service cost component will be eligible for capitalization in assets. Disclosure of the line(s) used to present the other components of net periodic benefit cost, if the components are not presented separately in the income statement, is also required. The new standard is effective for public business entities for fiscal years beginning after December 15, 2017 and interim periods therein. The guidance on the presentation of the components of net periodic benefit cost in the income statement is to be applied retrospectively. The guidance limiting the capitalization of net periodic benefit cost in assets to the service cost component is to be applied prospectively. We are currently analyzing the impact of ASU No. 2017-07 on our condensed consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which requires inventory to be measured at the lower of cost and net realizable value rather than at the lower of cost or market value. The new standard is effective for public business entities for fiscal years beginning after December 15, 2016 and interim periods therein. The guidance is to be applied prospectively. We adopted ASU No. 2015-11 as of the first quarter of 2017 and the adoption had no impact on our condensed consolidated financial statements.

~~3. Business combination~~

~~Description of the Transaction~~

On June 1, 2016, pursuant to the Share Purchase Agreement, we completed the Acquisition, and acquired all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.à.r.l., since renamed Incyte Biosciences Luxembourg S.à.r.l., the parent company of ARIAD’s European subsidiaries responsible for the development and commercialization of ICLUSIG (ponatinib) in the European Union (“EU”) and other countries including Switzerland, Norway, Turkey, Israel and Russia (the “Territory”) in exchange for an upfront payment of $147.5 million, including customary working capital adjustments (the “Upfront Payment”). ICLUSIG is approved in Europe for the treatment of patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia who are resistant to or intolerant of certain second generation BCR-ABL inhibitors and all patients who have the T3151 mutation. The acquisition of ARIAD Pharmaceuticals (Luxembourg) S.à.r.l. included a fully integrated and established pan-European team including medical, sales and marketing personnel. The existing platform and infrastructure acquired is expected to further our strategic plan and accelerate the establishment of our operations in Europe.

In connection with the closing of the Acquisition, we entered into an Amended and Restated Buy-in License Agreement with ARIAD (the “License Agreement”). Under the terms of the License Agreement, we were granted an exclusive license to develop and commercialize ICLUSIG in the Territory. ARIAD is eligible to receive from us tiered

16

~~Table of Contents~~

royalties ranging between 32% and 50% on net sales of ICLUSIG in the Territory. The royalties are subject to reduction for certain events related to exclusivity and, if necessary, any third-party patent rights. In addition, ARIAD is eligible to receive up to $135.0 million in potential future development and regulatory approval milestone payments for ICLUSIG in new oncology indications in the Territory (the “Milestones”), together with additional milestone payments for non-oncology indications, if approved, in the Territory. Under our agreement with ARIAD, we have agreed to fund a portion of the ongoing ICLUSIG clinical studies OPTIC and OPTIC-2L, which are being conducted by ARIAD, by paying up to $7.0 million in both 2016 and 2017 (the “Development Costs”). During the quarter ended September 30, 2017, ARIAD discontinued the OPTIC-2L clinical study.

The terms of the License Agreement also include a limited option for a potential future acquirer of ARIAD to purchase the European development and commercialization rights to ICLUSIG from us (the “Buy-Back Provision”). We concluded the Buy-Back Provision was not a derivative as it did not provide for explicit or implicit net settlement, cannot be readily settled net by a means outside of the contract, and does not provide for delivery of an asset that puts the recipient in a position that is not substantially different from net settlement. We also considered the probability of a potential future buyer exercising the Buy-Back Provision to be near zero and have concluded that any fair value assigned to this provision was de minimis. Takeda Pharmaceutical Company Limited acquired ARIAD in February 2017 but did not exercise the Buy-Back Provision, and the Buy-Back Provision lapsed.

Unless terminated earlier in accordance with its provisions, our obligations to pay full royalties under the License Agreement will continue to be in effect on a country-by-country basis until the latest to occur of (1) the expiration date of the composition patent in the relevant country, (2) the expiration of any regulatory marketing exclusivity period or other statutory designation that provides similar exclusivity for the commercialization of ICLUSIG in such country and (3) the seventh anniversary of the first commercial sale of ICLUSIG in such country. We will be obligated to pay royalties at a reduced rate for a specified period of time following such full royalty term. The License Agreement may be terminated in its entirety by us for convenience on 12 months’ notice after the third anniversary of the effective date of the License Agreement. The License Agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the License Agreement.

~~Fair Value of Consideration Transferred~~

The preliminary fair value of consideration transferred totaled $440.5 million, which consisted of $147.5 million in cash pursuant to the Share Purchase Agreement, including net working capital adjustments, and $293.0 million of contingent consideration related to the License Agreement. Contingent consideration includes the future payments that we may pay to ARIAD for our royalty obligations on future net sales of ICLUSIG, as well as for any future potential milestone payments related to new oncology or non-oncology indications for ICLUSIG.

The preliminary fair value of contingent consideration was determined using an income approach based on estimated ICLUSIG revenues in the Territory for both the approved third line treatment, as well as the second line treatment that was under development and was therefore contingent on future clinical results and European Medicines Agency (“EMA”) approval. The probability of technical success (“PTS”) of the second line indication was estimated at 25% based on the early stage of development and competitive market landscape, and the estimated future cash flows for the second line indication were probability weighted accordingly. The total projected cash flows of the third line and second line indications were estimated over 18 years, and discounted to present value using a discount rate of 10%. In addition, based on the believed limited effectiveness of ICLUSIG beyond the existing oncology indications, the fact that no development is currently ongoing for any new oncology or any non-oncology indications, and the lack of intention by us, ARIAD, or another market participant, to develop ICLUSIG in additional oncology or non-oncology indications, the fair value of any cash flows for any new oncology or non-oncology indication was determined to be nil. The present value of the contingent consideration was $293.0 million as of the Acquisition date.

~~Assets Acquired and Liabilities Assumed~~

The Acquisition has been accounted for as a business combination under the acquisition method of accounting. The following table summarizes the final fair values of the assets acquired and liabilities assumed as of the acquisition date.

17

~~Table of Contents~~

Acquisition

(in thousands)

Fair Values

Current assets

$
21,363

Property and equipment

850

Restricted cash

432

Intangible assets(a)

283,000

Total identifiable assets

305,645

Current liabilities

(15,538)

Other long term liabilities

(5,226)

Total liabilities assumed

(20,764)

Goodwill(b)

155,593

Total fair value of consideration transferred

$
440,474

~~(a)~~As of the effective date of the Acquisition, identifiable intangible assets are required to be measured at fair value. The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. We used an income approach to estimate the preliminary fair value of the intangibles which includes licensed intellectual property and IPR&D. The assumptions used to estimate the cash flows of the licensed intellectual property included a discount rate of 15%, estimated gross margins of 98%, income tax rates ranging from 7.8% in periods in which we have established tax holidays to 13.8% thereafter, and operating expenses consisting of direct costs based on the anticipated level of revenues as well as the $7.0 million of research and development cost sharing payments we owe in 2016 and 2017. The assumptions used to estimate the cash flows of the IPR&D (which related to the potential approval of ICLUSIG as a second line treatment and, as described in Note 8 below, has subsequently been written off) included a PTS of 25%, discount rate of 16%, estimated gross margins of 98%, income tax rates ranging from 7.8% in periods in which we have established tax holidays to 13.8% thereafter, and operating expenses consisting of direct costs based on the anticipated level of revenues as well as probability weighted milestone payments estimated for 2020 related to the clinical results and potential approval of ICLUSIG as a second line treatment. The licensed intellectual property has a weighted-average useful life of approximately 12.5 years and will be amortized using the straight-line method. Amortization expense of the licensed intellectual property is recorded in cost of product revenues on the condensed consolidated statement of operations. The IPR&D was considered an indefinite-lived intangible until the completion or abandonment of the related research and development activities.

~~(b)~~Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The Goodwill is related to the existing platform, infrastructure, and workforce which is expected to generate synergies and further our strategic plan in Europe. Goodwill is not amortized and none of the goodwill is expected to be deductible for tax purposes.

~~Pro Forma Impact of Business Combination~~

The following unaudited pro forma information presents condensed consolidated results of operations for the three and nine months ended September 30, 2016, as if the Acquisition had occurred as of January 1, 2015 (in thousands).

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,


2016

2016

Pro forma revenues

$
269,469

$
821,743

Pro forma net income

$
36,877

$
91,248

The unaudited pro forma condensed consolidated results of operations were prepared using the acquisition method of accounting and are based on the historical financial information of our company and the acquired business which has been adjusted for events that are (1) directly attributable to the Acquisition, (2) factually supportable, and (3) expected to have continuing impact on the combined results. The unaudited pro forma information reflects primarily the following adjustments:

18

~~Table of Contents~~

·

~~To record amortization expense related to fair value adjustments recorded on the acquired definite lived intangibles;~~

·

~~To eliminate ARIAD Europe’s interest expense on the intercompany loan in accordance with the terms of the Acquisition;~~

·

~~To remove balances attributable to the ARIAD Australia entity which are not material. This entity was previously consolidated by ARIAD Europe; however it was not included in the Acquisition; and~~

·

To remove the recognition of revenue relating to distribution agreements in historic periods for those arrangements in which we have no continuing performance obligation and, therefore, the fair value of the assumed deferred revenue balance was zero.

The unaudited pro forma information is not necessarily indicative of the results that would have been obtained if the Acquisition had occurred as of the beginning of the period presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings.

4. Fair value of financial instruments

FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (“the exit price”) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.

Recurring Fair Value Measurements

Our marketable securities consist of investments in ~~corporate debt securities and~~ U.S. government debt securities that are classified as available-for-sale.

At ~~September~~June 30, ~~2017~~2020 and December 31, ~~2016,~~2019, our Level 2 ~~corporate~~U.S. government debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments. Our long term investments classified as Level 1 were valued using ~~the unadjusted~~their respective closing stock ~~price~~prices on The ~~NASDAQ~~Nasdaq Stock Market.

~~Our policy is to recognize~~We did not experience any transfers ~~into and transfers out~~ of financial instruments between the fair value hierarchy levels ~~as of~~during the ~~end of the reporting period. During the three~~six months ended ~~September~~June 30, ~~2017, we transferred a long term investment with a carrying value~~2020.

17

Table of $78.3 million from Level 2 to Level 1 due to the lapse of the marketability restrictions. The investment is now valued using the unadjusted closing stock price on The NASDAQ Stock Market. There were no transfers out of Level 1 to Level 2 during the period.Contents

The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis ~~as of September 30, 2017~~ (in thousands):


	Fair Value Measurement at Reporting Date Using:
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs		Balance as of
	(Level 1)		(Level 2)		(Level 3)		June 30, 2020
Cash and cash equivalents	$	1,326,730	$	—	$	—	$	1,326,730
Debt securities (government)		—		262,756		—		262,756
Long term investments (Note 9)		248,731		—		—		248,731
Total assets	$	1,575,461	$	262,756	$	—	$	1,838,217


	Fair Value Measurement at Reporting Date Using:
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs		Balance as of
	(Level 1)		(Level 2)		(Level 3)		December 31, 2019
Cash and cash equivalents	$	1,832,684	$	—	$	—	$	1,832,684
Debt securities (government)		—		284,870		—		284,870
Long term investments (Note 9)		133,657		—		—		133,657
Total assets	$	1,966,341	$	284,870	$	—	$	2,251,211

19

~~Table of Contents~~

Fair Value Measurement at Reporting Date Using:

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

Balance as of


(Level 1)

(Level 2)

(Level 3)

September 30, 2017

Cash and cash equivalents

$
1,128,046

$
—

$
—

$
1,128,046

Debt securities (corporate and government)

—

153,343

—

153,343

Long term investments (Note 9)

169,020

—

—

169,020

Total assets

$
1,297,066

$
153,343

$
—

$
1,450,409

The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as ~~of September 30, 2017~~ (in thousands):


	Fair Value Measurement at Reporting Date Using:
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs		Balance as of
	(Level 1)		(Level 2)		(Level 3)		September 30, 2017
Contingent consideration (Note 3)	$	—	$	—	$	284,000	$	284,000

									Fair Value Measurement at Reporting Date Using:
									Quoted Prices in		Significant Other		Significant
									Active Markets for		Observable		Unobservable
									Identical Liabilities		Inputs		Inputs		Balance as of
									(Level 1)		(Level 2)		(Level 3)		June 30, 2020
Acquisition-related contingent consideration									$	—	$	—	$	274,000	$	274,000
Total liabilities	$	—	$	—	$	284,000	$	284,000	$	—	$	—	$	274,000	$	274,000


	Fair Value Measurement at Reporting Date Using:
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Liabilities		Inputs		Inputs		Balance as of
	(Level 1)		(Level 2)		(Level 3)		December 31, 2019
Acquisition-related contingent consideration	$	—	$	—	$	277,000	$	277,000
Total liabilities	$	—	$	—	$	277,000	$	277,000

The following is a rollforward of our Level 3 liabilities (in thousands):

Level 3
Balance at January 1, 2017

$
301,000
Contingent consideration earned during the period but not yet paid

(5,657)
Payments made during the period

(9,429)
Change in fair value of contingent consideration

(1,914)
Balance at September 30, 2017

$
284,000


	2020
Balance at January 1,	$	277,000
Contingent consideration earned during the period but not yet paid		(7,054)
Payments made during the period		(8,627)
Change in fair value of contingent consideration		12,681
Balance at June 30,	$	274,000

The fair value of the contingent consideration was determined on the date of acquisition, June 1, 2016, using an income approach based on estimated ICLUSIG revenues in the ~~Territory~~European Union and other countries for ~~both~~ the approved third line treatment ~~as well as the second line treatment that was under development until discontinued in the third quarter~~over 18 years, and discounted to present value at a rate of ~~2017.~~10%. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the ~~condensed~~ consolidated statements of operations. The valuation inputs utilized to estimate the fair value of the contingent consideration as of June 30, 2020 included a weighted

18

Table of Contents

average cost of capital of 10% and updated projections of future ICLUSIG revenues in the European Union and other countries for the approved third line treatment. The change in fair value of the contingent consideration during the three and ~~nine~~six months ended ~~September~~June 30, ~~2017 is~~2020 was due primarily to the passage of time ~~and a benefit of $24.0 million recorded~~as there were no other significant changes in the key assumptions during the ~~third quarter related to the lack of expected future sales royalties payable due to the discontinued OPTIC-2L clinical trial.~~period.

We make payments to ~~ARIAD~~Takeda quarterly based on the royalties or any additional milestone payments earned in the previous quarter. ~~During the three months ended September~~At June 30, ~~2017,~~2020 and December 31, 2019, contingent consideration earned but not yet paid was ~~$5.7~~$7.1 million and ~~we paid ARIAD $5.1~~$23.0 million, ~~for royalties earned in the second quarter of 2017 that were~~respectively, and was included in accrued and other current ~~liabilities at June 30, 2017.~~liabilities.

20

~~Table of Contents~~

~~The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis as of December 31, 2016 (in thousands):~~

Fair Value Measurement at Reporting Date Using:

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

Balance as of


(Level 1)

(Level 2)

(Level 3)

December 31, 2016

Cash and cash equivalents

$
652,343

$
—

$
—

$
652,343

Debt securities (corporate and government)

—

156,203

—

156,203

Long term investment (Note 9)

31,987

—

—

31,987

Total assets

$
684,330

$
156,203

$
—

$
840,533

~~The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as of December 31, 2016 (in thousands):~~

Fair Value Measurement at Reporting Date Using:

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

Balance as of


(Level 1)

(Level 2)

(Level 3)

December 31, 2016

Contingent consideration (Note 3)

$
—

$
—

$
301,000

$
301,000

Total liabilities

$
—

$
—

$
301,000

$
301,000

The following is a summary of our marketable security portfolio ~~as of September 30, 2017 and December 31, 2016, respectively.~~for the periods presented (in thousands):

Net

Net

Amortized

Unrealized

Unrealized

Estimated


Cost

Gains

Losses

Fair Value

(in thousands)

September 30, 2017








Debt securities (corporate and government)

$
153,650

$
—

$
(307)

$
153,343

December 31, 2016

Debt securities (corporate and government)

$
156,330

$
—

$
(127)

$
156,203


			Net
	Amortized		Unrealized		Estimated
	Cost		Gains		Fair Value
June 30, 2020
Debt securities (government)	$	262,556	$	200	$	262,756

December 31, 2019
Debt securities (government)	$	284,795	$	75	$	284,870

Our available-for-sale debt securities generally have contractual maturity dates of between 12 to 18 months. Debt security assets were assessed for risk of expected credit losses per our accounting policy as described in Note 2. As of June 30, 2020 and December 31, 2019, the available-for-sale debt securities were held in US-government backed funds and Treasury assets and were assessed on an individual security basis to have a de minimis risk of credit loss.

5. Concentration of credit risk and current expected credit losses

In November 2009, we entered into a collaboration and license agreement with Novartis. In December 2009, we entered into a license, development and commercialization agreement with Lilly. In ~~November 2009,~~December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (“Innovent”). In July 2019, we entered into a collaboration and license agreement with ~~Novartis.~~Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, “Zai Lab”). The ~~concentration of credit risk related to our collaborative~~above collaboration partners ~~is as follows:~~

Percentage of Total

Percentage of Total

Contract Revenues for the

Contract Revenues for the

Three Months Ended

Nine Months Ended

September 30,

September 30,


2017

2016


2017

2016


Collaboration Partner A

—
%
—
%

24
%
7
%

Collaboration Partner B

100
%
100
%

76
%
93
%

~~Collaboration Partner A and Collaboration Partner B~~ comprised, in ~~the~~ aggregate, ~~23%~~45% and ~~23%~~30% of the accounts receivable balance as of ~~September~~June 30, ~~2017~~2020 and December 31, ~~2016,~~2019, respectively.

21

~~Table of Contents~~

For further information relating these collaboration and license agreements,refer to Note 9 to the condensed consolidated financial statements.

In November 2011, we began commercialization and distribution of JAKAFI and in April 2020, we began commercialization and distribution of PEMAZYRE to a number of customers. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI and PEMAZYRE product revenues is as follows:


	Percentage of Total Net				Percentage of Total Net
	Product Revenues for the				Product Revenues for the
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016

									Percentage of Total Net				Percentage of Total Net
									Product Revenues for the				Product Revenues for the
									Three Months Ended				Six Months Ended
									June 30,				June 30,
									2020		2019		2020		2019
Customer A	24	%	25	%	25	%	26	%	20	%	20	%	19	%	19	%
Customer B	16	%	19	%	16	%	18	%	14	%	13	%	13	%	14	%
Customer C	14	%	13	%	13	%	13	%	16	%	16	%	17	%	16	%
Customer D	8	%	8	%	8	%	8	%	11	%	11	%	11	%	12	%

We are exposed to risks associated with extending credit to customers related to the sale of products. ~~Customer~~Customers A, ~~Customer~~ B, ~~Customer~~ C and ~~Customer~~ D comprised, in ~~the~~ aggregate, ~~44%~~29% and ~~41%~~39% of the accounts receivable balance as of ~~September~~June 30, ~~2017~~2020 and December 31, ~~2016,~~2019, respectively.

The concentration of credit risk relating to ICLUSIG product revenues or accounts receivable is not significant.

19

Table of Contents

We assessed our collaborative and customer receivable assets as of June 30, 2020 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis.

6.Inventory

Our inventory balance consists of the ~~following:~~following (in thousands):


	September 30,		December 31,
	2017		2016
	(in thousands)

					June 30,		December 31,
					2020		2019
Raw materials	$	109	$	109	$	1,275	$	1,275
Work-in-process		11,188		15,084		10,619		8,634
Finished goods		3,261		4,106		13,995		6,596
		14,558		19,299
						25,889		16,505
Inventories-current		3,261		4,106		16,335		11,400
Inventories-non-current	$	11,297	$	15,193
Inventories-noncurrent					$	9,554	$	5,105

Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. ~~The ICLUSIG inventories acquired on~~At June 1, 2016 totaling $4.0 million were recorded at fair value less costs to sell, and therefore, resulted in a higher cost of ICLUSIG revenues over a one year period from the acquisition date. At September 30, ~~2017, $3.3~~2020, $16.3 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At ~~September~~June 30, ~~2017, $11.3~~2020, $9.6 million of inventory was classified as ~~non-current~~noncurrent on the condensed consolidated balance sheets as we did not expect this inventory to be consumed for commercial use within the next twelve months. We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.

22

~~Table of Contents~~

7. Property and equipment, net

Property and equipment, net consists of the ~~following:~~following (in thousands):


	September 30,		December 31,
	2017		2016
	(in thousands)

					June 30,		December 31,
					2020		2019
Office equipment	$	10,554	$	9,243	$	14,482	$	15,303
Laboratory equipment		44,299		37,203		72,915		70,510
Computer equipment		47,522		38,184		59,642		59,069
Land		5,350		4,125		10,294		10,203
Building and leasehold improvements		208,171		130,734		206,498		208,293
		315,896		219,489
Operating lease right-of-use assets						23,532		19,672
Construction in progress						196,850		116,387
						584,213		499,437
Less accumulated depreciation and amortization		(69,071)		(51,810)		(130,436)		(121,870)
Property and equipment, net	$	246,825	$	167,679	$	453,777	$	377,567

In February 2018, we signed an agreement to rent a building in Morges, Switzerland for an initial term of 15 years plus one year of free rent, with multiple options to extend for an additional 20 years. The building will serve as our new European headquarters and will consist of approximately 100,000 square feet of office space. This building will allow for consolidation of our European operations that are currently located in Geneva and Lausanne, Switzerland. Building permits were granted by the local government authorities in September ~~2016,~~2018 and construction activity began immediately thereafter. In June 2019, we ~~entered into two agreements~~obtained control of the Morges building to begin our construction activity. At that time, we determined the lease to be a finance lease and recorded a lease liability of $31.1 million and a finance lease right-of-use asset of $29.1 million, net of a lease incentive from our landlord of $2.0 million. As of June 30, 2020 we have capitalized approximately $22.4 million in on site preparation, design and construction costs.

20

Table of Contents

In July 2018, we signed an agreement to purchase ~~two~~land located in Yverdon, Switzerland. The land was purchased, in cash, for approximately $4.8 million. Upon this parcel, we are constructing a large molecule production facility. Construction activity commenced in July 2018 and as of June 30, 2020, we have capitalized approximately $127.4 million in costs for construction, ground preparation and architectural and engineering studies. We currently anticipate the facility will be completed in the second half of 2020.

We are the lessee of several contracts, including those to secure fleet vehicles, buildings and equipment. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. Some of our building leases include options to renew and the exercise of these options is at ~~1701 Augustine Cut-off~~our discretion. Our current operating lease liabilities are reflected in ~~Wilmington, Delaware.~~ accrued and other current liabilities and our noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheets and are as follows (in thousands):


	June 30,		December 31,
	2020		2019
Current
Operating lease liabilities	$	10,059	$	9,343
Finance lease liabilities		1,189		664
Noncurrent
Operating lease liabilities		13,956		11,854
Finance lease liabilities		31,917		31,918
Total lease liabilities	$	57,121	$	53,779

The ~~purchase closed~~cash paid for amounts included in ~~March 2017~~the measurement of our operating lease liabilities for the six months ended June 30, 2020 and 2019 was $5.9 million and $5.4 million, respectively, in operating cash flows. The cash paid for amounts included in the measurement of our finance lease liabilities for the six months ended June 30, 2020 and 2019 was $0.4 million, in financing cash flows.

As of June 30, 2020, our finance and operating leases had a ~~total purchase price~~weighted average lease term of approximately ~~$8.1~~15.2 and 5.3 years, respectively. The discount rate of our leases is an approximation of an estimated incremental borrowing rate and is dependent upon the term and economics of each agreement. The weighted average discount rate of our finance and operating leases is approximately 3.6% and 4.4%, respectively.

For the three and six months ended June 30, 2020, we incurred approximately $2.9 million ~~consisting~~and $6.1 million, respectively, of ~~$1.2~~expense related to our operating leases, approximately $0.7 million and $1.3 million, respectively, of ~~land~~amortization on our finance lease right-of-use assets and ~~$6.9~~approximately $0.3 million and $0.6 million, respectively, of ~~buildings~~interest expense on our finance lease liabilities. For the three and ~~leasehold improvements, which~~six months ended June 30, 2019, we ~~estimated using~~incurred approximately $3.6 million and $7.3 million, respectively, of expense related to our operating leases, approximately $0.2 million and $0.4 million, respectively, of amortization on our finance lease right-of-use assets and a de minimis amount of interest expense on our finance lease liabilities.

Rent expense for the ~~assistance~~three and six months ended June 30, 2020 was $2.9 million and $6.4 million, respectively. Rent expense for the three and six months ended June 30, 2019 was $3.7 million and $7.0 million, respectively. For the three and six months ended June 30, 2020 and 2019, the cost of our short term leases with a ~~third party valuation specialist.~~ term less than 12 months was de minimis.

21

Table of Contents

8. Intangible assets and goodwill

Intangible Assets, Net

The components of intangible assets ~~as of September 30, 2017~~ were as follows (in thousands, except for useful life):

Weighted-

Gross

Net

Average Useful

Carrying

Accumulated

Carrying


Lives (Years)

Amount

Amortization

Amount


Finite-lived intangible assets:










Licensed IP(1)

12.5

$
271,000

$
28,715

$
242,285

Indefinite-lived intangible assets:

Acquired IPR&D(1)

N/A

—

—

—

$
271,000

$
28,715

$
242,285

Balance at June 30, 2020

Balance at December 31, 2019

Weighted-

Gross

Net

Gross

Net

Average Useful

Carrying

Accumulated

Carrying

Accumulated

Carrying

Lives (Years)

Amount

Amortization

Amount

Amortization

Amount

Finite-lived intangible assets:

Licensed IP

12.5

$

271,000

$

87,940

$

183,060

$

271,000

$

77,172

$

193,828

~~(1)~~ We acquired certain intangible assets as part of the Acquisition, as described further in Note 3. During the three months ended September 30, 2017, we wrote-off the acquired IPR&D asset of $12.0 million due to the discontinuation of the OPTIC-2L study. The write-off of the IPR&D asset was recorded in research and development expense on the condensed consolidated statements of operations.

Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets is as follows (in thousands):

Remainder of

2017

2018

2019

2020

2021

Thereafter
Amortization expense
$
5,384

$
21,536

$
21,536

$
21,536

$
21,536

$
150,757


		Remainder of
		2020		2021		2022		2023		2024		Thereafter
Amortization expense	$	10,768	$	21,536	$	21,536	$	21,536	$	21,536	$	86,148

Goodwill

There were no0 changes to the carrying amount of goodwill for the ~~nine~~six months ended ~~September~~June 30, ~~2017.~~2020.

23

~~Table of Contents~~

9. License agreements

Novartis

In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. Novartis also received worldwide exclusive development and commercialization rights to our ~~c-MET~~MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.

Under this agreement, we received an upfront payment and immediate milestone payment totaling $210.0 million and were initially eligible to receive up to $1.2 billion in milestone payments across multiple indications upon the achievement of pre-specified events, including up to $174.0 million for the achievement of development milestones, up to $495.0 million for the achievement of regulatory milestones and up to $500.0 million for the achievement of ~~commercialization~~sales milestones. In April 2016, we amended this agreement to provide that Novartis has exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the graft-versus-host-disease (“GVHD”) field. We became eligible to receive up to $75.0 million of additional potential development and regulatory milestones relating to GVHD. Exclusive of the upfront payment of $150.0 million received in 2009 and the immediate milestone of $60.0 million earned in 2010, we have recognized and received, in the aggregate, ~~$132.0~~$157.0 million for the achievement of development milestones, ~~and $215.0~~$280.0 million for the achievement of regulatory milestones and ~~$20.0~~$120.0 million for the achievement of sales milestones through ~~September~~June 30, ~~2017.~~2020.

~~During~~We recognize development and regulatory milestones upon confirmation of achievement of the ~~nine months ended September 30, 2017, under this agreement,~~event, as development and regulatory approvals are events not controllable by us but rather development activities of Novartis and decisions made by regulatory agencies. We recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Novartis.

22

Table of Contents

In May 2020, we recognized a $25.0 million development milestone payment based on the formal initiation by Novartis of a Phase III clinical trial evaluating ruxolitinib in GVHD. In 2016, we recognized a $5.0 million payment in exchange for the development and commercialization rights to ruxolitinib in GVHD outside of the United States and a ~~$40.0~~$45.0 million regulatory milestone for the ~~reimbursement~~FDA approval of JAKAVI in Europe for the treatment of patients with polycythemia vera. In 2015, we recognized a $5.0 million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib for a third indication, a $25.0 million regulatory milestone triggered by the Committee for Medicinal Products for Human Use of the European Medicines Agency adopting a positive opinion for JAKAVI (ruxolitinib)as TABRECTA for the treatment of adult patients with ~~polycythemia vera who are resistant~~metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to ~~or intolerant of hydroxyurea,~~MET exon 14 skipping (METex14) as detected by an FDA-approved test. In June 2020, we recognized a ~~$15.0~~$20.0 million regulatory milestone for the Japanese Ministry of Health, Labour and Welfare approval of ~~JAKAVI in Japan~~TABRECTA for the treatment of patients with polycythemia vera, and a $20.0 million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $300.0 million. In 2014, we recognized a $60.0 million regulatory milestone related to reimbursement of JAKAVI in Europe, a $25.0 million regulatory milestone for the approval of JAKAVI in Japan for the treatment of patients with myelofibrosis and a $7.0 million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib inMETex14 mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer. In 2013, we recognized a $25.0 million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib. In 2012, we recognized a $40.0 million regulatory milestone payment for the achievement of a predefined milestone for the European Union regulatory approval of JAKAVI. In 2011, we recognized a $15.0 million development milestone for the achievement of a predefined milestone in the Phase I dose-escalation trial for capmatinib in patients with solid tumors and a $10.0 million regulatory milestone for the approval of JAKAFI in the United States. In 2010, we recognized $50.0 million in development milestones for the initiation of the global phase III trial, RESPONSE, in patients with polycythemia vera. We determined that each of these milestones were substantive as their achievement required substantive efforts by us and was at risk until the milestones were ultimately achieved.

We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States, and tiered, worldwide royalties on future capmatinib net sales that range from 12% to 14%. Since the achievement of the $60.0 million regulatory milestone related to reimbursement of JAKAVI in Europe in September 2014, we are obligated to pay to Novartis tiered royalties in the low ~~single digits~~single-digits on future JAKAFI net sales within the United States. During the three and ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020, such royalties payable to Novartis on net sales within the United States totaled ~~$14.9~~$23.2 million and ~~$35.7~~$40.7 million, respectively,

24

~~Table of Contents~~

and are reflected in cost of product revenues on the condensed consolidated statements of operations. During the three and ~~nine~~six months ended ~~September~~June 30, ~~2016,~~2019, such royalties payable to Novartis on net sales within the United States totaled ~~$11.0~~$20.1 million and ~~$25.1~~$33.5 million, respectively, and are reflected in cost of product revenues on the condensed consolidated statements of operations. At June 30, 2020 and December 31, 2019, $70.7 million and $50.2 million, respectively, of accrued royalties payable to Novartis were included in accrued and other current liabilities on the condensed consolidated balance sheets. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.

The Novartis agreement will continue on a program-by-program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product-by-product and country-by-country basis until the latest to occur of ~~(1)~~(i) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, ~~(2)~~(ii) the expiration of regulatory exclusivity for the licensed product in such country and ~~(3)~~(iii) a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.

We determined that there were two deliverables under the agreement: (i) the ex-U.S. license for ruxolitinib and (ii) our obligations in connection with our participation on the joint development committee for myelofibrosis and polycythemia vera/essential thrombocythemia. We concluded that these deliverables should be accounted for as a single unit of accounting and the $150.0 million upfront payment received in December 2009 and the immediate $60.0 million milestone payment received in January 2010 should be recognized on a straight line basis through December 2013, when we estimated we would complete our obligations in connection with our participation on the joint development committee for myelofibrosis and polycythemia vera, our estimated performance period under the agreement. We completed this substantive performance obligation related to this arrangement in December 2013.

At December 31, 2009, we recorded $10.9 million of reimbursable costs incurred prior to the effective date of the agreement as deferred revenue on the consolidated balance sheet. These costs were recognized on a straight line basis through December 2013 consistent with the aforementioned upfront and milestone payments. Future reimbursableReimbursable costs incurred after the effective date of the agreement with Novartis are recorded net against the related research and development expenses. Research and development expenses for the three and six months ended June 30, 2020 were net of $0.0 million and $0.3 million, respectively, of costs reimbursed by Novartis. Research and development expenses for the three and six months ended June 30, 2019 were net of $0.4 million and $1.0 million, respectively, of costs reimbursed by Novartis. At ~~September~~June 30, ~~2017~~2020 and December 31, ~~2016, $1.0~~2019, $0.1 million and ~~$0.6~~$0.4 million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets. ~~Research~~

Milestone and development expenses for the three and nine months ended September 30, 2017 were net of $0.4 million and $1.9 million, respectively, of costs reimbursed by Novartis. Research and development expenses for the three and nine months ended September 30, 2016 were net of $0.3 million and $0.7 million, respectively, of costs reimbursed by Novartis.

~~Contract~~contract revenue under the Novartis agreement ~~was $0.0 million and $25.0 million~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017, respectively. Contract~~2020 was $90.0 million. Milestone and contract revenue under the Novartis agreement ~~was $0.0 million and $5.0 million~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016.~~2019 was $0.0 million. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States ~~was $41.3 million and $104.0 million~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020 was $66.2 million and $122.6 million, respectively. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States ~~was $29.6 million and $77.5 million~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016, respectively. At September 30, 2017 and December 31, 2016, $41.3~~2019 was $56.9 million and ~~$33.3~~$102.5 million, ~~respectively,~~respectively. Product royalty revenue related to Novartis net sales of ~~product royalties were included in accounts receivable on~~TABRECTA worldwide for the ~~condensed consolidated balance sheets.~~three and six months ended June 30, 2020 was $0.7 million.

Lilly -– Baricitinib

In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases. We received an upfront payment of $90.0 million, and were initially eligible to receive up to $665.0 million in substantive milestone payments across multiple indications upon the achievement of pre-specified events, including up to $150.0 million for the

23

Table of Contents

achievement of development milestones, up to $365.0 million for the achievement of regulatory milestones and up to $150.0 million for the achievement of ~~commercialization~~sales milestones. Exclusive of the upfront payment of $90.0 million

25

~~Table of Contents~~

received in 2009, we have recognized and received, in ~~the~~ aggregate, ~~$99.0~~$149.0 million for the achievement of development milestones and ~~$135.0~~$235.0 million for the achievement of regulatory milestones through ~~September~~June 30, ~~2017.~~ 2020.

We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Lilly and decisions made by regulatory agencies. We recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Lilly.

In ~~April~~January 2016, Lilly submitted an NDA to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency for baricitinib as treatment for rheumatoid arthritis. In February 2017, we and Lilly announced that the ~~FDA had issued a complete response letter for the New Drug Application of~~European Commission approved baricitinib as a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis. The letter indicates that the FDA is unable to approve the application in its current form. Specifically, the FDA indicated that additional clinical data are needed to determine the most appropriate doses. The FDA also stated that additional data are necessary to further characterize safety concerns across treatment arms. In August 2017, we and Lilly announced that a resubmission of the NDA for baricitinib is now expected before the end of January 2018. The resubmission package will include new safety and efficacy data. The companies anticipate the FDA will classify the application as a Class II resubmission, which would start a new six-month review cycle.

During the nine months ended September 30, 2017, under this agreement, we recognized a $15.0 million regulatory milestone payment for the approval of baricitinib for the treatment of rheumatoid arthritis by Japan’s Ministry of Health, Labor and Welfare and a $65.0 million regulatory milestone payment for the approval of baricitinibOLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis in adult patients ~~by the European Commission.~~who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs. In ~~2016, we recognized a $35.0 million regulatory milestone~~July 2017, Japan's Ministry of Health, Labor and Welfare granted marketing approval for the submission of an NDA to the FDA for the approval of oral once-daily baricitinib for the treatment of moderate-to-severe rheumatoid arthritis and a $20.0 million regulatory milestone for the submission of a Marketing Authorization Application to the European Medicines Agency for the approval of oral once-daily baricitinib for the treatment of moderate-to-severe rheumatoid arthritis. In 2012, we recognized a $50.0 million development milestone for the initiation of the rheumatoid arthritis Phase III program for baricitinib. In 2010, we recognized a $30.0 million development milestone based upon the initial three month data in the Phase IIa clinical trial of baricitinib OLUMIANTfor the treatment of rheumatoid arthritis ~~and a $19.0 million development milestone for~~in patients with inadequate response to standard-of-care therapies. In June 2018, the ~~Phase IIb clinical trial initiation~~FDA approved the 2mg dose of ~~baricitinib~~OLUMIANT for the treatment of rheumatoid arthritis. We determined that each of these milestones were substantive as their achievement required substantive efforts by us and was at risk until the milestones were ultimately achieved. In July 2010, we elected to co-develop baricitinibadults with ~~Lilly in~~moderately-to-severely active rheumatoid arthritis and we are responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. In January 2017, we exercised our co-development option in psoriatic arthritiswho have had an inadequate response to fund 30% of future global development costs through regulatory approval, including post-launch studies required by a regulatory authority. We also exercised our co-development options in both atopic dermatitis and axial spondyloarthritis, should Lilly decide to progress into a pivotal program in these indications.one or more tumor necrosis factor inhibitor therapies.

We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding 30% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop. For indications that we elect not to ~~co‑develop,~~co-develop, we would receive tiered, ~~double‑digit~~double-digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized. We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement. In February 2017, the European Commission approved baricitinib, which is marketed as OLUMIANT, for the treatment of moderate-to-severe rheumatoid arthritis in adult patients.

Research and development expenses recorded under the Lilly agreement representing 30% of the global development costs for baricitinib for the treatment of rheumatoid arthritis, psoriatic arthritis and atopic dermatitis were $9.1 million and $27.2 million for the three and nine months ended September 30, 2017, respectively. Research and development expenses recorded under the Lilly agreement representing 30% of the global development costs for baricitinib for the treatment of rheumatoid arthritis were $10.6 million and $21.0 million for the three and nine months ended September 30, 2016, respectively. We have retained certain mechanisms to give us cost protection as baricitinib advances in clinical development. We can defer our portion of co-development study costs by indication if they exceed a predetermined level. This deferment would be credited against future milestones or royalties and we would still be eligible

26

~~Table of Contents~~

~~for the full incremental royalties related to the co-development option. In addition, even if~~If we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we co-funded. We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement.

In July 2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and became responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We subsequently elected to co-develop baricitinib with Lilly in psoriatic arthritis, atopic dermatitis, alopecia areata, systemic lupus erythematosus and axial spondyloarthritis and were responsible for funding 30% of future global development costs for those indications through regulatory approval, including post-launch studies required by a regulatory authority. In April 2019, we elected to end additional co-funding of the development of baricitinib effective as of January 1, 2019. We will continue to receive royalties on global net sales of OLUMIANT, pursuant to the terms in the Lilly agreement, as described above.

In May 2020, we amended our agreement with Lilly to enable Lilly to commercialize baricitinib for the treatment of COVID-19. In addition to the royalties described above, we will be entitled to receive additional royalty payments with rates in the low teens on global net sales of baricitinib for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold.

The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product-by-product and country-by-country basis until the latest to occur of ~~(1)~~(i) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, ~~(2)~~(ii) the expiration of regulatory exclusivity for the licensed product in such country and ~~(3)~~(iii) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.

~~We determined that there were two deliverables under the agreement: (i) the worldwide license~~24

Table of Contents

Milestone and (ii) our obligations in connection with a co-development option. We concluded that these deliverables should be accounted for as a single unit of accounting and the $90.0 million upfront payment should be recognized on a straight line basis as revenue through December 2016, our estimated performance period under the agreement. We completed our substantive performance obligation related to this arrangement in December 2016.

~~Contract~~contract revenue under the Lilly agreement ~~was $15.0 million and $80.0 million~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017, respectively. Contract~~2020 and 2019 was $0.0 million. Product royalty revenue ~~under the~~related to Lilly ~~agreement was $3.2 million and $64.6 million~~global net sales of OLUMIANT for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016,~~2020 was $25.8 million and $51.3 million, respectively. Product royalty revenue related to Lilly global net sales of OLUMIANT ~~was $3.2 million and $4.5 million~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2019 was $19.1 million and $35.2 million, respectively. ~~At September 30, 2017, $3.2 million of product royalties were included in accounts receivable on the condensed consolidated balance sheet.~~

Lilly - Ruxolitinib

In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the GVHD field. WeUpon execution of the amendment, we paid Lilly an upfront payment of $35.0 million and Lilly is eligible to receive up to $40.0 million in ~~additional~~ regulatory milestone payments relating to ruxolitinib in the GVHD field. ~~During~~In May 2019, the ~~nine months ended September 30, 2016, the $35.0~~approval of JAKAFI in steroid-refractory acute GVHD triggered a $20.0 million ~~upfront~~milestone payment ~~was recorded in research and development expense on the condensed consolidated statements of operations.~~ to Lilly.

Agenus

In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus’ antibody discovery platforms. The agreement became effective on February 18, 2015, upon the expiration of the waiting period under the ~~Hart Scott Rodino~~Hart-Scott-Rodino Antitrust Improvements Act of 1976. Upon closing of the agreement, we paid Agenus total consideration of $60.0 million.

In February 2017, we and Agenus amended this agreement (the “Amended Agreement”).

Under the terms of the Amended Agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial ~~four~~4 program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, ~~three~~3 more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets were profit-share programs until February 2017, while the other targets currently under collaboration are royalty-bearing programs. The Amended Agreement converted the programs relating to GITR and OX40 to royalty-bearing programs and removed from the collaboration the profit-share programs relating to the two undisclosed targets, with one reverting to us and one reverting to Agenus. Should any of those removed programs be successfully developed by a party, the other party will be eligible

27

~~Table of Contents~~

to receive the same milestone payments as the royalty-bearing programs and royalties at a 15% rate on global net sales. There are currently no profit-share programs. For each royalty-bearing product other than GITR and OX40, Agenus will be eligible to receive tiered royalties on global net sales ranging from 6% to 12%. For GITR and OX40, Agenus will be eligible to receive 15% royalties on global net sales.

~~Under~~In 2017 under the Amended Agreement, we paid Agenus $20.0 million in accelerated milestones relating to the clinical development of the GITR and OX40 programs, which iswas recorded in research and development ~~expense on the condensed consolidated statement of operations during the nine months ended September 30, 2017.~~expense. Agenus iswas initially eligible to receive up to an additional $510.0 million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration. The agreement may be terminated by us for convenience upon 12 months’ notice and may also be terminated under certain other circumstances, including material breach. In 2018, we paid Agenus a $5.0 million development milestone for the LAG-3 program and a $5.0 million development milestone for the TIM-3 program, which were recorded in research and development expense.

In connection with the Amended Agreement, we also agreed to purchase 10.0 million shares of Agenus Inc. common stock for an aggregate purchase price of $60.0 million in cash, or $6.00 per share. We completed the purchase of the shares on February 14, 2017, when the closing price on The ~~NASDAQ~~Nasdaq Stock Market for Agenus Inc. shares was $4.40 per share. The shares we acquired were not registered under the Securities Act of 1933 on the purchase date and ~~are~~were subject to certain security specific restrictions for a period of time, and accordingly, we estimated a discount for lack of marketability on the shares on the issuance date of $4.5 million, which resulted in a ~~total~~net fair value of the shares on the issuance date of $39.5 million. Therefore, of the total consideration paid of $60.0 million, $39.5 million was allocated to

25

Table of Contents

our stock purchase in Agenus Inc. and was recorded within long term investments ~~on the condensed consolidated balance sheets~~ and $20.5 million was allocated to research and development ~~expense on the condensed consolidated statement of operations during the nine months ended September 30, 2017.~~expense.

We ~~have~~ concluded Agenus Inc. is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. ~~From the date~~After completion of our ~~initial~~ stock ~~purchase in February 2015 and up to the date of our second stock purchase in February 2017, we owned between 9% and 11% of the outstanding shares of~~purchases from Agenus Inc. ~~common stock. As a result~~, we held an approximate ownership interest of ~~our February 2017 stock purchase, we owned approximately~~ 18% ~~of the outstanding shares of Agenus Inc. common stock as of September 30, 2017. We~~and, under circumstances present at that time, concluded that we ~~have~~had the ability to exercise significant influence, but not control, over Agenus Inc. ~~based~~, primarily ~~on our ownership interest, the fact that we have been the largest Agenus stockholder since the date of our initial stock purchase,~~due to the level of intra-entity transactions between us and Agenus related to development expenses, as well as other qualitative factors. WeIn the second quarter of 2020, we sold an aggregate of approximately 1.2 million shares of Agenus Inc. common stock, reducing our ownership interest to approximately 9.8% as of June 30, 2020. The sales transactions were priced at market, with per share pricing ranging from $3.57 to $4.21, resulting in gross proceeds of approximately $4.5 million. While we believe that we continue to be the largest stockholder of Agenus Inc., as a result of having a less than 10% ownership interest and the recent diversification of Agenus Inc.’s development pipeline with other collaboration partners, we concluded that we no longer have ~~elected~~significant influence over Agenus Inc. As such, as of June 30, 2020, we no longer account for our equity investment in Agenus Inc. as an equity method investment previously accounted for under the fair value ~~option to~~option. We will account for our ~~long term~~ investment in Agenus Inc. at fair value, whereby the investment is marked to market through earnings in each reporting period. ~~We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence.~~ For the three and ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020, we recorded an unrealized gain of ~~$10.2~~$26.2 million and ~~$6.8~~an unrealized loss of $2.7 million, respectively, based on the change in fair market value of ~~our investment in~~ Agenus Inc.’s common stock during these periods. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2016,~~2019, we recorded an unrealized gain of ~~$24.3~~$0.5 million and ~~$20.5~~$11.0 million, respectively, based on the change in fair market value of ~~our investment in~~ Agenus Inc.’s common stock during these periods. The fair market value of our long term investment in Agenus ~~was $78.3 million~~Inc. at ~~September~~June 30, ~~2017~~2020 and ~~$32.0 million at~~ December 31, ~~2016. For the three and six months ended June 30, 2017, Agenus Inc. reported total revenues of $4.2~~2019 was $65.1 million and ~~$31.2~~$72.3 million, ~~respectively, and a net loss of $31.7 million and $48.8 million, respectively, within its consolidated financial statements.~~respectively.

Research and development expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 also included ~~$29.7~~$0.2 million and ~~$48.6~~$0.3 million, respectively, of ~~additional~~ development costs incurred pursuant to the Agenus ~~agreement.~~arrangement. Research and development expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016~~2019 also included ~~$3.9~~$0.5 million and ~~$12.0~~$0.9 million, respectively, of ~~additional~~ development costs incurred pursuant to the Agenus ~~agreement.~~arrangement. At ~~September~~June 30, ~~2017~~2020 and December 31, ~~2016,~~2019, a total of ~~$3.5~~$1.5 million and ~~$11.4~~$1.6 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance ~~sheet.~~sheets.

~~Hengrui~~

In September 2015, we entered into a License and Collaboration Agreement with Jiangsu Hengrui Medicine Co., Ltd. (“Hengrui”). Under the terms of this agreement, we received exclusive development and commercialization

28

~~Table of Contents~~

rights worldwide, with the exception of Mainland China, Hong Kong, Macau and Taiwan, to INCSHR1210, an investigational PD-1 monoclonal antibody, and certain back-up compounds. INCSHR1210 is currently in clinical development.

Under the terms of this agreement, we paid Hengrui an upfront payment of $25.0 million in 2015 which was recorded in research and development expense on the condensed consolidated statement of operations. Hengrui is also eligible to receive potential milestone payments of up to $770.0 million, consisting of $90.0 million for regulatory approval milestones, $530.0 million for commercial performance milestones, and $150.0 million for a clinical superiority milestone. Also, Hengrui may be eligible to receive tiered royalties in the high-single digits to mid-double digits based on net sales in our territories. Each company will be responsible for costs relating to the development and commercialization of the PD-1 monoclonal antibody in their respective territories. The agreement will continue on a country-by-country basis until we have no royalty payment obligations with respect to such country or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated in its entirety by us for convenience, and may also be terminated under certain other circumstances, including material breach.

Research and development expenses for the three and nine months ended September 30, 2017 included $0.4 million and $2.0 million, respectively, of development costs incurred pursuant to the Hengrui agreement. Research and development expenses for the three and nine months ended September 30, 2016 included $3.3 million and $5.5 million, respectively, of development costs incurred pursuant to the Hengrui agreement.

Merus

In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. (“Merus”). Under this agreement, which became effective in January 2017, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus’ technology platform. The collaboration encompasses up to eleven independent ~~programs, including two of Merus’ current preclinical immuno-oncology discovery~~ programs. We

The most advanced collaboration program is MCLA-145, a bispecific antibody targeting PD-L1 and CD137, for which we received exclusive development and commercialization rights outside of the United States to products and product candidates resulting from one of Merus’ current preclinical discovery programs, referred to as “Program 1.” We also received worldwide exclusive development and commercialization rights to products and product candidates resulting from the other current Merus preclinical discovery program that is subject to the collaboration and to up to nine additional programs.States. Merus retained exclusive development and commercialization rights in the United States to products and product candidates resulting from Program 1 and options, subject to certain conditions, to co-fund development of products resulting from two other programs in exchange for a share of profits in the United States. Should Program 1 fail to successfully complete IND-enabling toxicology studies, Merus would be granted an additional option to co-fund development of a program in exchange for a share of profits in the United States. All costs related to the collaboration are subject to joint research and development plans.MCLA-145. Each party will share equally the costs of mutually agreed global development activities for ~~Program 1,~~MCLA-145, and fund itself any independent development activities in its territory. WeMerus will be responsible for ~~all research,~~commercializing MCLA-145 in the United States and we will be responsible for commercializing it outside of the United States.

In addition to receiving rights to MCLA-145 outside of the United States, we received worldwide exclusive development and commercialization ~~costs relating~~rights to ~~all other~~up to ten additional programs. Of these ten additional programs, Merus retained the option, subject to ~~Merus’ election~~certain conditions, to co-fund development ~~and co-detail described above.~~of up to two such programs. If Merus exercises its co-funding option for a program, Merus would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. All costs related to the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. We will be responsible for all research, development and commercialization costs relating to all other programs.

26

Table of Contents

In February 2017, we paid Merus an upfront non-refundable payment of $120.0 ~~million, which is recorded in research and development expense on the condensed consolidated statement of operations.~~million. For each program as to which Merus does not have commercialization or ~~co-development~~development co-funding rights, Merus will be eligible to receive up to $100.0 million in future contingent development and regulatory milestones, and up to $250.0 million in commercialization milestones as well as tiered royalties ranging from 6% to 10% of global net sales. For each program as to which Merus exercises its option to co-fund development, Merus will be eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and be eligible to receive tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to ~~non-co-developed~~ programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to

29

~~Table of Contents~~

4% of net sales in the United States. For ~~Program 1,~~MCLA-145, we and Merus will each be eligible to receive tiered royalties on net sales in the other party’s territory at rates ranging from 6% to 10%.

The Merus agreement will continue on a program-by-program basis until we have no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. The agreement may be terminated in its entirety or on a program-by-program basis by us for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement. If the agreement is terminated with respect to one or more programs, all rights in the terminated programs revert to Merus, subject to payment to us of a reverse royalty of up to 4% on sales of future products, if Merus elects to pursue development and commercialization of products arising from the terminated programs.

In addition, in December 2016, we entered into a Share Subscription Agreement with Merus, pursuant to which we agreed to purchase 3.2 million common shares of Merus for an aggregate purchase price of $80.0 million in cash, or $25.00 per share.

We agreed to certain standstill provisions whereby we are obligated to refrain from taking certain actions with respect to Merus or Merus’ common shares during a period ending on the earliest of (a) three years from the closing date of our share purchase, (b) the date Merus publicly announces any merger or similar business combination or another party announces an intention to acquire a substantial portion of Merus’ securities, and (c) the termination of the Collaboration and License Agreement. The standstill provisions are subject to certain exceptions, including an exception that allows us to maintain our percentage ownership following equity financings by Merus. We also agreed, subject to limited exceptions, not to sell or otherwise transfer any of our Merus shares for a period, referred to as the Lock-Up Period, ending on the earlier of 18 months after the closing date of the sale of the Shares or the end of the standstill period. In addition, if the standstill period has not been terminated earlier upon the occurrence of certain events, for a period of three years after the Lock-Up Period, we will be restricted from selling or otherwise transferring more than one-third of our Merus shares during any 12-month period or 10% of our Merus shares during any three-month period, unless Merus consents otherwise. We have further agreed that during the standstill period, we will vote all of our Merus shares in accordance with the recommendation of a majority of Merus’ supervisory board. However, we may vote our Merus shares at our own discretion for certain extraordinary matters, including a change in control of Merus. Merus has agreed to customary resale registration rights with respect to our Merus shares; however, any such resales will be subject to the Lock-Up Period and volume limitations on sale and transfer described above.

We completed the purchase of the shares on January 23, 2017 when the closing price on The ~~NASDAQ~~Nasdaq Stock Market for Merus shares was $24.50 per share. The shares we acquired were not registered under the Securities Act of 1933 on the purchase date and ~~are~~were subject to certain security specific restrictions for a period of time, and accordingly, we estimated a discount for lack of marketability on the shares on the issuance date of $5.6 million, which resulted in a ~~total~~net fair value of the shares on the issuance date of $72.8 million. Of the total consideration paid of $80.0 million, $72.8 million was allocated to our stock purchase in Merus and was recorded as a long term investment ~~on the condensed consolidated balance sheets~~ and $7.2 million was allocated to research and development ~~expense on the condensed consolidated statement of operations during the nine months ended September 30, 2017.~~expense. The fair market value of our total long term investment in Merus at June 30, 2020 and December 31, 2019 was ~~$63.6~~$51.5 million ~~as of September 30, 2017.~~and $45.1 million, respectively.

We ~~have~~ concluded Merus is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of ~~September~~June 30, ~~2017,~~2020, we owned approximately ~~17%~~11% of the outstanding common shares of Merus ~~common stock~~ and conclude that we have the ability to exercise significant influence, but not control, over Merus based primarily on our ownership interest, the level of intra-entity transactions between us and Merus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Merus whereby the investment is marked to market through earnings in each reporting period. We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three and six months ended ~~September~~June 30, ~~2017,~~2020, we recorded an unrealized gain of ~~$12.9~~$12.7 million and ~~for~~$6.4 million, respectively, based on the ~~nine~~change in fair market value of Merus’ common shares during these periods. For the three and six months ended ~~September~~June 30, ~~2017~~2019, we recorded an unrealized loss of ~~$9.2~~$0.4 million and an unrealized gain of $2.1 million, respectively, based on the change in fair market value of Merus’ common ~~stock~~shares during these periods.

30

~~Table~~For the three months ended March 31, 2020, Merus reported within its Form 10-Q total revenues of ~~Contents~~

approximately $6.3 million and net loss of approximately $16.5 million within their condensed consolidated financial statements.

Research and development expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 included $1.9 million and $4.2 million, respectively, of additional development costs incurred pursuant to the Merus agreement. Research and development expenses for the three and six months ended June 30, 2019 included $1.7 million and $4.3 million, respectively, of additional development costs incurred pursuant to the Merus agreement. At ~~September~~June 30, ~~2017,~~2020 and December

27

Table of Contents

31, 2019, a total of ~~$1.8~~$2.0 million and $1.6 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance ~~sheet.~~sheets.

Calithera

In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. (“Calithera”). Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including CB-1158, which is currently in ~~phase~~Phase I clinical trials, for hematology and oncology indications. We have agreed to co-fund 70% of the global development costs for the development of the licensed products for hematology and oncology indications. Calithera will have the right to conduct certain clinical development under the collaboration, including combination studies of a licensed product with a proprietary compound of Calithera. We will be entitled to 60% of the profits and losses from net sales of licensed product in the United States, and Calithera will have the right to co-detail licensed products in the United States, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products outside the United States. Calithera may opt out of its co-funding obligation, in which case the U.S. profit sharing will no longer be in effect, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products both in the United States and outside the United States, and additional royalties to reimburse Calithera for previously incurred development costs.

In January 2017, we paid Calithera an upfront license fee of $45.0 million and have agreed to pay potential development, regulatory and sales milestone payments of over $430.0 million if the profit share is in effect, or $750.0 million if the profit share terminates. In 2017, we paid Calithera a $12.0 million milestone for the achievement of pharmacokinetic and pharmacodynamics goals for CB-1158 which was recorded in research and development expense.

The Calithera agreement will continue on a product-by-product and country-by-country basis for so long as we are developing or commercializing products in the United States (if the parties are sharing profits in the United States) and until we have no further royalty payment obligations, unless earlier terminated according to the terms of the agreement. The agreement may be terminated in its entirety or on a product-by-product and/or a country-by-country basis by us for convenience. The agreement may also be terminated by us for Calithera’s uncured material breach, by Calithera for our uncured material breach and by either party for bankruptcy or patent challenge. If the agreement is terminated early with respect to one or more products or countries, all rights in the terminated products and countries revert to Calithera.

In addition, in January 2017, we entered into a Stock Purchase Agreement with Calithera for the purchase of ~~1,720,430~~1.7 million common shares of Calithera for an aggregate purchase price of $8.0 million in cash, or $4.65 per share. We completed the purchase of the shares on January 30, 2017 when the closing price on The ~~NASDAQ~~Nasdaq Stock Market was $6.75 per share. The shares we acquired were registered under the Securities Act of 1933 on the purchase date and there ~~are~~were no security specific restrictions for these shares, and therefore the value of the 1.7 million shares acquired by us was $11.6 million. We paid total consideration of $53.0 million to Calithera, composed of the $45.0 million upfront license fee and the $8.0 million stock purchase price. Of the $53.0 million, $11.6 million was allocated to our stock purchase in Calithera and was recorded within long term investments ~~on the condensed consolidated balance sheets~~ and $41.4 million was allocated to research and development ~~expense on the condensed consolidated statement of operations during the nine months ended September 30, 2017.~~expense. The fair market value of our long term investment in Calithera ~~is $27.1~~at June 30, 2020 and December 31, 2019 was $9.1 million ~~as of September 30, 2017.~~and $9.8 million, respectively.

We ~~have~~ concluded Calithera is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of ~~September~~June 30, ~~2017,~~2020, we owned approximately 5%2% of the outstanding shares of Calithera common stock and there are several other stockholders who hold larger positions of Calithera. As we do not hold a significant position of the voting shares of Calithera and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in Calithera for the foreseeable future and therefore, we are accounting for our shares held in Calithera ~~as an available-for-sale investment, whereby~~at fair value, and the investment is marked to market through earnings in each ~~period with unrealized gains and losses recorded in accumulated other comprehensive income (loss).~~reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance ~~sheet.~~

31

~~Table of Contents~~

sheets. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020 we recorded an unrealized gain of $1.5 million and ~~$15.5~~an unrealized loss of $0.7 million, respectively, ~~within other comprehensive income~~ based on the change in fair market value of Calithera’s common

28

Table of Contents

stock during these periods. For the three and six months ended June 30, 2019 we recorded an unrealized loss of $4.9 million and $0.2 million, respectively, based on the change in fair market value of Calithera’s common stock during these periods.

In March 2017, Calithera earned a $12.0 million milestone payment from us for the achievement of pharmacokinetic and pharmacodynamics goals for CB-1158 which is recorded in research and development expense on our condensed consolidated statement of operations during the nine months ended September 30, 2017. Research and development expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 also included ~~$2.3~~$1.9 million and ~~$5.9~~$4.4 million, respectively, of additional development costs incurred pursuant to the Calithera agreement. Research and development expenses for the three and six months ended June 30, 2019 also included $5.4 million and $10.0 million, respectively, of additional development costs incurred pursuant to the Calithera agreement. At ~~September~~June 30, ~~2017,~~2020 and December 31, 2019, a total of ~~$2.0~~$1.3 million and $1.1 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.

MacroGenics

In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics, Inc. (“MacroGenics”). Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics’ INCMGA0012 (formerly MGA012), an investigational monoclonal antibody that inhibits PD-1. Except as set forth in the succeeding sentence, we will have sole authority over and bear all costs and expenses in connection with the development and commercialization of INCMGA0012 in all indications, whether as a monotherapy or as part of a combination regimen. MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012. In addition, MacroGenics has the right to manufacture a portion of both companies’ global clinical and commercial supply needs of INCMGA0012. In 2017, we paid MacroGenics an upfront payment of $150.0 million, which was recorded in research and development expense. MacroGenics was initially eligible to receive up to $420.0 million in future contingent development and regulatory milestones and up to $330.0 million in commercial milestones as well as tiered royalties ranging from 15% to 24% of global net sales. In 2018, we paid MacroGenics a $10.0 million and a $5.0 million milestone for the achievement of certain clinical milestones as part of our collaboration and license agreement, which were recorded in research and development expense.

The MacroGenics agreement will continue until we are no longer commercializing, developing or manufacturing INCMGA0012 or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated in its entirety or on a licensed product by licensed product basis by us for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement.

Research and development expenses for the three and six months ended June 30, 2020 also included $16.3 million and $32.7 million, respectively, of additional development costs incurred pursuant to the MacroGenics agreement. Research and development expenses for the three and six months ended June 30, 2019 also included $9.8 million and $19.2 million, respectively, of additional development costs incurred pursuant to the MacroGenics agreement. At June 30, 2020 and December 31, 2019, a total of $0.5 million and $1.0 million of such costs were included in accrued and other liabilities on the condensed consolidated balance ~~sheet.~~sheets.

Syros

In January 2018, we entered into a target discovery, research collaboration and option agreement with Syros Pharmaceuticals, Inc. (“Syros”). Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to 7 validated targets. We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. We have agreed to pay Syros up to $54.0 million in target selection and option exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration against each of the seven selected and validated targets, we have agreed to pay up to $50.0 million in potential development and regulatory milestones and up to $65.0 million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of products resulting from the collaboration. In January 2018, we paid Syros an upfront non-refundable (except in the event of a material breach of the agreement by Syros) payment of $10.0 million, which was recorded in research and development expense.

29

Table of Contents

In addition, in January 2018, we entered into a Stock Purchase Agreement with Syros for the purchase of 0.8 million common shares of Syros for an aggregate purchase price of $10.0 million in cash, or $12.61 per share. We agreed to not sell or otherwise transfer any of our Syros shares for a period, referred to as the Lock-Up Period, of 12 months after the closing date of the sale. We completed the purchase of the shares on January 8, 2018 when the closing price on The Nasdaq Stock Market was $9.77 per share. The shares we acquired were not registered on the purchase date, and accordingly, we estimated a discount for lack of marketability on the shares of $0.1 million, which resulted in a net fair value of the shares on the issuance date of $7.6 million. Of the $10.0 million aggregate purchase price paid, $7.6 million was allocated to our stock purchase in Syros and was recorded within long term investments and $2.4 million, representing premium paid on the purchase, was allocated to research and development expense. Also in January 2018, we entered into an Amended Stock Purchase Agreement with Syros for the purchase of an additional 0.1 million common shares of Syros for an aggregate purchase price of $1.4 million in cash, or $9.55 per share. The shares were acquired in February 2018 and the $1.4 million aggregate purchase price was recorded within long term investments on the condensed consolidated balance sheets. All acquired shares were subsequently registered under the Securities Act of 1933 in February 2018. The fair market value of our long term investment in Syros as of June 30, 2020 and December 31, 2019 was $10.0 million and $6.5 million, respectively.

We concluded Syros is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of June 30, 2020, we owned approximately 2% of the outstanding shares of Syros common stock and there are several other stockholders who hold larger positions of Syros. As we do not hold a significant position of the voting shares of Syros and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in Syros for the foreseeable future and therefore, are accounting for our shares held in Syros at fair value, and the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and six months ended June 30, 2020, we recorded an unrealized gain of $4.4 million and $3.5 million, respectively, based on the change in fair market value of Syros’ common stock during these periods. For the three and six months ended June 30, 2019, we recorded an unrealized gain of $0.2 million and $3.5 million, respectively, based on the change in fair market value of Syros’ common stock during these periods.

Innovent

In December 2018, we entered into a research collaboration and licensing agreement with Innovent. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to our clinical-stage product candidates pemigatinib, itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In January 2019, we recognized an upfront payment under this agreement of $40.0 million upon our transfer of the functional intellectual property related to the clinical-stage product candidates to Innovent, which was recorded in milestone and contract revenues on the condensed consolidated statement of operations. The upfront milestone was recognized as revenue at a point in time upon our transfer of the licenses to Innovent for the right to use the functional intellectual property. In June 2019, we recognized the $20.0 million milestone for the first related IND filing in China, which was recorded in milestone and contract revenues. In addition, we were initially eligible to receive up to an additional $129.0 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Innovent and decisions made by regulatory agencies.

In April 2020, we recognized a $5.0 million milestone for the FDA approval of pemigatinib as PEMAZYRE, which was recorded in milestone and contract revenues.

In the event of commercialization of the licensed molecule, we are eligible to receive up to $202.5 million in potential sales milestones from Innovent. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Innovent. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the three product candidates in the Innovent territories.

30

Table of Contents

Research and development expenses for the three and six months ended June 30, 2020 were net of $2.6 million of costs reimbursed by Innovent. Research and development expenses for the three and six months ended June 30, 2019 were net of $0.5 million of costs reimbursed by Innovent. At June 30, 2020 and December 31, 2019, $2.2 million and $3.0 million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets.

Zai Lab

In July 2019, we entered into a collaboration and license agreement with Zai Lab. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In August 2019, we recognized an upfront payment under this agreement of $17.5 million upon our transfer of the functional intellectual property related to the licensed product candidate to Zai Lab, which was recorded in milestone and contract revenues. The upfront milestone was recognized as revenue at a point in time upon our transfer of the license to Zai Lab for the right to use the functional intellectual property.

The agreement allows for Zai Lab to continue development of the licensed molecule and to submit the licensed molecule to authorities for regulatory approval within the agreement territory, upon which we are eligible for up to $22.5 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Zai Lab and decisions made by regulatory agencies.

In the event of commercialization of the licensed molecule, we are eligible to receive up to $37.5 million in potential sales milestones from Zai Lab. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Zai Lab. We are also eligible to receive tiered royalties from the low to mid-twenties on future product sales resulting from the collaboration. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab’s licensed territories.

Research and development expenses for the three and six months ended June 30, 2020 were net of $0.0 million and $0.2 million, respectively, of costs reimbursed by Zai Lab. At June 30, 2020 and December 31, 2019, $0.2 million and $0.5 million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets.

MorphoSys

In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG (together with MorphoSys AG, “MorphoSys”), covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc. In December 2019, MorphoSys submitted a Biologics License Application to the FDA for tafasitamab for the treatment of relapsed or refractory diffuse large B cell lymphoma. The agreement became effective in March 2020 after clearance by the German and Austrian antitrust authorities and expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.

Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and MorphoSys responsible for 45% of such costs. Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to

31

Table of Contents

territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan.

In March 2020, we paid MorphoSys an upfront non-refundable payment of $750.0 million which was recorded in research and development expense on the condensed consolidated statement of operations for the three months ended March 31, 2020. MorphoSys is eligible to receive up to $740.0 million in future contingent development and regulatory milestones and up to $315.0 million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. MorphoSys’ right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.

In addition, under the collaboration agreement and pursuant to a related purchase agreement, we agreed to purchase American Depositary Shares (“ADSs”), each representing 0.25 of an ordinary share of MorphoSys AG, for an aggregate purchase price of $150.0 million or $41.33 per ADS (such ADSs to be purchased, the “New ADSs”). We agreed, subject to limited exceptions, not to sell or otherwise transfer any of the New ADSs for an 18-month period after the closing date of the sale. We completed the purchase of the ADSs on March 3, 2020 when the closing price on The Nasdaq Stock Market was $27.65 per ADS. The New ADSs were not registered under the Securities Act of 1933 on the purchase date, and accordingly, we estimated a discount for lack of marketability on the shares of $4.9 million, which resulted in a net fair value of the shares on the issuance date of $95.5 million. Of the $150.0 million aggregate purchase price paid, $95.5 million was allocated to our stock purchase in MorphoSys and was recorded within long term investments and $54.5 million, representing the premium paid on the purchase, was allocated to research and development expense. The fair market value of our long term investment in MorphoSys as of June 30, 2020 was $113.1 million.

We concluded MorphoSys is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of June 30, 2020, we owned approximately 3% of the outstanding shares of MorphoSys common stock and there are several other stockholders who hold larger positions of MorphoSys. As we do not hold a significant position of the voting shares of MorphoSys and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in MorphoSys for the foreseeable future and therefore, are accounting for our shares held in MorphoSys at fair value, and the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three and six months ended June 30, 2020, we recorded an unrealized gain of $27.5 million and $17.6 million, respectively, based on the change in fair market value of MorphoSys’ common stock during these periods.

Our 50% share of the United States loss for the commercialization of tafasitamab was $13.3 million and $15.4 million, respectively, for the three and six months ended June 30, 2020 and is recorded as collaboration loss sharing on the condensed consolidated statement of operations. Research and development expenses for the three and six months ended June 30, 2020, includes $15.7 million and $27.3 million related to our 55% share of the co-development costs for tafasitamab. At June 30, 2020, $37.5 million was included in accrued and other liabilities on the condensed consolidated balance sheet for amounts due to MorphoSys under the agreement.

10. Stock compensation

We recorded ~~$34.9~~$46.3 million and ~~$99.3~~$88.8 million of stock compensation expense on our condensed consolidated statements of operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020, respectively. We recorded ~~$26.5~~$40.6 million and ~~$68.6~~$81.2 million of stock compensation expense on our condensed consolidated statements of operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016,~~2019, respectively. Stock compensation expense included within our condensed consolidated statements of operations included research and development expense of ~~$23.4~~$32.5 million, ~~$67.8~~$61.2 million, ~~$16.2~~$27.6 million and ~~$42.8~~$55.0 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 and ~~2016,~~2019, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included selling, general and administrative expense of ~~$11.5~~$13.6 million, ~~$31.5~~$27.1 million, ~~$10.3~~$12.8 million and $25.8 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~ 2020

32

Table of Contents

and ~~2016,~~2019, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included cost of product revenues of $0.2 million, $0.5 million, $0.2 million and $0.4 million, respectively, for the three and six months ended June 30, 2020. For the three and six months ended June 30, 2020 and 2019, we capitalized $0.1 million, $0.3 million, $0.1 million and $0.2 million, respectively, of stock compensation expense as part of the cost of an asset.

We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:


	Employee Stock Options								Employee Stock Purchase Plan
	For the Three Months Ended				For the Nine Months Ended				For the Three Months Ended				For the Nine Months Ended
	September 30,								September 30,
	2017		2016		2017		2016		2017		2016		2017		2016

																	Employee Stock Options								Employee Stock Purchase Plan
																	For the Three Months Ended				For the Six Months Ended				For the Three Months Ended				For the Six Months Ended
																	June 30,								June 30,
																	2020		2019		2020		2019		2020		2019		2020		2019
Average risk-free interest rates	1.81	%	1.05	%	1.79	%	1.31	%	1.47	%	0.77	%	1.37	%	0.77	%	0.33	%	2.26	%	1.32	%	2.49	%	0.16	%	1.75	%	0.19	%	2.10	%
Average expected life (in years)	4.99		4.96		5.24		4.99		0.50		0.50		0.50		0.50		5.48		5.55		4.80		5.34		0.50		0.50		0.50		0.50
Volatility	48	%	50	%	49	%	50	%	39	%	38	%	41	%	48	%	39	%	39	%	40	%	45	%	38	%	37	%	48	%	34	%
Weighted-average fair value (in dollars)	55.80		36.66		53.81		39.29		20.46		18.33		19.89		18.94		34.13		30.92		29.49		31.47		19.50		13.11		17.47		13.69

The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of zero is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. Nonemployee awards are measured on the grant date by estimating the fair value of the equity instruments to be issued using the expected term, similar to our employee awards.

Option activity under ~~the~~our 2010 Amended and Restated Stock Incentive Plan (the “2010 Stock Plan”) was as follows:


		Shares Subject to
		Outstanding Options
	Shares Available		Weighted Average
	for Grant	Shares	Exercise Price
Balance at December 31, 2016	6,327,138	11,504,572	$	48.40

					Shares Subject to
					Outstanding Options
						Weighted Average
					Shares	Exercise Price
Balance at December 31, 2019					12,632,657	$	81.42
Options granted	(2,437,233)	2,437,233	$	120.15	1,123,442	$	83.01
Options exercised	—	(2,546,517)	$	30.68	(1,602,004)	$	49.13
Options cancelled	116,586	(116,586)	$	96.30	(274,941)	$	93.91
Balance at September 30, 2017	4,006,491	11,278,702	$	67.41
Balance at June 30, 2020					11,879,154	$	85.63

32

~~Table of Contents~~

In July 2016, we revised the terms of our annual stock option grants to provide that new option grants would generally have a 10-year term and vest over four years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments. Previously, our option grants generally had ~~7-year~~7-year terms and vested over three years, with 33% vesting after one year and the remainder vesting in 24 equal monthly installments.

33

Table of Contents

Restricted stock unit (“RSU”) and performance share (“PSU”) award activity under the 2010 Stock Plan was as follows:


		Shares Subject to
	Shares Available	Outstanding Awards
	for Grant	Shares	Grant Date Value
Balance at December 31, 2016	1,146,152	1,246,570	$	82.05

					Shares Subject to
					Outstanding Awards
					Shares	Grant Date Value
Balance at December 31, 2019					2,602,376	$	79.69
RSUs granted	(396,331)	396,331	$	126.45	415,017	$	81.56
RSUs released					(92,818)	$	85.93
RSUs cancelled	41,376	(41,376)	$	89.68	(62,956)	$	80.10
RSUs released	—	(382,133)	$	127.72
PSUs released	—	(43,376)	$	122.29
Balance at September 30, 2017	791,197	1,176,016	$	100.86
PSUs cancelled					(142,250)	$	68.79
Balance at June 30, 2020					2,719,369	$	80.33

In January 2014, we began granting RSUs and PSUs to our employees at the share price on the date of grant. Each RSU represents the right to acquire ~~one~~1 share of our common stock. Each RSU granted prior to July 2016 was subject to cliff vesting after three years. In July 2016, we revised the terms of our RSU grants to provide that the awards will vest 25% annually over four years.

~~Also, in January 2014, Hervé Hoppenot, our President~~In June 2018, we granted 190,000 RSUs and ~~Chief Executive Officer, was~~446,500 PSUs under long term incentive plans with performance and/or service-based milestones with graded and/or cliff vesting over three to four years. In April 2019, we granted ~~a one-time grant~~an additional 100,000 PSUs under one of ~~400,000 RSUs outside~~the existing long term incentive plans with performance based milestones and cliff vesting. For one of the existing long term incentive plans, under which 106,500 PSUs were granted, the actual number of shares of our common stock into which each PSU may convert was subject to a multiplier of up to 267% based on the level at which the performance conditions were achieved. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 142% based on the performance conditions being achieved as of March 31, 2019 and will continue to vest through June 2022. For an existing long term incentive plan, under which 150,000 PSUs were granted, the actual number of shares of our common stock into which each PSU may convert was subject to a multiplier of up to 100% if all performance conditions were achieved or 0% if no performance conditions were achieved. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 100% based on the performance conditions being achieved as of December 31, 2019 and will cliff vest in June 2021.

Compensation expense for the performance-based awards is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. For the period ended June 30, 2020, the stock compensation expense recorded during the period was for service-based awards and performance conditions deemed probable of achievement and/or achieved. For PSUs containing performance conditions which were not deemed probable of achievement at June 30, 2020, no stock compensation expense was recognized.

In July 2018, we granted 77,243 PSUs to executives with performance milestones and graded vesting over four years. The shares of our common stock into which each PSU may convert is subject to a multiplier up to 150% based on the level at which the performance condition is achieved. Compensation expense for the performance-based awards is recorded over the estimated service period when the performance condition is deemed probable of achievement. The actual number of shares of our common stock into which each PSU converted was at a multiplier of 83% based on the performance condition being achieved as of December 31, 2018. These PSUs will continue to vest through July 2022.

In July 2019, we granted 86,975 PSUs to executives with a performance milestone and graded vesting over four years. The shares of our common stock into which each PSU may convert is subject to a multiplier up to 125% based on the level at which the performance condition is achieved. Compensation expense for the performance-based awards is recorded over the estimated service period when the performance condition is deemed probable of achievement. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 101.8% based on the performance condition being achieved as of December 31, 2019. These PSUs will continue to vest through July 2023.

34

Table of Contents

The following table summarizes our shares available for grant under the 2010 Stock Incentive Plan. Vesting of the RSUs will be subject to Mr. Hoppenot’s continued employment on the applicable vesting dates, with one-sixth of the RSUs vesting at the end of each of the calendar years 2014 through 2019, subject to earlier acceleration of vesting upon the occurrence of certain events in accordance with the terms of his employment agreement. As of September 30, 2017, a cumulative total of 200,000 RSUs granted to Mr. Hoppenot had vested and were released, leaving 200,000 RSUs outstanding.Plan:


		Shares Available
		for Grant
Balance at December 31, 2019		9,882,122
Options, RSUs and PSUs granted		(1,953,476)
Options, RSUs and PSUs cancelled		506,744
Balance at June 30, 2020		8,435,390

Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of 5% for our options, RSUs and ~~RSUs.~~PSUs. Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.

Total compensation cost of options granted but not yet vested, as of ~~September~~June 30, ~~2017,~~2020, was ~~$110.4~~$79.9 million, which is expected to be recognized over the weighted average period of approximately 1.3 years. Total compensation cost of RSUs granted but not yet vested, as of June 30, 2020, was $77.9 million, which is expected to be recognized over the weighted average period of approximately 1.6 years. Total compensation cost of ~~RSUs~~PSUs granted but not yet vested, as of ~~September~~June 30, ~~2017,~~2020, was ~~$65.0~~$21.4 million, which is expected to be recognized over the weighted average period of ~~approximately 1.6 years. There were no unvested PSUs as~~1.5 years, should the underlying performance conditions be deemed probable of ~~September 30, 2017.~~achievement.

~~The~~

11. Accrued and other current liabilities

Accrued and other current liabilities consisted of the following ~~table summarizes our share activity:~~(in thousands):


		~~Shares Issued~~
		~~and Outstanding~~
~~Balance at December 31, 2016~~		~~188,848,752~~
~~Exercise of stock options and issuance under ESPP~~		~~2,643,324~~
~~Settlement of employee restricted stock units and performance shares~~		~~285,958~~
~~Conversion of convertible senior notes~~		~~14,296,332~~
~~Public issuance of common stock~~		~~4,945,000~~
~~Balance at September 30, 2017~~		~~211,019,366~~


	June 30,		December 31,
	2020		2019
Royalties	$	77,800	$	73,221
Clinical related costs		95,172		88,710
Sales allowances		71,085		59,924
Construction in progress		14,817		12,732
Operating lease liabilities		10,059		9,343
Other current liabilities		71,957		42,020
Total accrued and other current liabilities	$	340,890	$	285,950

33

~~Table of Contents~~

~~11. Common stock offering~~

On September 7, 2017, we completed a public offering of 4,945,000 shares of our authorized but unissued common stock pursuant to an effective shelf registration statement. The underwriter had an option for a period of 30 days to purchase a maximum of 741,750 additional shares of our common stock, which expired unexercised. We sold the shares of common stock to the underwriter at a price of $131.46 per share, resulting in net proceeds, after deducting expenses related to the offering, of approximately $649.4 million.

12. Debt

The components of the convertible senior notes are as follows (in thousands):


				Carrying Amount,
	Interest Rates			September 30,		December 31,

											Carrying Amount,
								Interest Rates			June 30,		December 31,
Debt	September 30, 2017		Maturities	2017		2016		June 30, 2020		Maturities	2020		2019
0.375% Convertible Senior Notes due 2018	0.375	%	2018	$	7,303	$	340,916
1.25% Convertible Senior Notes due 2020	1.25	%	2020		16,408		310,565	1.25	%	2020	$	18,588	$	18,300
					23,711		651,481
Less current portion					—		—
				$	23,711	$	651,481

The carrying amount and fair value of our convertible senior notes are as follows (in thousands):


	September 30, 2017				December 31, 2016
	Carrying				Carrying
	Amount		Fair Value		Amount		Fair Value
0.375% Convertible Senior Notes due 2018	$	7,303	$	17,467	$	340,916	$	749,988

									June 30, 2020				December 31, 2019
									Carrying				Carrying
									Amount		Fair Value		Amount		Fair Value
1.25% Convertible Senior Notes due 2020		16,408		43,534		310,565		761,300	$	18,588	$	38,298	$	18,300	$	32,511
	$	23,711	$	61,001	$	651,481	$	1,511,288

The fair ~~values~~value of ~~the 0.375% Convertible Senior Notes due 2018 (the “2018 Notes”) and~~ the 1.25% Convertible Senior Notes due November 15, 2020 (the “2020 Notes”) ~~are~~is based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, ~~these convertible senior notes are~~is classified within Level 2 in the fair value hierarchy.

35

Table of Contents

Prior to May 14, 2014, the ~~2018 and~~ 2020 Notes were not convertible except in connection with a ~~make whole~~make-whole fundamental change, as defined in the ~~respective indentures.~~indenture. Beginning on, and including, May 15, 2014, the ~~2018 and~~ 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, ~~2018, in the case of the 2018 Notes, and May 15,~~ 2020 ~~in the case of the 2020 Notes,~~ only under the following circumstances: ~~(1)~~(i) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the ~~2018 Notes or~~ 2020 Notes ~~as applicable,~~ on each applicable trading day; ~~(2)~~(ii) during the ~~five~~5 business day period after any ~~five~~5 consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of ~~2018 Notes or~~the 2020 Notes ~~as applicable,~~ for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the ~~2018 Notes or~~ 2020 Notes ~~as applicable,~~ on each such trading day; or ~~(3)~~(iii) upon the occurrence of specified corporate events. On or after May 15, ~~2018, in the case of the 2018 Notes, and May 15,~~ 2020 ~~in the case of the 2020 Notes,~~ until the close of business on the second scheduled trading day immediately preceding the relevant maturity date, the 2020 Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.

On October 1, 2017, the 2018 Notes and 2020 Notes became convertible through at least December 31, 2017, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended

34

~~Table of Contents~~

September 30, 2017 as described in (1) above. Management’s intent is to settle any conversions of 2018 Notes or 2020 Notes during this period in shares of our common stock and, therefore, the 2018 Notes andThe 2020 Notes are reflected in ~~long term~~current liabilities on the condensed consolidated balance sheet ~~at September~~as of June 30, ~~2017.~~2020 due to their maturity date of November 15, 2020, unless earlier purchased or converted.

13. Employee benefit plans

~~During the nine months ended September 30, 2017, we entered into separately negotiated agreements with certain holders~~Defined Contribution Plans

We have a defined contribution plan qualified under Section 401(k) of the 2018 Notes pursuant to which such holders agreed to exchange a total of $367.2 million in aggregate principal amount of the 2018 Notes for the shares of our common stock into which the 2018 Notes were originally convertible, aggregating 7.1 million shares, an additional 0.1 million of premium shares (equivalent to $12.6 million in value)Internal Revenue Code covering all U.S. employees and $2.0 million in cash. Similarly we entered into separately negotiated agreements with certain holders of the 2020 Notes pursuant to which such holders agreed to exchange a total of $355.6 million in aggregate principal amount of the 2020 Notes for the shares of our common stock into which the 2020 Notes were originally convertible, aggregating 6.9 million shares, an additional 0.2 million of premium shares (equivalent to $26.8 million in value) and $7.0 million in cash. Included in the agreements were those with entities affiliated with Julian C. Baker, one of our directors, which agreed to exchange $259.0 million in aggregate principal amount of the 2018 Notes and $274.5 million in aggregate principal amount of the 2020 Notes for an aggregate of 10.6 million shares.

Pursuant to the guidance within the ASC 470-20-40-20, we measured the difference between the fair value and carrying value of the liability portion of the Notes which resulted in recording expense related to senior note conversions of $1.4 million related to the 2018 Notes and $5.1 million related to the 2020 Notes. The estimated fair value of the debt component was determined using a valuation model which is subject to judgement. Assumptions used within the valuation model include an estimated credit rating and an estimated market-based cost of debt. These assumptions were used to perform a discounted cash flow analysis on the future interest and principal payments to determine the estimated fair value of the debt at inducement.

In addition, the fair value of the premium shares issued pursuant to these agreements as well as the cash paid in connection with the agreements totaled $48.4 million and is also included within expense related to senior note conversions on the condensed consolidated statement of operations during the nine months ended September 30, 2017.

~~13. Defined benefit pension obligation~~

~~In connection with the Acquisition, we assumed a~~ defined ~~benefit pension plan for the former ARIAD employees. In addition, we established another defined benefit pension plan~~contribution plans for other Incyte employees in ~~Europe. The~~Europe and Japan. Employees may contribute a portion of their compensation, which is then matched by us, subject to certain limitations. Defined contribution expense for the three and six months ended June 30, 2020 was $3.3 million and $6.6 million, respectively. Defined contribution expense for the three and six months ended June 30, 2019 was $3.1 million and $6.0 million, respectively.

Defined Benefit Pension Plans

We have defined benefit pension plans for our employees in Europe which provide benefits to employees upon retirement, death or disability. The assets of the pension plans are held in collective investment accounts represented by the cash surrender value of an insurance policy and are classified as Level 2 within the fair value hierarchy.

The net periodic benefit cost was as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016

									Three Months Ended				Six Months Ended
									June 30,				June 30,
									2020		2019		2020		2019
Service cost	$	760	$	365	$	2,056	$	503	$	1,477	$	1,288	$	2,934	$	2,550
Interest cost		57		29		155		39		47		86		93		169
Expected return on plan assets		(43)		(23)		(116)		(31)		(31)		(61)		(61)		(120)
Amortization of prior service cost		12		—		37		—		53		62		107		107
Amortization of actuarial losses		34		—		102		—		167		46		334		112
Net periodic benefit cost	$	820	$	371	$	2,234	$	511	$	1,713	$	1,421	$	3,407	$	2,818

The components of net periodic benefit cost other than the service cost component are included in other income (expense), net on the condensed consolidated statements of operations. We expect to contribute a total of ~~$2.1~~$4.0 million to the pension plans in ~~2017~~2020 inclusive of the amounts contributed to the plan during the current period. As of ~~September~~June 30, ~~2017~~2020 and December 31, ~~2016, $7.3~~2019, $25.2 million and ~~$7.1~~$24.1 million, respectively, of accrued pension obligation is recorded in other long term liabilities on the condensed consolidated balance sheets.

36

Table of Contents

14. Income taxes

The Company is subject to U.S. federal, state and foreign income taxes. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020, we recorded income tax expense of approximately ~~$7.3~~

35

~~Table of Contents~~

$17.0 million and ~~an income tax benefit of $0.5~~$33.5 million, ~~respectively, compared to~~respectively. For the three and six months ended June 30, 2019, we recorded income tax expense of approximately ~~$1.4~~$3.4 million and ~~$2.6~~$5.1 million, ~~for the three and nine months ended September 30, 2016.~~respectively. The change in tax expense ~~or benefit~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017 and 2016~~2020 was primarily driven by ~~the difference in projected annual~~increased federal and state tax liabilities that are not fully sheltered by net operating ~~income~~losses or ~~loss compared to our actual results as well as the recognition of certain discrete items~~research and development tax credit carryforwards. The increase was also driven by reduced tax benefits for stock-based compensation in the current period. ~~As a result, our year-to-date recorded effective tax rate may differ significantly from our full year effective tax rate.~~

As of ~~September~~June 30, ~~2017,~~2020, a full valuation allowance continues to be recorded against our U.S. and Swiss net deferred tax assets. ~~This position is based on an~~Based upon our analysis of ~~positive~~our historical operating results, as well as projections of our future taxable income (losses) during the periods in which the temporary differences will be recoverable, we believe the uncertainty regarding the realization of our U.S. and ~~negative evidence, including analyzing three-year cumulative pre-tax income or loss,~~Swiss net deferred tax assets requires a full valuation allowance against such net assets as of June 30, 2020. When performing our assessment on projections of future taxable income (losses), we consider factors such as ~~well as~~the likelihood of regulatory approval and commercial success of products currently under development, among other ~~quantitative and qualitative information.~~factors.

~~Our liability for~~The balance of our unrecognized tax benefits (including penalties and interest) increased by approximately ~~$3.6~~$0.8 million during the ~~nine~~six months ended ~~September~~June 30, ~~2017, of which only $0.6 million was recorded as an increase to noncurrent other liabilities on the condensed consolidated balance sheet.~~2020. The overall net increase is primarily driven by unrecognized tax benefits related to current year ~~operations.~~

~~In October 2017, we secured an incentive~~operations and research and development tax ~~holiday~~credits offset by audit settlements in ~~Switzerland that exempts us from certain Swiss income taxes for~~Wisconsin and Italy. After considering valuation allowance impacts, the change in unrecognized tax benefits resulted in a ~~period of 10 years.~~$0.2 million decrease to noncurrent other liabilities on the condensed consolidated balance sheet.

15. Net income (loss) per share

Net income (loss) per share was calculated as follows for the periods ~~indicated:~~indicated below:

Three Months Ended

Nine Months Ended


September 30,

September 30,

(in thousands, except per share data)


2017

2016


2017

2016

Basic Net Income (Loss) Per Share

Basic net income (loss)

$
36,054

$
36,877

$
(163,513)

$
95,349

Weighted average common shares outstanding

206,796

188,029

202,399

187,632

Basic net income (loss) per share

$
0.17

$
0.20

$
(0.81)

$
0.51

Diluted Net Income (Loss) Per Share

Diluted net income (loss)

$
36,054

$
36,877

$
(163,513)

$
95,349

Weighted average common shares outstanding

206,796

188,029

202,399

187,632

Dilutive stock options and RSUs

5,814

6,236

—

6,122

Weighted average shares used to compute diluted net income (loss) per share

212,610

194,265

202,399

193,754

Diluted net income (loss) per share

$
0.17

$
0.19

$
(0.81)

$
0.49


	Three Months Ended				Six Months Ended
	June 30,				June 30,
(in thousands, except per share data)		2020	2019			2020	2019
Basic Net Income (Loss) Per Share
Basic net income (loss) per share	$	290,298	$	105,318	$	(430,344)	$	207,630
Weighted average common shares outstanding		217,549		214,620		217,135		214,342

Basic net income (loss) per share	$	1.33	$	0.49	$	(1.98)	$	0.97

Diluted Net Income (Loss) Per Share
Diluted net income (loss)	$	290,298	$	105,318	$	(430,344)	$	207,630
Weighted average common shares outstanding		217,549		214,620		217,135		214,342

Dilutive stock options and awards		2,885		2,863		—		2,932

Weighted average shares used to compute diluted net income (loss) per share		220,434		217,483		217,135		217,274

Diluted net income (loss) per share	$	1.32	$	0.48	$	(1.98)	$	0.96

3637

Table of Contents

The ~~following~~ potential common shares that were excluded from the ~~calculations~~diluted net income (loss) per share computation are as ~~their effect would be anti-dilutive:~~follows:


	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2017	2016	2017	2016

					Three Months Ended		Six Months Ended
					June 30,		June 30,
					2020	2019	2020	2019
Outstanding stock options and awards	2,399,468	3,119,097	12,654,718	2,947,152	4,970,884	9,165,776	14,598,523	9,221,941
Common shares issuable upon conversion of the 2018 Notes	149,527	7,245,206	149,527	7,245,206
Common shares issuable upon conversion of the 2020 Notes	368,939	7,241,284	368,939	7,241,284	365,752	368,939	365,752	368,939
Total potential common shares excluded from diluted net loss per share computation	2,917,934	17,605,587	13,173,184	17,433,642
Total potential common shares excluded from diluted net income (loss) per share computation					5,336,636	9,534,715	14,964,275	9,590,880

16. Contingencies

In ~~February 2016,~~December 2018, we received a ~~Paragraph IV certification notice (the “Notice Letter”~~civil investigative demand from the U.S. Department of Justice (“DOJ”) ~~regarding an Abbreviated New Drug Application submitted~~for documents and information relating to our speaker programs and patient assistance programs, including our support of non-profit organizations that provide financial assistance to eligible patients. We have cooperated with this inquiry. In November 2019, the qui tam complaint underlying the DOJ inquiry was unsealed (“Complaint”), at which time we learned that a former employee whom we had terminated had made certain allegations relating to the ~~U.S. Food~~programs described above. We then became aware that the DOJ had not intervened in the qui tam action, and, ~~Drug Administration requesting approval~~ to ~~market a generic version~~our knowledge, the DOJ has not intervened to date. We filed an answer to the Complaint on January 22, 2020, and the action is proceeding. We cannot predict the outcome or the timing of ~~Jakafi (ruxolitinib). The Notice Letter purports to challenge patents covering ruxolitinib phosphate and its use that expire in 2028. The Notice Letter does not challenge~~ the ~~ruxolitinib composition~~ultimate resolution of ~~matter patent, which expires on December 24, 2027. We do not believe there is any kind~~the investigation or qui tam action, or reasonably estimate the possible range of loss, if any, that may result from these matters. Accordingly, no reserve has been made with respect to these matters as of June 30, 2020.

In the ordinary course of our business, we may become involved in lawsuits, proceedings, and other disputes, including commercial, intellectual property, regulatory, employment, and other matters. We record a reserve for these matters when it is both probable ~~or estimable related to this matter at this time.~~that a liability has been incurred and the amount of the loss can be reasonably estimated.

17. Subsequent ~~Events~~

~~MacroGenics~~event

In ~~October 2017,~~July 2020, we ~~entered into a Global Collaboration~~ and ~~License Agreement (the “Agreement”)~~our collaboration partner MorphoSys AG announced that the FDA approved MONJUVI® (tafasitamab-cxix) in combination with ~~MacroGenics, Inc. (“MacroGenics”). Under~~lenalidomide for the ~~terms~~treatment of ~~the Agreement, we received exclusive development~~adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and ~~commercialization rights worldwide to MGA012, an investigational monoclonal antibody that inhibits programmed~~who are not eligible for autologous stem cell death protein 1 (PD‑1). MGA012 is currently in clinical development by MacroGenics. We have agreed to pay MacroGenics an upfront payment of $150.0 million. MacroGenics will be eligible to receive up to $420.0 million in future contingent development and regulatory milestones and up to $330.0 million in commercialization milestones as well as tiered royalties ranging from 15% to 24% of global net sales. The effectiveness of the Agreement is conditionedtransplant. MONJUVI was approved under accelerated approval based on the early termination or expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976; provided, that certain provisions, including those relating to indemnification and termination for material breach, became effective upon execution of the Agreement.overall response rate.

3738

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations as of and for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements as of and for the year ended December 31, ~~2016~~2019 included in our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2019 previously filed with the SEC.

This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. Often, these statements include the words “believe,” “expect,” “target,” “anticipate,” “intend,” “plan,” “seek,” “estimate,” “potential,” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” or “may,” or the negative of these terms, and other similar expressions. These forward-looking statements include statements as to:

·

●

the discovery, development, formulation, manufacturing and commercialization of our compounds, our drug candidates and JAKAFI®/JAKAVI® (ruxolitinib), PEMAZYRE^® (pemigatinib), ICLUSIG® (ponatinib) and ~~ICLUSIG~~® ~~(ponatinib)~~MONJUVI® (tafasitamab);

·

●

~~the expected benefits from our acquisition of ARIAD Pharmaceuticals (Luxembourg) S.à.r.l. and~~ our plans to further develop our ~~European operations;~~

operations outside of the United States;

·

●

conducting clinical trials internally, with collaborators, or with clinical research organizations;

·

●

our collaboration and strategic relationship ~~strategy;~~strategy, and anticipated benefits and disadvantages of entering into collaboration agreements;

·

●

our licensing, investment and commercialization strategies, including our plans to commercialize JAKAFI, PEMAZYRE, ICLUSIG and ~~ICLUSIG;~~

MONJUVI;

·

●

the regulatory approval process, including obtaining U.S. Food and Drug Administration and other international health authorities approval for our products in the United States and abroad;

·

●

the safety, effectiveness and potential benefits and indications of our drug candidates and other compounds under development;

·

●

the timing and size of our clinical trials; the compounds expected to enter clinical trials; timing of clinical trial results;

·

●

our ability to manage expansion of our drug discovery and development operations;

·

●

future required expertise relating to clinical trials, manufacturing, sales and marketing;

·

●

obtaining and terminating licenses to products, drug candidates or technology, or other intellectual property rights;

·

●

the receipt from or payments pursuant to collaboration or license agreements resulting from milestones or royalties;

·

●

plans to develop and commercialize products on our own;

·

●

plans to use ~~third party~~third-party manufacturers;

●

plans for our manufacturing operations;

39

Table of Contents

·

●

expected expenses and expenditure levels; expected uses of cash; expected revenues and sources of revenues, including milestone payments; expectations with respect to inventory;

38

~~Table of Contents~~

·

●

expectations with respect to reimbursement for our products;

·

●

the expected impact of recent accounting ~~pronouncements;~~

pronouncements and changes in tax laws;

·

●

expected losses; fluctuation of losses; currency translation impact associated with collaboration royalties;

·

●

our profitability; the adequacy of our capital resources to continue operations;

·

●

the need to raise additional capital;

·

●

the costs associated with resolving matters in litigation;

·

●

our expectations regarding competition;

·

●

expectations relating to our new European headquarters, including construction activities, and the anticipated completion date for our large molecule production facility;

●

our investments, including anticipated expenditures, losses and expenses;

·

●

our patent prosecution and maintenance efforts; and

·

●

the potential effects of the COVID-19 pandemic and efforts undertaken or to be undertaken by us or applicable governmental authorities on local and global economic conditions, and on our ~~indebtedness,~~business, results of operations and ~~debt service obligations.~~

financial condition.

These ~~forward‑looking~~forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from those projected and include, but are not limited to:

·

●

our ability to successfully commercialize JAKAFI, ICLUSIG, PEMAZYRE and ~~ICLUSIG;~~

MONJUVI;

·

●

our ability to maintain at anticipated levels reimbursement for our products from government health administration authorities, private health insurers and other organizations;

·

●

our ability to establish and maintain effective sales, marketing and distribution capabilities;

·

●

the risk of reliance on other parties to manufacture our products, which could result in a short supply of our products, increased costs, and withdrawal of regulatory approval;

·

●

our ability to maintain regulatory approvals to market our products;

·

●

our ability to achieve a significant market share in order to achieve or maintain profitability;

·

●

the risk of civil or criminal penalties if we market our products in a manner that violates health care fraud and abuse and other applicable laws, rules and regulations;

·

●

our ability to discover, develop, formulate, manufacture and commercialize our drug candidates;

·

●

the risk of unanticipated delays in, or discontinuations of, research and development efforts;

·

●

the risk that previous preclinical testing or clinical trial results are not necessarily indicative of future clinical trial results;

40

Table of Contents

·

●

risks relating to the conduct of our clinical trials;

·

●

changing regulatory requirements;

·

●

the risk of adverse safety findings;

39

~~Table of Contents~~

·

●

the risk that results of our clinical trials do not support submission of a marketing approval application for our drug candidates;

·

●

the risk of significant delays or costs in obtaining regulatory approvals;

·

●

risks relating to our reliance on ~~third party~~third-party manufacturers, collaborators, and clinical research organizations;

·

●

risks relating to the development of new products and their use by us and our current and potential collaborators;

·

●

risks relating to our inability to control the development of ~~out‑licensed~~out-licensed compounds or drug candidates;

·

●

risks relating to our collaborators’ ability to develop and commercialize JAKAVI, OLUMIANT, TABRECTA and the drug ~~candidates;~~

candidates licensed from us;

·

●

costs associated with prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights;

·

●

our ability to maintain or obtain adequate product liability and other insurance coverage;

·

●

the risk that our drug candidates may not obtain or maintain regulatory approval;

·

●

the impact of technological advances and competition, including potential generic competition;

·

●

our ability to compete against third parties with greater resources than ours;

·

●

risks relating to changes in pricing and reimbursement in the markets in which we may compete;

·

●

risks relating to governmental healthcare reform efforts, including efforts to control, set or cap pricing for our commercial drugs in the U.S and abroad;

●

competition to develop and commercialize similar drug products;

·

●

our ability to obtain and maintain patent protection and freedom to operate for our discoveries and to continue to be effective in expanding our patent coverage;

·

●

the impact of changing laws on our patent portfolio;

·

●

developments in and expenses relating to litigation;

·

●

~~the satisfaction of conditions to closing for land purchase agreements;~~

·

our ability to ~~in‑license~~in-license drug candidates or other technology;

●

unanticipated construction, other delays or changes in plans relating to our new European headquarters and large molecule production facility;

41

Table of Contents

·

●

our ability to integrate successfully acquired businesses, development programs or technology;

·

●

~~our substantial leverage;~~

·

our ability to obtain additional capital when needed;

·

●

fluctuations in net cash provided and used by operating, financing and investing activities;

·

●

our ability to analyze the effects of new accounting pronouncements and apply new accounting rules;

·

●

our history of operating losses; ~~and~~

40

~~Table of Contents~~

·

●

risks related to public health pandemics such as the COVID-19 pandemic; and

●

the risks set forth under “Risk Factors.”

Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

In this report all references to “Incyte,” “we,” “us,” “our” or the “Company” mean Incyte Corporation and our subsidiaries, except where it is made clear that the term means only the parent company.

Incyte, JAKAFI and ~~JAKAFI~~PEMAZYRE are our registered trademarks. We also refer to trademarks of other corporations and organizations in this Quarterly Report on Form 10-Q.

Overview

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware. We conduct our European clinical development operations from our offices in Geneva, Switzerland, and Lausanne, ~~Switzerland, and have recently opened~~Switzerland; our Japanese office is in Tokyo.

COVID-19

Effects of the COVID-19 Pandemic on Our Business

In December 2019, coronavirus disease of 2019, or COVID-19, was first reported in Wuhan, China. In March 2020, the World Health Organization declared COVID-19 a pandemic (“the COVID-19 Pandemic”) and certain governments, including the State of Delaware where our primary offices and laboratory spaces are located, enacted stay-at-home orders and sweeping restrictions to travel and business activity were initiated by corporations and governments.

We took aggressive, proactive actions early on to protect the health of our employees, and their families, including voluntarily requiring almost all personnel across our global enterprise to work remotely and restricting access to our sites to personnel who were required to perform critical business continuity activities. In May 2020, we initiated a return to full laboratory work at our facilities in Wilmington, Delaware, as well as a gradual return to office-based working, where allowed under local guidelines, at our offices in North America, Europe and Japan.

While we currently believe we are well-positioned to function in a hybrid on-site and virtual or remote fashion, the extent of the COVID-19 Pandemic’s effect on our operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, protective measures, and the reimposition of protective measures, implemented by governmental authorities or by us to protect our employees, and effects of the pandemic and such protective measures on our suppliers, collaborators, services providers and healthcare organizations serving patients, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. As a result, it is not currently possible to ascertain or predict the overall long-term impact of the COVID-19 Pandemic on our business.

42

Table of Contents

To date, we have not seen a material effect on the results of our commercial operations, or our manufacturing supply chain, and we have increased manufacturing efforts of ruxolitinib to respond to the COVID-19 Pandemic and to pre-clinical and clinical study requests. New patient starts for JAKAFI treatment decreased as a result of shelter in place and other protective measures, and if decreases in new patient starts continue, our revenues in future periods could be adversely affected. We continue to anticipate that short-term effects may continue to emerge across different aspects of our global clinical trial programs. For example, while we expect ongoing monitoring of already-enrolled patients to continue, difficulties in monitoring may result as a consequence of shelter in place orders and other protective measures implemented by governmental authorities or clinical trial sites. In addition, new patient recruitment in certain clinical trials has been and may in the future be impacted, in particular with respect to our earlier stage clinical trials. We also expect the conduct of clinical trials may continue to vary by disease state and by severity of disease, as well as by geography, as some regions are more adversely impacted. Until our return to full laboratory work, our discovery laboratories were staffed by essential personnel, and hence certain discovery programs experienced delays. Still, we caution that the duration and severity of the continuing COVID-19 Pandemic remains uncertain and we may not yet be able to assess its consequences accurately or fully at this time.

Clinical Trials to Address COVID-19

In April 2020, we announced the initiation of a Phase III clinical trial (RUXCOVID) to evaluate the efficacy and safety of ruxolitinib plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm. The SoC therapy is currently evolving and could be subject to change. We sponsor this collaborative study in the United States and our collaboration partner Novartis International Pharmaceutical Ltd. sponsors the study outside of the United States.

We have also opened a second Phase III clinical trial in the United States to evaluate the efficacy and safety of ruxolitinib plus SoC, compared to SoC therapy alone, in COVID-19 patients on mechanical ventilation and who have acute respiratory distress syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. The SoC therapy is currently evolving and could be subject to change.

We have launched an Expanded Access Program in the United States to allow eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib.

In April 2020, our collaboration partner Eli Lilly and Company announced that it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to study baricitinib as an arm in NIAID's Adaptive COVID-19 Treatment Trial. The study is investigating the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19 in the US, and Lilly is also planning an expansion to include Europe and Asia.

In addition, in June 2020, Lilly announced that the first patient had been enrolled in a Phase III randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib in hospitalized adults with COVID-19.

Marketed Indications - JAKAFI (ruxolitinib)

JAKAFI (ruxolitinib) is our first product to be approved for sale in the United States. It was approved by the U.S. Food and Drug Administration (FDA) in November 2011 for the treatment of ~~patients~~adults with intermediate or ~~high‑risk~~high-risk myelofibrosis, ~~and~~ in December 2014 for the treatment of ~~patients~~adults with polycythemia vera who have had an inadequate response to or are intolerant of ~~hydroxyurea.~~hydroxyurea and in May 2019 for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. Myelofibrosis and polycythemia vera are both myeloproliferative neoplasms (MPNs), a type of rare blood ~~cancers.~~cancer, and GVHD is an adverse immune response to an allogeneic hematopoietic stem cell transplant (HSCT). Under our collaboration agreement with Novartis, ~~International Pharmaceutical Ltd.,~~ Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib outside of the United States under the name JAKAVI.

43

Table of Contents

In 2003, we initiated a research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The JAK family is composed of four tyrosine kinases—JAK1, JAK2, JAK3 and Tyk2—that are involved in the signaling of a number of cytokines and growth factors. JAKs are central to a number of biologic processes, including the formation and development of blood cells and the regulation of immune functions. Dysregulation of the ~~JAK‑STAT~~JAK-STAT signaling pathway has been associated with a number of diseases, including myeloproliferative neoplasms, other hematological malignancies, rheumatoid arthritis and other chronic inflammatory diseases. Myeloproliferative neoplasms are a closely related group of blood diseases in which blood cells, specifically platelets, white blood cells, and red blood cells, grow or act abnormally. These diseases include myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET).

We have discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the most advanced compound in our JAK program. It is an oral JAK1 and JAK2 inhibitor.

JAKAFI is marketed in the United States through our own specialty sales force and commercial team. JAKAFI was the first ~~FDA‑approved~~FDA-approved JAK inhibitor for any indication and was the first FDA-approved product in all three of its current indications. JAKAFI remains the first-line standard of care in MF and remains the only FDA-approved product ~~approved by the FDA~~ for ~~use in MF~~PV and ~~PV.~~steroid-refractory acute GVHD. The FDA has granted JAKAFI orphan drug status for MF, PV, ET, acute lymphoblastic leukemia (ALL) and ~~graft-versus-host-disease (GVHD).~~GVHD.

To help ensure that all eligible ~~MF and PV~~ patients have access to JAKAFI, we have established a patient assistance program called IncyteCARES (CARES stands for Connecting to Access, Reimbursement, Education and Support). IncyteCARES helps ensure that any patient with intermediate or ~~high‑risk~~high-risk MF, or uncontrolled PV or steroid-refractory acute GVHD who meets certain eligibility criteria and is prescribed JAKAFI has access to the product regardless of ability to pay and has access to ongoing support and educational resources during treatment. ~~In addition, IncyteCARES works closely with payers to help facilitate insurance coverage of JAKAFI.~~

41

~~Table of Contents~~

JAKAFI is distributed primarily through a network of specialty pharmacy providers and wholesalers that allow for efficient delivery of the medication by mail directly to patients or direct delivery to the patient’s pharmacy. Our distribution process uses a model that is ~~well‑established~~well-established and familiar to physicians who practice within the oncology field.

To further support appropriate use and future development of JAKAFI, our U.S. Medical Affairs department is responsible for providing appropriate scientific and medical education and information to physicians, preparing scientific presentations and publications, and overseeing the process for supporting investigator sponsored trials.

Myelofibrosis. Myelofibrosis is a rare, ~~life‑threatening~~life-threatening condition. MF, considered the most serious of the myeloproliferative neoplasms, can occur either as primary MF, or as secondary MF that develops in some patients who previously had polycythemia vera or essential thrombocythemia. We estimate there are between 16,000 and 18,500 patients with MF in the United States. Based on the modern prognostic scoring systems referred to as International Prognostic Scoring System and Dynamic International Prognostic Scoring System, we believe intermediate and ~~high‑risk~~high-risk patients represent 80% to 90% of all patients with MF in the United States and encompass patients over the age of 65, or patients who have or have ever had any of the following: anemia, constitutional symptoms, elevated white blood cell or blast counts, or platelet counts less than 100,000 per microliter of blood.

Most MF patients have enlarged spleens and many suffer from debilitating symptoms, including abdominal discomfort, pruritus (itching), night sweats and cachexia (involuntary weight loss). There were no FDA approved therapies for MF until the approval of JAKAFI.

The FDA approval was based on results from two randomized Phase III trials ~~(COMFORT‑I~~(COMFORT-I and ~~COMFORT‑II)~~COMFORT-II), which demonstrated that patients treated with JAKAFI experienced significant reductions in splenomegaly (enlarged spleen). ~~COMFORT‑I~~COMFORT-I also demonstrated improvements in symptoms. The most common hematologic adverse reactions in both trials were thrombocytopenia and anemia. These events rarely led to discontinuation of JAKAFI treatment. The most common ~~non‑hematologic~~non-hematologic adverse reactions were bruising, dizziness and headache.

In August 2014, the FDA approved supplemental labeling for JAKAFI to include ~~Kaplan‑Meier~~Kaplan-Meier overall survival curves as well as additional safety and dosing information. The overall survival information is based on ~~three‑year~~three-year data from ~~COMFORT‑I~~COMFORT-I and II, and shows that at three years the probability of survival for patients treated with JAKAFI in ~~COMFORT‑I~~COMFORT-I was 70% and for those patients originally randomized to placebo it was 61%. In ~~COMFORT‑II,~~COMFORT-II, at three years the probability of survival for patients treated with JAKAFI was 79% and for patients originally randomized to best

44

Table of Contents

available therapy it was 59%. In December 2016, we announced an exploratory pooled analysis of data from the five-year follow-up of the COMFORT-I and COMFORT-II trials of patients treated with JAKAFI, which further supported previously published overall survival findings.

In September 2016, we announced that JAKAFI had been included as a recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for myelofibrosis, underscoring the important and long-term clinical benefits seen in patients treated with JAKAFI.

In October 2017, the FDA approved updated labeling for JAKAFI to include the addition of new patient-reported outcome (PRO) data from the COMFORT-I study, as well as updating the warning related to progressive multifocal leukoencephalopathy. An exploratory analysis of PRO data of patients with myelofibrosis receiving JAKAFI showed improvement in fatigue-related symptoms at Week 24. Fatigue response (defined as a reduction of 4.5 points or more from baseline in the ~~PROMIS®~~PROMIS^® Fatigue total score) was reported in 35% of patients treated with JAKAFI versus 14% of the patients treated with placebo.

In September 2016, we announced that JAKAFI had been included as a recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for myelofibrosis, underscoring the important and long-term clinical benefits seen in patients treated with JAKAFI.

Polycythemia Vera. PV is a myeloproliferative neoplasm typically characterized by elevated hematocrit, the volume percentage of red blood cells in whole blood, which can lead to a thickening of the blood and an increased risk of blood clots, as well as an elevated white blood cell and platelet count. When phlebotomy can no longer control PV, chemotherapy such as hydroxyurea, or interferon, is utilized. Approximately 25,000 patients with PV in the United States are considered uncontrolled because they have an inadequate response to or are intolerant of hydroxyurea, the most commonly used chemotherapeutic agent for the treatment of PV.

42

~~Table of Contents~~

In December 2014, the FDA approved JAKAFI for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. The approval of JAKAFI for PV was based on data from the pivotal Phase III RESPONSE trial. In this trial, patients treated with JAKAFI demonstrated superior hematocrit control and reductions in spleen volume compared to best available therapy. In addition, a greater proportion of patients treated with JAKAFI achieved complete hematologic remission—which was defined as achieving hematocrit control, and lowering platelet and white blood cell counts. In the RESPONSE trial, the most common hematologic adverse reactions (incidence > 20%) were thrombocytopenia and anemia. The most common ~~non‑hematologic~~non-hematologic adverse events (incidence >10%) were headache, abdominal pain, diarrhea, dizziness, fatigue, pruritus, dyspnea and muscle spasms.

In March 2016, the FDA approved supplemental labeling for JAKAFI to include additional safety data as well as efficacy analyses from the RESPONSE trial to assess the durability of response in JAKAFI treated patients after 80 weeks. At this time, 83% patients were still on treatment, and 76% of the responders at 32 weeks maintained their response through 80 weeks.

In June 2016, we announced data from the Phase 3III RESPONSE-2 study of JAKAFI in patients with inadequately controlled PV that was resistant to or intolerant of hydroxyurea who did not have an enlarged spleen. These data showed that JAKAFI was superior to best available therapy in maintaining hematocrit control (62.2% vs. 18.7%, respectively; P<0.0001) without the need for phlebotomy.

In August 2017, we announced that JAKAFI had been included as a recommended treatment in the latest NCCN Guidelines for patients with polycythemia vera who have had an inadequate response to first-line therapies, such as hydroxyurea.

Graft-versus-host disease. GVHD is a condition that can occur after an allogeneic HSCT (the transfer of genetically dissimilar stem cells or tissue). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack various tissues. 12-month survival rates in patients with Grade III or IV steroid-refractory acute GVHD are 50% or less, and the incidence of steroid-refractory acute and chronic GVHD is approximately 3,000 per year in the United States.

In June 2016, we announced that the FDA granted Breakthrough Therapy designation for ruxolitinib in patients with acute GVHD. In May 2019, the FDA approved JAKAFI for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. The approval was based on data from REACH1, an open-label, single-arm,

45

Table of Contents

multicenter study of JAKAFI in combination with corticosteroids in patients with steroid-refractory grade II-IV acute GVHD. The overall response rate (ORR) in patients refractory to steroids alone was 57% with a complete response (CR) rate of 31%. The most frequently reported adverse reactions among all study participants were infections (55%) and edema (51%), and the most common laboratory abnormalities were anemia (75%), thrombocytopenia (75%) and neutropenia (58%).

We have retained all development and commercialization rights to JAKAFI in the United States and are eligible to receive development and ~~commercial~~sales milestones as well as royalties from product sales outside the United States. We hold patents that cover the composition of matter and use of ruxolitinib, which patents, including applicable extensions, expire in late 2027.

Marketed Indications - ICLUSIG (ponatinib)

In June 2016, we acquired the European operations of ARIAD Pharmaceuticals, ~~Inc~~Inc. (ARIAD) and obtained an exclusive license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. ICLUSIG is a kinase inhibitor. The primary target for ICLUSIG is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase ~~chronic myeloid leukemia (CML)~~CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients with ~~Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)~~Ph+ ALL who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

Marketed Indications - PEMAZYRE (pemigatinib)

In April 2020, we announced that the FDA approved PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. PEMAZYRE is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response (DOR).

Cholangiocarcinoma is a rare cancer that arises from the cells within the bile ducts. It is often diagnosed late (stages III and IV) and the prognosis is poor. The incidence of cholangiocarcinoma with FGFR2 fusions or rearrangements is increasing, and it is currently estimated that there are 2,000-3,000 patients in the U.S., Europe and Japan.

The approval of PEMAZYRE was based on data from FIGHT-202, a multi-center, open-label, single-arm study evaluating PEMAZYRE as a treatment for adults with cholangiocarcinoma. In FIGHT-202, and in patients harboring FGFR2 fusions or rearrangements (Cohort A), PEMAZYRE monotherapy resulted in an overall response rate of 36% (primary endpoint), and median DOR of 9.1 months (secondary endpoint). Warnings and precautions included in the PEMAZYRE prescribing information include potential for eye problems such as dry or inflamed eyes, inflamed cornea, increased tears and a disorder of the retina; high levels of phosphate in the blood; and, for women who are pregnant, a risk of harm to the unborn baby or loss of pregnancy. FIGHT-302, a Phase III trial of pemigatinib for the first-line treatment of patients with cholangiocarcinoma and FGFR2 fusions or rearrangements, is ongoing.

We have retained all rights to PEMAZYRE globally, other than those granted to Innovent Biologics, Inc. to develop and commercialize pemigatinib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.

Marketed Indications - MONJUVI (tafasitamab)

In July 2020, we and our collaboration partner MorphoSys AG announced that the FDA approved MONJUVI (tafasitamab-cxix), a CD19-directed cytolytic antibody that is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including

46

Table of Contents

DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). MONJUVI was approved under accelerated approval based on overall response rate.

DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide, comprising 40% of all cases. DLBCL is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs. It is an aggressive disease with 30-40% of patients not responding to initial therapy or relapsing thereafter. We estimate that there are ~10.000 patients diagnosed in the U.S. each year with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) who are not eligible for ASCT.

The approval of MONJUVI was based on data from the MorphoSys-sponsored Phase II L-MIND study, an open label, multicenter, single arm trial of MONJUVI in combination with lenalidomide as a treatment for adult patients with r/r DLBCL. Results from the study showed an objective response rate (ORR) of 55% (39 out of 71 patients; primary endpoint) and a complete response (CR) rate of 37% (26 out of 71 patients). The median duration of response (mDOR) was 21.7 months. The most frequent serious adverse reactions were infections (26%), including pneumonia (7%) and febrile neutropenia (6%).

In January 2020, we entered into a collaboration and licensing agreement with MorphoSys to further develop and commercialize MONJUVI globally. We will co-commercialize MONJUVI with MorphoSys in the United States, and we have exclusive commercialization rights outside the United States.

Clinical Programs in Oncology

We believe that the future of cancer treatment lies in the use of targeted therapies, which aim to block the effects of cancer-causing mutations, and immune therapies, which seek to recruit the patient’s own immune system to tackle ~~cancer, and targeted therapies, which aim to block, directly or indirectly, the effects of cancer-causing mutations.~~cancer. Our most advanced programs are detailed below.

~~We also have~~JAK Inhibition

As part of our ongoing LIMBER (Leadership in MPNs BEyond Ruxolitinib) clinical development initiative, which is designed to improve and expand therapeutic options for patients with myeloproliferative neoplasms, we are evaluating combinations of ruxolitinib with other therapeutic modalities, as well as developing a ~~number~~once-a-day formulation of ~~other early programs at various stages of preclinical~~ruxolitinib for potential use as monotherapy and ~~clinical testing. We intend to describe these programs once~~combination therapy. Based on positive Phase II data, we ~~have obtained clinical proof‑of‑concept and established that~~are preparing a ~~compound within a specific~~pivotal trial program ~~warrants further development.~~

43

~~Table of Contents~~

~~Targeted Therapies~~

~~Building upon positive, independently published third-party data~~ of ruxolitinib in combination with parsaclisib (PI3Kδ) as both first-line therapy for MF patients and in MF patients with an inadequate response to ruxolitinib monotherapy. Additional Phase II trials combining ruxolitinib with investigational agents from our portfolio such as INCB57643 (BET) and INCB00928 (ALK2) in patients with MF are in preparation. Development of the combination of ruxolitinib and INCB53914 (PIM) has been discontinued. There are currently no plans for the further development of INCB53914.

As part of our development efforts to evaluate JAK inhibition in GVHD, ~~we have initiated~~ the REACH clinical program ~~to evaluate~~is evaluating ruxolitinib in patients with steroid-refractory ~~GVHD. REACH1,~~GVHD and includes REACH2, a ~~pivotal Phase II trial in steroid-refractory acute GVHD was initiated in December 2016. REACH2, the~~ Novartis-sponsored Phase III trial in steroid-refractory acute GVHD, and REACH3, ~~the~~a Phase III trial in steroid-refractory chronic GVHD that is co-sponsored by Incyte and ~~Novartis, are both now underway.~~ Novartis.

In ~~June 2016,~~October 2019, we and Novartis announced that REACH2 met its primary endpoint of superior ORR at Day 28 with ruxolitinib treatment compared to best available therapy. No new safety signals were observed, and the ~~FDA granted Breakthrough Therapy Designation for~~ ruxolitinib safety profile in ~~patients~~REACH2 was consistent with that seen in previously reported studies in steroid-refractory acute GVHD. In April ~~2016,~~2020, we and Novartis announced ~~an agreement~~that data from REACH2 were published in The New England Journal of Medicine.

In July 2020, we and Novartis announced that REACH3 met its primary endpoint of superior ORR at Month 6 with ~~Eli Lilly~~ruxolitinib treatment compared to best available therapy, as well as both key secondary endpoints, significantly improving patient-reported symptoms and ~~Company enabling us to develop~~failure-free survival. No new safety signals were observed, and ~~commercialize~~the ruxolitinib safety profile in ~~the United States for the treatment~~REACH3 was consistent with that seen in previously reported studies in steroid-refractory chronic GVHD.

47

Table of ~~GVHD. We also announced an agreement with Novartis granting Novartis exclusive research, development and commercialization rights for ruxolitinib in GVHD outside the United States.~~Contents

A ~~proof-of-concept~~second JAK inhibitor in development is itacitinib, which is a selective JAK1 inhibitor. Itacitinib is being evaluated in GRAVITAS-309, a pivotal Phase III trial of itacitinib ~~a selective JAK1 inhibitor, is ongoing for the treatment of~~in patients with ~~acute~~steroid-naïve chronic GVHD. ~~Based on preliminary data from this trial, a pivotal program investigating itacitinib for the treatment of patients with treatment-naïve acute GVHD was initiated in July 2017.~~ The FDA has granted itacitinib orphan drug status for GVHD.

~~GVHD~~FGFR Inhibition

Pemigatinib is a ~~condition~~potent and selective inhibitor of the fibroblast growth factor receptor (FGFR) isoforms 1, 2 and 3 with demonstrated activity in preclinical studies. The FGFR family of receptor tyrosine kinases can act as oncogenic drivers in a number of liquid and solid tumor types.

We initiated the FIGHT clinical program to evaluate pemigatinib across a spectrum of cancers that can occur after an allogeneic transplant (the transfer of genetically dissimilar stem cells or tissue). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body. We estimate that the long-term survivalare driven by FGF/FGFR alterations. The program initially included three Phase II trials – FIGHT-201 in patients with ~~corticosteroid-refractory GVHD is approximately 5% to 30%~~bladder cancer, FIGHT-202 in patients with cholangiocarcinoma, and ~~that the diagnosed incidence of acute and chronic GVHD is approximately 17,000 per year across the United States and Europe.~~

~~Following positive proof-of-concept~~FIGHT-203 in patients with 8p11 myeloproliferative syndrome (8p11 MPN). Based on data generated from these ongoing trials, we have ~~opened~~initiated additional trials, including FIGHT-205, which is evaluating pemigatinib plus pembrolizumab versus pemigatinib alone versus standard of care for metastatic or unresectable urothelial carcinoma in cisplatin-ineligible patients whose tumors express FGFR3 mutation or rearrangement, and FIGHT-207 which is a ~~pivotal program investigating ruxolitinib~~solid tumor-agnostic trial evaluating pemigatinib in patients with driver-alterations of FGF/FGFR.

In April 2020, we announced the FDA approval of pemigatinib as PEMAZYRE for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Pemigatinib was previously granted Breakthrough Therapy designation by the FDA as a treatment for patients with ~~essential thrombocythemia. ET is~~previously treated, advanced/metastatic or unresectable FGFR2 translocated cholangiocarcinoma and has Breakthrough Therapy designation as a ~~Philadelphia chromosome negative myeloproliferative neoplasm, characterized by the overproduction of platelets in the bone marrow. The pivotal RESET-272 trial will enroll ET~~treatment for patients ~~that~~with myeloid/lymphoid neoplasms with FGFR1 rearrangement (8p11 MPN) who have relapsed or are refractory to ~~or intolerant of hydroxyurea,~~initial chemotherapy. In January 2020, we announced that the ~~current standard of care~~Marketing Authorization Application (MAA) for ~~first-line~~pemigatinib as a treatment of ~~these patients.~~adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy had been validated by the European Medicines Agency (EMA).

CD19 antagonism

In January 2020, we and MorphoSys announced a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary anti-CD19 antibody tafasitamab (MOR208) globally. The agreement became effective March 2020. Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B cell malignancies. We have rights to co-commercialize tafasitamab in the U.S. with MorphoSys, and we have exclusive development and commercialization rights outside of the U.S.

Tafasitamab is being investigated as a ~~portfolio~~therapeutic option in B cell malignancies in a number of ~~wholly-owned selective JAK1 inhibitors, including itacitinib~~ongoing combination trials. An open-label Phase II combination trial (L-MIND) is investigating the safety and ~~INCB52793. The clinical program to evaluate itacitinib in solid tumors includes a clinical trial~~efficacy of tafasitamab in combination with ~~AstraZeneca/MedImmune’s EGFR inhibitor osimertinib. INCB52793 is in a Phase I/II trial~~lenalidomide in patients with ~~advanced malignancies.~~relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL), and the ongoing Phase III B-MIND trial is assessing the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. First-MIND is a Phase Ib safety trial of tafasitamab as a first-line therapy for patients with DLBCL.

PI3K-delta Inhibition

The PI3K-delta pathway mediates oncogenic signaling in B cell malignancies. ~~INCB50465~~Parsaclisib is a PI3K-delta inhibitor that has demonstrated potency and selectivity in preclinical studies and has potential therapeutic utility in the treatment of patients with lymphoma. We ~~have~~ initiated the CITADEL clinical program to evaluate ~~INCB50465~~parsaclisib in non-Hodgkin lymphomas, ~~including patients with diffuse large b-cell lymphoma (DLBCL),~~and we are currently running Phase II trials in follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

INCB54828 is an inhibitor of the FGFR isoforms 1, 2 and 3 that has demonstrated potency and selectivity in preclinical studies. The FGFR family of receptor tyrosine kinases can act as oncogenic drivers in a number of liquid and solid tumor types. We initiated the FIGHT clinical program to evaluate INCB54828 across a spectrum of cancers that are driven by FGF/FGFR mutations. The program now has three Phase II trials enrolling – FIGHT-201 in patients with bladder cancer, FIGHT-202 in patients with cholangiocarcinoma, and FIGHT-203 in patients with 8p11 myeloproliferative syndrome (8p11 MPN).

~~BRDs are a family of proteins which play important roles in mediating gene transcription, most notably by facilitating the~~ expression of oncogenes such as MYC, one of the most frequently dysregulated oncogenes in all human cancer. We have two BRD inhibitors, INCB54329 and INCB57643, in open-label dose-escalation trials in patients with advanced malignancies. The evaluation of these two compounds has enabled an assessment of relative pharmacodynamics and, based on these emerging data, we have now decided to focus our development activities on INCB57643.

INCB53914 is a pan-PIM kinase inhibitor that has demonstrated potency and selectivity in preclinical studies. PIM kinases integrate signals from multiple pathways important for the survival and proliferation of malignant cells. Over

4448

Table of Contents

expression of PIM kinases has been reported in human hematological cancers with each isoform showing a distinct expression pattern among the various malignancy subtypes. A clinical trial of INCB53914 in advanced malignancies is underway.

INCB59872 is an LSD1 inhibitor. LSD1 is a key enzyme that is involved in epigenetic regulation of gene transcription. Dysregulated LSD1 activity can perturb normal gene expression, leading to cellular transformation. In particular, the function of LSD1 has been reported to maintain stem cell-like gene expression patterns in various cancers, including acute myeloid leukemia and small cell lung cancer. A proof-of-concept clinical trial of INCB59872 is underway.

INCB62079 is a selective, irreversible inhibitor of FGFR4 that has exhibited 250 times greater selectivity for FGFR4 than other FGFR isoforms in preclinical studies. Preclinical data has also demonstrated the compound’s selective activity against cancer cell lines with FGF19-FGFR4 pathway activation, and dose-dependent activity in murine models of FGF19-driven hepatocellular carcinoma. A Phase I/II dose escalation trial in patients with advanced hepatocellular carcinoma and other malignancies is now underway.


	~~Indication~~	~~Status Update~~
~~Ruxolitinib (JAK1/JAK2)~~	~~Steroid-refractory acute GVHD~~	~~Pivotal Phase II (REACH1); Phase III (REACH2)~~
~~Ruxolitinib (JAK1/JAK2)~~	~~Steroid-refractory chronic GVHD~~	~~Phase III (REACH3)~~
~~Ruxolitinib (JAK1/JAK2)~~	~~Essential thrombocythemia~~	~~Pivotal Phase II (RESET-272) open for enrollment~~
~~Itacitinib (JAK1)~~	~~Treatment-naïve acute GVHD~~	~~Phase III (GRAVITAS-301)~~
~~Itacitinib (JAK1)~~	~~Non-small cell lung cancer~~	~~Phase I/II in combination with osimertinib (EGFR)~~
~~INCB52793 (JAK1)~~	~~Advanced malignancies~~	~~Phase I/II dose-escalation~~
~~INCB50465 (PI3Kδ)~~	~~Diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma~~	~~Phase II (CITADEL-202 initiated; CITADEL-203, CITADEL-204, CITADEL-205 all open for enrollment)~~
~~INCB54828 (FGFR1/2/3)~~	~~Bladder cancer, cholangiocarcinoma, 8p11 MPNs~~	~~Phase II (FIGHT-201, FIGHT-202, FIGHT-203)~~
~~INCB57643 (BRD)~~	~~Advanced malignancies~~	~~Phase I/II dose-escalation~~
~~INCB53914 (PIM)~~	~~Advanced malignancies~~	~~Phase I/II dose-escalation~~
~~INCB59872 (LSD1)~~	Acute myeloid leukemia, small cell lung cancer	~~Phase I/II dose-escalation~~
~~INCB62079 (FGFR4)~~	~~Hepatocellular carcinoma~~	~~Phase I/II dose-escalation~~

~~Immune Therapies~~

The enzyme indoleamine 2, 3‑dioxygenase‑1 (IDO1) is a key regulator of the mechanisms that are responsible for allowing tumors to escape from a patient’s immune surveillance. IDO1 expression by tumor cells, or by antigen presenting cells such as macrophages and dendritic cells in tumors, creates an environment in which tumor specific cytotoxic T lymphocytes are rendered functionally inactive or are no longer able to attack a patient’s cancer cells. By inhibiting IDO1, it is proposed that this “brake” on the anti‑tumor immune response is removed, allowing anti‑tumor specific cytotoxic T cells, generated in a patient spontaneously in response to the tumor, or through a therapy designed to stimulate the immune response, to have greater anti‑tumor efficacy.

45

~~Table of Contents~~

Epacadostat is a novel, potent and selective inhibitor of the enzyme IDO1, and the ECHO clinical development program will investigate the development of epacadostat in combination with other therapeutic agents, including checkpoint inhibitors, vaccines, epigenetic therapies, and chemotherapies. During 2014, we signed clinical trial collaboration agreements with Merck, Bristol-Myers Squibb, AstraZeneca/MedImmune and Roche/Genentech to evaluate epacadostat with their respective anti-PD-1 and anti-PD-L1 agents, pembrolizumab, nivolumab, durvalumab and atezolizumab, respectively, in Phase I/II trials. We have global development and commercialization rights to epacadostat for all indications.

In October 2015, we and Merck announced an expansion of the companies’ ongoing clinical trial collaboration to include ECHO-301, a Phase III study evaluating the combination of epacadostat with pembrolizumab as a first-line treatment for patients with advanced or metastatic melanoma. In July 2017, the FDA granted Fast Track designation to the ECHO-301 trial to demonstrate a statistically robust and clinically meaningful improvement in progression free survival and/or overall survival compared to patients treated with pembrolizumab alone.

In March 2017, we and Merck announced details of the companies’ planned expansion of the ongoing clinical trial collaboration to include four additional tumor types, evaluating epacadostat plus pembrolizumab in patients with non-small cell lung (NSCLC), renal, bladder, and head & neck cancers. Initial regulatory feedback on the designs of these Phase III trials in additional tumor types has been received, and these trials are expected to be initiated in 2017. In April 2017, we and Bristol-Myers Squibb announced an expansion of our clinical trial collaboration to include two pivotal programs in NSCLC and head & neck cancer. Phase III trials in these additional tumor types are also expected to be initiated in 2017.

In October 2017, we and AstraZeneca announced an expansion of our clinical trial collaboration to include a Phase III trial of epacadostat in combination with AstraZeneca’s PD-L1 inhibitor durvalumab in patients with Stage III NSCLC.

~~In June 2017, we and Roche/Genentech decided to close ECHO-110, the Phase I/II dose escalation trial of epacadostat in combination with atezolizumab, to future enrollment.~~

In January 2017, we licensed worldwide rights from Calithera Biosciences, Inc. to develop and commercialize INCB01158, a first-in-class, small molecule arginase inhibitor in hematology and oncology. In preclinical models, arginase inhibition has been shown to enhance anti-tumor immunity both as a single agent and in combination with other immuno-modulatory therapeutics. INCB01158 is currently being studied as a monotherapy and in combination with the anti-PD-1 agent pembrolizumab.

~~INCSHR1210 is an anti-PD-1 monoclonal antibody that we have licensed under our agreement with Jiangsu Hengrui Medicine Co., Ltd. (Hengrui). Many tumor cells express PD-L1, an immunosuppressive~~ PD-1 ligand. Inhibition of the interaction between PD-1 and PD-L1, known as immune checkpoint blockade, can enhance T-cell responses and mediate preclinical antitumor activity. The dose-escalation portion of the proof-of-concept clinical trial of INCSHR1210 in patients with advanced solid tumors has been completed, revealing a side-effect profile that is different from that seen with other PD-1 inhibitors. Enrollment of new subjects into Part 2 of the Phase I trial was reinitiated in order to confirm the compound’s side effect profile, and enrollment of new subjects has now been halted.Antagonism

In October 2017, we and MacroGenics, Inc. announced an exclusive global collaboration and license agreement for MacroGenics’ ~~MGA012,~~retifanlimab (formerly INCMGA0012), an investigational monoclonal antibody that inhibits PD-1. ~~Upon closing,~~Under this collaboration, we ~~will obtain~~obtained exclusive worldwide rights for the development and commercialization of ~~MGA012~~retifanlimab in all indications. ~~Enrollment in the dose escalation portion of the Phase 1 study of MGA012 has been completed and the~~The molecule is currently being evaluated ~~as monotherapy across four solid tumor types in the dose expansion portion of the study.~~

We have two co-stimulatory antibodies in clinical development. INCAGN1876 is an anti-GITR agonist antibody and INCAGN1949 is an anti-OX40 agonist antibody. Both are programs within our antibody discovery alliance with Agenus Inc. GITR and OX40 are costimulatory receptors that are expressed on effector T cells and is important for T cell survival and enhanced cytokine production. Both are also expressed on regulatory T cells and can abrogate their suppressive function. Preclinical data demonstrate that anti-GITR and anti-OX40 agonist antibodies inhibit tumor growth

46

~~Table of Contents~~

~~by enhancing the levels and function of effector T cells and by decreasing regulatory T cells. Clinical trials of~~ both ~~INCAGN1876 and INCAGN1949 were initiated in 2016, and both agents are being studied~~ as a monotherapy and in combination therapy across various tumor types. Potentially registration-enabling trials in squamous cell carcinoma of the anal canal (SCAC), microsatellite instability-high (MSI-H) endometrial cancer and Merkel cell carcinoma are ongoing.

Preparations are ongoing to initiate both the Phase III POD1UM-304 trial of retifanlimab in combination with ~~other immune checkpoint inhibitors.~~platinum-based chemotherapy as a first-line treatment for patients with non-small cell lung cancer (NSCLC) and the Phase III POD1UM-303 trial of retifanlimab in combination with platinum-based chemotherapy as a first-line treatment for patients with SCAC.

~~We have also launched two platform studies~~Retifanlimab has been granted Fast Track designation for the treatment of certain patients with advanced or metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer and for the treatment of certain patients with locally advanced or metastatic SCAC. The FDA has granted orphan drug designation to ~~investigate the effects of PD-1, JAK1, IDO1 and PI3Kδ inhibition on the tumor microenvironment. The PD-1 platform study is investigating the effects of adding either itacitinib (JAK1)~~retifanlimab as a treatment for patients with locally advanced or ~~INCB50465 (PI3Kδ) to pembrolizumab (PD-1). The JAK1 platform study is investigating all-oral doublets combining either INCB50465 (PI3Kδ) or epacadostat (IDO1) with itacitinib (JAK1).~~metastatic SCAC.


		Indication and status
ruxolitinib (JAK1/JAK2)	~~Indication~~Steroid-refractory chronic GVHD: Phase III (REACH3)¹Primary endpoint met	~~Status Update~~Refractory myelofibrosis: Phase III with parsaclisib (PI3Kδ) in preparation; Phase II with INCB57643 (BET) in preparation Myelofibrosis: Phase II with INCB00928 (ALK2) in preparation
~~Epacadostat (IDO1)~~Once-a-day ruxolitinib (JAK1/JAK2)	~~Unresectable or metastatic, advanced melanoma~~	~~Phase III (ECHO-301) in combination with pembrolizumab (PD-1)~~Myelofibrosis and polycythemia vera: clinical pharmacology studies
~~Epacadostat (IDO1)~~itacitinib (JAK1)	~~NSCLC, renal, bladder, head & neck cancer~~	Treatment-naïve chronic GVHD: Phase III ~~in combination with pembrolizumab (PD-1) expected to begin in 2017~~(GRAVITAS-309)
~~Epacadostat (IDO1)~~pemigatinib (FGFR)	~~NSCLC, head & neck cancer~~	Cholangiocarcinoma: Phase II (FIGHT-202), Phase III ~~in combination with nivolumab (PD-1) expected to begin in 2017~~(FIGHT-302); MAA under review Bladder cancer: Phase II (FIGHT-201, FIGHT-205) 8p11 MPN: Phase II (FIGHT-203) Tumor agnostic: Phase II (FIGHT-207)
~~Epacadostat (IDO1)~~tafasitamab (CD19)²	~~NSCLC~~	r/r DLBCL: Phase II (L-MIND); Phase III ~~in combination with durvalumab (PD-L1) expected to begin in H1 2018~~(B-MIND); MAA under review 1L DLBCL: Phase Ib (First-MIND)
~~Epacadostat (IDO1)~~parsaclisib (PI3Kδ)	~~Multiple tumor types~~	Follicular lymphoma: Phase II ~~(ECHO-202) expansion cohorts in combination with pembrolizumab (PD-1)~~(CITADEL-203) Marginal zone lymphoma: Phase II (CITADEL-204) Mantle cell lymphoma: Phase II (CITADEL-205)
~~Epacadostat (IDO1)~~retifanlimab (PD-1)³	~~Multiple tumor types~~MSI-high endometrial cancer: Phase II (POD1UM-101) Merkel cell carcinoma: Phase II (POD1UM-201) SCAC: Phase II (POD1UM-202); Phase III (PODIUM-303) in preparation NSCLC: Phase III (POD1UM-304) in preparation

^1. Clinical development of ruxolitinib in GVHD conducted in collaboration with Novartis.

^2. Tafasitamab development in collaboration with MorphoSys.

^3. Retifanlimab licensed from MacroGenics.

49

Table of Contents

Earlier-Stage Programs

We also have a number of other earlier-stage clinical programs, as detailed in the table below. We intend to describe these programs more fully if we obtain clinical proof-of-concept and establish that a program warrants further development in a specific indication or group of indications. Based on emerging data from the LSD1 inhibitor program, development of INCB59872 has been discontinued.


Modality	~~Phase II (ECHO-204) expansion cohorts in combination with nivolumab (PD-1)~~Candidates
~~Epacadostat (IDO1)~~Small molecules	~~Multiple tumor types~~INCB01158 (ARG)¹, INCB81776 (AXL/MER), epacadostat (IDO1), INCB86550 (PD-L1)		~~Phase II (ECHO-203) expansion cohorts in combination with durvalumab (PD-L1)~~
~~INCB01158 (ARG)~~1Monoclonal antibodies²	~~Solid tumors~~INCAGN1876 (GITR), INCAGN2385 (LAG-3), INCAGN1949 (OX40), INCAGN2390 (TIM-3)		~~Phase I/II~~
~~INCSHR1210 (PD-1)~~2Bispecific antibodies	~~Solid tumors~~MCLA-145 (PD-L1xCD137)³	~~Phase I/II dose-escalation completed; enrollment halted~~
~~INCAGN1876 (GITR)~~3	~~Solid tumors~~	~~Phase I/II~~
~~INCAGN1949 (OX40)~~3	~~Solid tumors~~	~~Phase I/II~~
~~PD-1 platform study~~	~~Solid tumors~~	~~Phase I/II, pembrolizumab (PD-1) in combination with itacitinib (JAK1) or INCB50465 (PI3Kδ)~~
~~JAK1 platform study~~	~~Solid tumors~~	~~Phase I/II, itacitinib (JAK1) in combination with epacadostat (IDO1) or INCB50465 (PI3Kδ)~~

^1. INCB01158 ~~co-developed~~development in collaboration with Calithera Biosciences, Inc.

^2. ~~INCSHR1210 licensed from Hengrui~~

3. ~~INCAGN1876 & INCAGN1949 from discovery alliance~~ Discovery collaboration with Agenus Inc.

^3. MCLA-145 development in collaboration with Merus N.V.

Clinical Programs outside Oncology

~~In January 2017, we initiated a Phase II trial of ruxolitinib~~Ruxolitinib cream ~~for the topical treatment of atopic~~

Atopic dermatitis. Atopic dermatitis is a skin disorder that causes the skin to become red, scaly, and itchy. Onset can occur at any age, but is ~~much~~ more common in infants and children. In the United States, we estimate that there are approximately 10 million diagnosed and ~~European prevalence are estimated at 10.3 million patients~~treated adolescent and ~~6.5 million patients, respectively.~~

47

~~Table of Contents~~

~~A Phase II trial of topical ruxolitinib in~~adult patients with ~~vitiligo,~~mild to moderate atopic dermatitis.

In April 2020, safety and efficacy data from the two Phase III trials in the TRuE-AD program evaluating ruxolitinib cream in mild-to-moderate atopic dermatitis were presented at the Revolutionizing Atopic Dermatitis (RAD) virtual symposium; both trials met their primary endpoints. The 44-week long-term safety and efficacy portion of both the TRuE-AD1 and TRuE-AD2 trials are ongoing.

Vitiligo. Vitiligo is a ~~long term~~long-term skin condition characterized by patches of the skin losing their ~~pigment,~~pigment. It is estimated that vitiligo affects 0.5-2% of the US population and, therefore, there are at least 1.5 million patients in the United States with this disorder. There are no FDA approved treatments for repigmentation of vitiligo lesions.

In June 2019, primary endpoint data after 6 months of therapy from the Phase II trial of ruxolitinib cream in patients with vitiligo showed a significant benefit over vehicle control, and a global, pivotal Phase III program was initiated in ~~June 2017.~~September 2019. In October 2019, updated data from the Phase II trial showed, after 12 months of therapy, additional improvement in the repigmentation of vitiligo lesions.

Other

A Phase II trial of INCB54707, a JAK1 selective inhibitor, is ongoing in patients with hidradenitis suppurativa, an inflammatory skin disease. A Phase II trial of parsaclisib in patients with autoimmune hemolytic anemia (AIHA), a rare red blood cell disorder, is also ongoing. The FDA has granted orphan drug designation to parsaclisib as a treatment for patients with AIHA.

A Phase II trial of INCB00928 is in preparation for patients with fibrodysplasia ossificans progressiva (FOP), a disorder in which muscle tissue and connective tissue are gradually replaced by bone. The FDA has granted Fast Track designation and orphan drug designation to INCB00928 as a treatment for patients with FOP.

50

Table of Contents

		Indication and status
ruxolitinib cream¹ (JAK1/JAK2)	Atopic dermatitis: Phase III (TRuE-AD1, TRuE-AD2; primary endpoints met)	Vitiligo: Phase III (TRuE-V1, TRuE-V2)
INCB54707 (JAK1)	~~Indication~~Hidradenitis suppurativa: Phase II	~~Status Update~~
~~Topical ruxolitinib (JAK1/JAK2)~~parsaclisib (PI3Kδ)	~~Atopic dermatitis~~	Autoimmune hemolytic anemia: Phase II ~~(topical formulation~~1)
~~Topical ruxolitinib (JAK1/JAK2)~~INCB00928 (ALK2)	~~Vitiligo~~	Fibrodysplasia ossificans progressiva: Phase II ~~(topical formulation~~1)in preparation

^1. Novartis’ rights for ruxolitinib outside of the United States under our Collaboration and License Agreement with Novartis do not include topical administration.

Partnered Programs

Baricitinib

We have a second JAK1 and JAK2 inhibitor, baricitinib, which is subject to our collaboration agreement with ~~Eli~~ Lilly, ~~and Company,~~ in which Lilly received exclusive worldwide development and commercialization rights to the compound for inflammatory and autoimmune diseases. The Phase III program of baricitinib in patients with rheumatoid arthritis incorporated all three rheumatoid arthritis populations (methotrexate naïve, biologic naïve, and tumor necrosis factor (TNF) inhibitor inadequate responders); used event rates to fully power the baricitinib program for structural comparison and non-inferiority vs. adalimumab; and evaluated patient-reported outcomes. All four Phase III trials met their respective primary endpoints.

In January 2016, Lilly submitted ~~a New Drug Application (NDA)~~an NDA to the FDA and ~~a Marketing Authorization Application (MAA)~~an MAA to the ~~European Medicines Agency~~EMA for baricitinib as treatment for rheumatoid arthritis. In February 2017, we and Lilly announced that the European Commission approved baricitinib as OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). In July 2017, ~~Japan's~~the Japanese Ministry of Health, ~~Labor~~Labour and Welfare (MHLW) granted marketing approval for OLUMIANTfor the treatment of rheumatoid arthritis (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies.

In ~~April 2017, we and Lilly announced that~~June 2018, the FDA ~~had issued a complete response letter for~~approved the ~~New Drug Application~~2mg dose of ~~baricitinib as a once-daily oral medication~~OLUMIANT for the treatment of ~~moderate-to-severe~~adults with moderately-to-severely active rheumatoid ~~arthritis. The letter indicates that the FDA is unable~~arthritis (RA) who have had an inadequate response to approve the application in its current form. Specifically, the FDA indicated that additional clinical data are needed to determine the most appropriate doses. The FDA also stated that additional data are necessary to further characterize safety concerns across treatment arms. In August 2017, we and Lilly announced that a resubmission of the NDA for baricitinib is now expected before the end of January 2018. The resubmission package will include new safety and efficacy data. The companies anticipate the FDA will classify the application as a Class II resubmission, which would start a new six-month review cycle.one or more tumor necrosis factor (TNF) inhibitor therapies.

Rheumatoid Arthritis. Rheumatoid arthritis is an autoimmune disease characterized by aberrant or abnormal immune mechanisms that lead to joint inflammation and swelling and, in some patients, the progressive destruction of joints. Rheumatoid arthritis can also affect connective tissue in the skin and organs of the body.

Current rheumatoid arthritis treatments include the use of ~~non‑steroidal anti‑inflammatory~~non-steroidal anti-inflammatory drugs, ~~disease‑modifying anti‑rheumatic~~disease-modifying anti-rheumatic drugs, such as methotrexate, and the newer biological response modifiers that target ~~pro‑inflammatory~~pro-inflammatory cytokines, such as tumor necrosis factor, implicated in the pathogenesis of rheumatoid arthritis. None of these approaches to treatment is curative; therefore, there remains an unmet need for new safe and effective treatment options for these patients. Rheumatoid arthritis is estimated to affect about 1% of the world’s population.

48

~~Table of Contents~~

~~Psoriatic Arthritis~~. Psoriatic arthritis (PsA) is an inflammatory arthritis that is seen in association with skin psoriasis. It causes joint pain and swelling that can lead to damage of the joint if the inflammation is not controlled. Baricitinib has been shown to inhibit the JAK-STAT pathway in related conditions such as psoriasis in Phase II trials, and based on its activity profile, baricitinib also has the potential to demonstrate positive clinical outcomes in PsA. Lilly expects to initiate a Phase III program to evaluate the safety and efficacy of baricitinib in patients with PsA during 2018.

Atopic Dermatitis. Atopic dermatitis (AtD) is a condition that makes the skin red and itchy and which is common in children but can occur at any age. Atopic dermatitis is long lasting and tends to flare periodically and then subside. Lilly has conducted a Phase IIa trial and a Phase III program to evaluate the safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The JAK-STAT pathway has been shown to play an essential role in the dysregulation of immune responses in atopic dermatitis. Therefore, we believe that inhibiting cytokine pathways dependent on JAK1 and JAK2 may lead to positive clinical outcomes in atopic dermatitis.

51

Table of Contents

In ~~September 2017,~~February 2019, we and Lilly announced that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase III studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe AtD and, in August 2019, we and Lilly ~~plans to initiate~~announced that baricitinib met the primary endpoint in BREEZE-AD7, a Phase III ~~program to evaluate~~study evaluating the ~~safety~~efficacy and ~~efficacy~~safety of baricitinib in combination with standard-of-care topical corticosteroids in patients with moderate to severe AtD. In January 2020, we and Lilly announced that baricitinib met the primary endpoint in both BREEZE-AD4 and BREEZE-AD5, the results of which complete the placebo-controlled data program intended to support global registrations. In January 2020, Lilly announced that baricitinib had been submitted for regulatory review in Europe as a treatment for patients with moderate to severe AtD.

Systemic Lupus Erythematosus. Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs and heart, and the brain. Lilly has ~~initiated~~conducted a Phase II trial to evaluate the safety and efficacy of baricitinib in patients with SLE. Baricitinib’s activity profile suggests that it inhibits cytokines implicated in SLE such as type I interferon (IFN), type II IFN-γ, IL-6, and IL-23 as well as other cytokines that may have a role in SLE, including granulocyte macrophage colony stimulating factor (GM-CSF) and IL-12. The potential impact of baricitinib on the IFN pathway is highly relevant to SLE, as clinical and preclinical studies have established that this pathway is involved in the pathogenesis of SLE. Lilly is currently running a Phase III trial of baricitinib in patients with SLE.

Alopecia Areata. Alopecia areata is an autoimmune disorder in which the immune system attacks the hair follicles, causing hair loss in patches. In March 2020, Lilly announced that baricitinib received Breakthrough Therapy designation for the treatment of alopecia areata, based on the positive Phase II results of Lilly’s adaptive Phase II/III study BRAVE-AA1. The Phase III portion of BRAVE-AA1 is ongoing.

We exercised our co-development options in both rheumatoid arthritis and psoriatic arthritis to fund 30% of future global development costs through regulatory approval, including post-launch studies required by a regulatory authority, in exchange for increased tiered royalties ranging up to the high twenties on potential future sales. We also exercised our co-development options in both atopic dermatitis and axial spondyloarthritis, should Lilly decide to progress into a pivotal program in these indications.

Capmatinib

Capmatinib is a potent and highly selective ~~c-MET~~MET inhibitor. The investigational compound has demonstrated inhibitory activity in cell-based biochemical and functional assays that measure ~~c-MET~~MET signaling and ~~c-MET~~MET dependent cell proliferation, survival and migration. Under our agreement, Novartis received worldwide exclusive development and commercialization rights to capmatinib and certain ~~back‑up~~back-up compounds in all indications. Capmatinib is being evaluated in patients with hepatocellular carcinoma, ~~non‑small~~non-small cell lung cancer and other solid tumors, and may have potential utility as a combination agent.

c‑MET is a clinically validated receptor kinase cancer target. Abnormal c‑MET activation in cancer correlates with poor prognosis. Dysregulation of the c‑MET pathway triggers tumor growth, formation of new blood vessels that supply the tumor with nutrients, and causes cancer to spread to other organs. Dysregulation of the c‑MET pathway is seen in many types of cancers, including lung, kidney, liver, stomach, breast and brain.

In May 2020, we and Novartis announced the FDA approval of capmatinib as TABRECTA for the treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. TABRECTA is the first and only treatment approved to specifically target NSCLC with this driver mutation and is approved for first-line and previously treated patients regardless of prior treatment type.

The FDA approval of TABRECTA was based on results from the pivotal GEOMETRY mono-1 study. In the METex14 population (n=97), the confirmed overall response rate was 68% and 41% among treatment-naive (n=28) and previously treated patients (n=69), respectively, based on the Blinded Independent Review Committee (BIRC) assessment per RECIST v1.1. In patients taking TABRECTA, the study also demonstrated a median duration of response of 12.6 months in treatment-naive patients (19 responders) and 9.7 months in previously treated patients (28 responders). The most common treatment-related adverse events (AEs) (incidence ≥20%) are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

In June 2020, we and Novartis announced that the MHLW approved TABRECTA for METex14 mutation-positive advanced and/or recurrent unresectable NSCLC.

4952

Table of Contents

NSCLC is the most common type of lung cancer, impacting more than 2 million people per year globally. Approximately 3-4 percent of all patients with NSCLC have tumors with a mutation that leads to MET exon 14 skipping. Though rare, this mutation is an indicator of especially poor prognosis and poor responses to standard therapies, including immunotherapy.



		Indication and status
baricitinib (JAK1/JAK2)¹	~~Indication~~Atopic dermatitis: Phase III (BREEZE-AD)	~~Status Update~~Systemic lupus erythematosus: Phase III Severe alopecia areata: Phase III (BRAVE-AA1)
~~Baricitinib (JAK1/JAK2)~~1capmatinib (MET)²	~~Rheumatoid arthritis~~	~~Approved in Europe~~NSCLC (with MET exon 14 skipping mutations): FDA and ~~Japan; CRL issued by FDA~~MHLW approved
~~Baricitinib (JAK1/JAK2)~~1	~~Psoriatic arthritis~~	~~Lilly expects the Phase III program to start in 2018~~
~~Baricitinib (JAK1/JAK2)~~1	~~Atopic dermatitis~~	~~Lilly expects the Phase III program to start in late 2017~~
~~Baricitinib (JAK1/JAK2)~~1	~~Systemic lupus erythematosus~~	~~Phase II~~
~~Capmatinib (c-MET)~~2	~~NSCLC, liver cancer~~	~~Phase II in EGFR wild-type ALK negative NSCLC patients with c-MET amplification and mutation~~

^1. Baricitinib licensed to Lilly

^2. Capmatinib licensed to Novartis

License Agreements and Business Relationships

~~As part of our business strategy, we~~We establish business relationships, including collaborative arrangements with other companies and medical research institutions to assist in the clinical development and/or commercialization of certain of our drugs and drug candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies and medical research institutions.

Below is a brief description of our significant business relationships and collaborations and related license agreements that expand our pipeline and provide us with certain rights to existing and potential new products and technologies.

Novartis

In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to ruxolitinib and certain ~~back‑up~~back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. Novartis also received worldwide exclusive development and commercialization rights to our c‑MET inhibitor compound capmatinib and certain ~~back‑up~~back-up compounds in all indications. We retained options to ~~co‑develop~~co-develop and to ~~co‑promote~~co-promote capmatinib in the United States.

Under this agreement, we received an upfront payment and immediate milestone payment totaling $210.0 million and were initially eligible to receive additional payments of up to approximately $1.2 billion if defined development, regulatory and ~~commercialization~~sales milestones are achieved. We are also eligible to receive tiered, ~~double‑digit~~double-digit royalties ranging from the ~~upper‑teens~~upper-teens to the ~~mid‑twenties~~mid-twenties percent on future ruxolitinib net sales outside of the United States, and tiered, worldwide royalties on future capmatinib net sales that range from 12% to 14%. In addition, Novartis has received reimbursement and pricing approval for ruxolitinib in a specified number of countries, and we are now obligated to pay to Novartis tiered royalties in the low ~~single digits~~single-digits on future ruxolitinib net sales within the United States. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.

In April 2016, we amended this agreement to provide that Novartis has exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the GVHD field. Under this amendment, we received a $5.0 million payment in exchange for the development and commercialization rights

50

~~Table of Contents~~

to ruxolitinib in GVHD outside of the United States and became eligible to receive up to $75.0 million of additional potential development and regulatory milestones relating to GVHD.

53

Table of Contents

In ~~March 2017,~~May 2020, we recognized a $25.0 million development milestone ~~payment~~and a $45.0 million regulatory milestone for the ~~first patient first visit~~FDA approval of capmatinib as TABRECTA. In June 2020, we recognized a $20.0 million regulatory milestone for the MHLW approval of TABRECTA. Exclusive of the upfront payment of $150.0 million received in ~~a GVHD study.~~2009 and the immediate milestone of $60.0 million earned in 2010, we have recognized and received, in the aggregate, $157.0 million for the achievement of development milestones, $280.0 million for the achievement of regulatory milestones and $120.0 million for the achievement of sales milestones through June 30, 2020.

The Novartis agreement will continue on a ~~program‑by‑program~~program-by-program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a ~~product‑by‑product~~product-by-product and ~~country‑by‑country~~country-by-country basis until the latest to occur of ~~(1)~~(i) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, ~~(2)~~(ii) the expiration of regulatory exclusivity for the licensed product in such country and ~~(3)~~(iii) a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a ~~program‑by‑program~~program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.

Lilly

In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to baricitinib and certain ~~back‑up~~back-up compounds for inflammatory and autoimmune diseases. We received an initial payment of $90.0 million, and were initially eligible to receive additional payments of up to $665.0 million based on the achievement of defined development, regulatory and ~~commercialization~~sales milestones.

We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding 30% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop. For indications that we elect not to co-develop, we would receive tiered, double-digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized. If we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this, we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we co-funded. We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement.

In July 2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis, and ~~we are~~subsequently in several additional indications, and became responsible for funding 30% of the associated ~~future~~ global development costs for ~~this indication~~such indications from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. In ~~January 2017,~~April 2019, we elected to ~~co-develop~~end additional co-funding of the development of baricitinib ~~with~~in all indications, effective as of January 1, 2019. Pursuant to the terms of the Lilly agreement, we will continue to receive base tiered royalties on global net sales of OLUMIANT in ~~psoriatic arthritis. We also exercised our co-development options in both atopic dermatitis and axial spondyloarthritis, should Lilly decide to progress into a pivotal program in these indications.~~all indications, as well as pro-rated incremental royalties, as described above.

In March 2016, we entered into an amendment to the agreement with Lilly that allows us to engage in the development and commercialization of ruxolitinib in the GVHD field. WeUpon execution of the amendment, we paid Lilly an upfront payment of $35.0 million and Lilly is eligible to receive up to $40.0 million in ~~additional~~ regulatory milestone payments relating to ruxolitinib in the GVHD field.

In ~~February 2017, the European Commission announced~~May 2019, the approval of ~~baricitinib as OLUMIANT, triggering~~JAKAFI in steroid-refractory acute GVHD triggered a ~~$65.0 million milestone payment from Lilly. In July 2017, Japan's MHLW granted marketing approval for OLUMIANT, triggering a $15.0~~$20.0 million milestone payment to ~~Incyte from~~ Lilly.

54

Table of Contents

In May 2020, we amended our agreement with Lilly to enable Lilly to commercialize baricitinib for the treatment of COVID-19. In addition to the royalties described above, we will be entitled to receive additional royalty payments with rates in the low teens on global net sales of baricitinib for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold.

Exclusive of the upfront payment of $90.0 million received in 2009, we have recognized and received, in the aggregate, $149.0 million for the achievement of development milestones and $235.0 million for the achievement of regulatory milestones through June 30, 2020.

The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a ~~product‑by‑product~~product-by-product and ~~country‑by‑country~~country-by-country basis until the latest to occur of ~~(1)~~(i) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, ~~(2)~~(ii) the expiration of regulatory exclusivity for the licensed product in such country and ~~(3)~~(iii) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.

51

~~Table of Contents~~

Agenus

In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus’ antibody discovery platforms. In February 2017, we and Agenus amended this agreement.

Under the terms of this agreement, as amended, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets were profit-share programs until February 2017, while the other targets currently under collaboration are royalty-bearing programs. The February 2017 amendment converted the programs relating to GITR and OX40 to royalty-bearing programs and removed from the collaboration the profit-share programs relating to the two undisclosed targets, with one reverting to us and one reverting to Agenus. Should any of those removed programs be successfully developed by a party, the other party will be eligible to receive the same milestone payments as the royalty-bearing programs and royalties at a 15% rate on global net sales. There are currently no profit-share programs. For each royalty-bearing product other than GITR and OX40, Agenus will be eligible to receive tiered royalties on global net sales ranging from 6% to 12%. For GITR and OX40, Agenus will be eligible to receive 15% royalties on global net sales. Under the February 2017 amendment, we paid Agenus $20.0 million in accelerated milestones relating to the clinical development of the GITR and OX40 programs. Agenus iswas initially eligible to receive up to an additional $510.0 million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration. As of June 30, 2020, we have paid Agenus an aggregate of $10.0 million in development milestones. The agreement may be terminated by us for convenience upon 12 months’ notice and may also be terminated under certain other circumstances, including material breach.

~~Hengrui~~Takeda (ARIAD)

In ~~September 2015,~~June 2016, we ~~entered into a License and Collaboration Agreement with Hengrui. Under~~acquired from ARIAD Pharmaceuticals, Inc. all of the ~~terms~~outstanding shares of ~~this agreement, we received exclusive development and commercialization rights worldwide, with~~ARIAD Pharmaceuticals (Luxembourg) S.à.r.l., the ~~exception~~parent company of Mainland China, Hong Kong, Macau and Taiwan, to INCSHR1210, an investigational PD-1 monoclonal antibody, and certain back-up compounds. We paid to Hengrui an upfront payment of $25.0 million. Hengrui is also eligible to receive potential milestone payments of up to $770.0 million, consisting of $90.0 million for regulatory approval milestones, $530.0 million for commercial performance milestones, and $150.0 million for a clinical superiority milestone. Also, Hengrui may be eligible to receive tiered royalties in the high single digits to mid-double digits based on net sales in our territories. Each company will beARIAD’s European subsidiaries responsible for ~~costs relating to~~ the development and commercialization of ICLUSIG in the ~~PD-1 monoclonal antibody~~European Union and other countries. We obtained an exclusive license to develop and commercialize ICLUSIG in ~~its respective territories.~~Europe and other select countries. ARIAD was subsequently acquired by Takeda Pharmaceutical Company Limited in 2017. As such, Takeda will be eligible to receive from us tiered royalties on net sales of ICLUSIG in our territory and up to $135.0 million in potential future oncology development and regulatory

55

Table of Contents

approval milestone payments, together with additional milestone payments for non-oncology indications, if approved, in our territory.

The agreement will continue on a country-by-country basis until we have no royalty payment obligations with respect to such country or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated in its entirety by us for convenience, and may also be terminated under certain other circumstances, including material breach.

Merus

In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. Under this agreement, which became effective in January 2017, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus’ technology platform. The collaboration encompasses up to eleven independent ~~programs, including two of Merus’ current preclinical immuno-oncology discovery~~ programs. We

The most advanced collaboration program is MCLA-145, a bispecific antibody targeting PD-L1 and CD137, for which we received exclusive development and commercialization rights outside of the United States to products and product candidates resulting from one of Merus’ current preclinical discovery programs, referred to as “Program 1.” We also received worldwide exclusive development and commercialization rights to products and product candidates resulting from the other current Merus preclinical discovery program that is subject to the collaboration and to up to nine additional

52

~~Table of Contents~~

~~programs.~~States. Merus retained exclusive development and commercialization rights in the United States to products and product candidates resulting from Program 1 and options, subject to certain conditions, to co-fund development of products resulting from two other programs in exchange for a share of profits in the United States. Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. Should Program 1 fail to successfully complete IND-enabling toxicology studies, Merus would be granted an additional option to co-fund development of a program in exchange for a share of profits in the United States. All costs related to the collaboration are subject to joint research and development plans.MCLA-145. Each party will share equally the costs of mutually agreed global development activities for ~~Program 1,~~MCLA-145, and fund itself any independent development activities in its territory. WeMerus will be responsible for ~~all research,~~commercializing MCLA-145 in the United States and we will be responsible for commercializing it outside of the United States.

In addition to receiving rights to MCLA-145 outside of the United States, we received worldwide exclusive development and commercialization ~~costs relating~~rights to ~~all other~~up to ten additional programs. Of these ten additional programs, Merus retained the option, subject to ~~Merus’ election~~certain conditions, to co-fund development ~~and co-detail described above.~~of up to two such programs. If Merus exercises its co-funding option for a program, Merus would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. All ~~products as~~costs related to ~~which Merus has exercised its option to co-fund development would be~~the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. We will be responsible for all research, development and commercialization costs relating to all other programs.

In February 2017, we paid Merus an upfront non-refundable payment of $120.0 million. For each program as to which Merus does not have commercialization or ~~co-development~~development co-funding rights, Merus will be eligible to receive up to $100.0 million in future contingent development and regulatory milestones, and up to $250.0 million in commercialization milestones as well as tiered royalties ranging from 6% to 10% of global net sales. For each program as to which Merus exercises its option to co-fund development, Merus will be eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and be eligible to receive tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to ~~non-co-developed~~ programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to 4% of net sales in the United States. For ~~Program 1,~~MCLA-145, we and Merus will each be eligible to receive tiered royalties on net sales in the other party’s territory at rates ranging from 6% to 10%.

The Merus agreement will continue on a program-by-program basis until we have no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. The agreement may be terminated in its entirety or on a program-by-program basis by us for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement. If the agreement is terminated with respect to one or more programs, all rights in the terminated programs revert to Merus, subject to payment to us of a reverse royalty of up to 4% on sales of future products, if Merus elects to pursue development and commercialization of products arising from the terminated programs.

Calithera

In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase

56

Table of Contents

inhibitors, including INCB01158 (CB-1158), which is currently in ~~phase~~Phase I clinical trials, for hematology and oncology indications. We have agreed to co-fund 70% of the global development costs for the development of the licensed products for hematology and oncology indications. Calithera will have the right to conduct certain clinical development under the collaboration, including combination studies of a licensed product with a proprietary compound of Calithera. We will be entitled to 60% of the profits and losses from net sales of licensed product in the United States, and Calithera will have the right to co-detail licensed products in the United States, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products outside the United States. Calithera may opt out of its co-funding obligation, in which case the U.S. profit sharing will no longer be in effect, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products both in the United States and outside the United States, and additional royalties to reimburse Calithera for previously incurred development costs.

53

~~Table of Contents~~

Calithera retains rights to certain arginase inhibitors that are not part of the collaboration for specific orphan indications outside of hematology and oncology, subject to our rights to negotiate a license for any such programs under specified circumstances if Calithera elects to out-license them.

In January 2017, we paid Calithera an upfront license fee of $45.0 million and have agreed to pay potential development, regulatory and sales milestone payments of over $430.0 million if the profit share is in effect, or $750.0 million if the profit share terminates.

The Calithera agreement will continue on a product-by-product and country-by-country basis for so long as we are developing or commercializing products in the United States (if the parties are sharing profits in the United States) and until we have no further royalty payment obligations, unless earlier terminated according to the terms of the agreement. The agreement may be terminated in its entirety or on a product-by-product and/or a country-by-country basis by us for convenience. The agreement may also be terminated by us for Calithera’s uncured material breach, by Calithera for our uncured material breach and by either party for bankruptcy or patent challenge. If the agreement is terminated early with respect to one or more products or countries, all rights in the terminated products and countries revert to Calithera.

MacroGenics

In October 2017, we entered into a Global Collaboration and ~~MacroGenics announced an~~License Agreement with MacroGenics. Under this agreement, we received exclusive ~~global collaboration~~development and ~~license agreement for~~commercialization rights worldwide to MacroGenics’ ~~MGA012,~~INCMGA0012, an investigational monoclonal antibody that inhibits PD-1. WeExcept as set forth in the succeeding sentence, we will have ~~obtained exclusive worldwide rights for~~sole authority over and bear all costs and expenses in connection with the development and commercialization of ~~MGA012~~INCMGA0012 in all indications, ~~while~~whether as a monotherapy or as part of a combination regimen. MacroGenics ~~retains~~has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with MGA012. Upon closing, we will pay MacroGenics an upfront payment of $150.0 million. MacroGenics will also be eligible to receive up to $420.0 million in potential development and regulatory milestones, and up to $330.0 million in potential commercial milestones. If MGA012 is approved and commercialized, MacroGenics would be eligible to receive royalties, tiered from 15 percent to 24 percent, on future sales of MGA012.

We will lead global development of MGA012. MacroGenics retains the right to develop its pipeline assets in combination with MGA012, and we will commercialize MGA012 with MacroGenics commercializing its asset(s), if any such potential combinations are approved.INCMGA0012. In addition, MacroGenics ~~retains~~has the right to manufacture a portion of both companies’ global clinical and commercial supply needs of ~~MGA012.~~INCMGA0012. As of June 30, 2020, we have paid MacroGenics ~~intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018.~~

The transaction is expected to close in the fourth quarter of 2017, subject to the early termination or expiration of any applicable waiting periods under the Hart-Scott Rodino Act and customary closing conditions.

~~ARIAD Pharmaceuticals (Luxembourg) S.à.r.l. Acquisition~~

In June 2016, we acquired from ARIAD all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.à.r.l., the parent company of ARIAD’s European subsidiaries responsible for the development and commercialization of ICLUSIG in the European Union and other countries, including Switzerland, Norway, Turkey, Israel and Russia, in exchange for an upfront payment of ~~$147.5~~$150.0 million ~~including customary working capital adjustments. We obtained an exclusive license to develop~~ and ~~commercialize ICLUSIG in Europe and other select countries. ARIAD~~milestones totaling $15.0 million. MacroGenics will be eligible to receive up to an additional $405.0 million in future contingent development and regulatory milestones, and up to $330.0 million in commercial milestones as well as tiered royalties ranging from 15% to 24% of global net sales.

The MacroGenics agreement will continue until we are no longer commercializing, developing or manufacturing INCMGA0012 or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated in its entirety or on a licensed product by licensed product basis by us ~~tiered~~for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement.

Syros

In January 2018, we entered into a target discovery, research collaboration and option agreement with Syros Pharmaceuticals, Inc. Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those

57

Table of Contents

validated targets. We paid Syros $2.5 million in cash for access to proprietary technology and $7.5 million in cash for research and development services. We have agreed to pay Syros up to $54.0 million in target selection and option exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration against each of the seven selected and validated targets, we have agreed to pay up to $50.0 million in potential development and regulatory milestones and up to $65.0 million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of ~~ICLUSIG~~products resulting from the collaboration.

Innovent

In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to pemigatinib and our clinical-stage product candidates itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In January 2019, we recognized an upfront payment under this agreement of $40.0 million upon our ~~territory~~transfer of the intellectual property related to the clinical-stage product candidates to Innovent. In addition, we were initially eligible to receive $20.0 million in connection with the first related IND filing in China, up to an additional $129.0 million in potential development and regulatory milestones, and up to ~~$135.0~~$202.5 million in potential sales milestones. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the three product candidates in the Innovent territories. In June 2019, we recognized the $20.0 million milestone for the first related IND filing in China. In April 2020, we recognized a $5.0 million milestone for the FDA approval of pemigatinib as PEMAZYRE.

Zai Lab

In July 2019, we entered into a collaboration and license agreement with a subsidiary of Zai Lab Limited. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. We recognized an upfront payment under this agreement of $17.5 million in August 2019 upon our transfer of technology related to the licensed product candidate to Zai Lab, and are eligible to receive an additional $60.0 million in potential development, regulatory and sales milestones, as well as tiered royalties from the low to mid-twenties. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab’s licensed territories.

MorphoSys

In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG, covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc. The agreement became effective in March 2020 after clearance by the German and Austrian antitrust authorities and expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.

Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and MorphoSys responsible for 45% of such costs. Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan.

58

Table of Contents

In March 2020, we paid MorphoSys an upfront non-refundable payment of $750.0 million. MorphoSys is eligible to receive up to $740.0 million in future contingent development and regulatory ~~approval milestone payments, together with additional milestone payments~~milestones and up to $315.0 million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. MorphoSys’ right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for ~~non-oncology indications, if approved,~~that licensed product in ~~our territory.~~that country.

Our license agreement with ARIAD contained a limited buy-back option for the acquirer of ARIAD to reacquire the rights to ICLUSIG. Takeda Pharmaceutical Company Limited acquired ARIAD in February 2017 but did not exercise that option, and it has now lapsed.

Critical Accounting Policies and Significant Estimates

54

~~Table of Contents~~

The preparation of financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ~~on-going~~ongoing basis, we evaluate our estimates. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

We believe the following critical accounting policies ~~affect~~reflect the more significant judgments and estimates used in the preparation of our condensed consolidated financial ~~statements:~~statements. See Note 2 of Notes to the Condensed Consolidated Financial Statements for a complete list of our significant accounting policies.

·

~~Revenue recognition;~~

·

~~Research and development costs;~~

·

~~Stock compensation;~~

·

~~Convertible debt accounting;~~

·

~~Income taxes;~~

·

~~Business combinations; and~~

·

~~Contingent consideration.~~

Revenue Recognition. ~~Revenues are recognized~~ We recognize revenue only when ~~(1) persuasive evidence~~we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an ~~arrangement exists, (2) delivery~~entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has ~~occurred or services have been rendered, (3)~~a present right to payment, (ii) the ~~price is fixed or determinable~~customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance withrewards of ownership and (v) the ~~arrangement. We assess whether~~customer has accepted the ~~fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment.~~asset. We assess collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

Product Revenues

Our product revenues consist of U.S. sales of JAKAFI and PEMAZYRE and European sales of ICLUSIG. Product revenues are recognized once we ~~meet all four~~satisfy the performance obligation at a point in time under the revenue recognition criteria as described above. In November 2011, we began shipping JAKAFI to our customers in the U.S., which include specialty pharmacies and wholesalers. In June 2016, we acquired the right to and began shipping ICLUSIG to our customers in the European Union and certain other jurisdictions, which include retail pharmacies, hospital pharmacies and distributors.

We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. ~~Product shipping~~These sales allowances and ~~handling costs~~accruals are ~~included~~recorded based on estimates which are described in ~~cost~~detail below. Estimates are assessed as of ~~product revenues.~~the end of each reporting period and are updated to reflect current information. We believe that our sales allowances and accruals are reasonable and appropriate based on current facts and circumstances.

Customer Credits: Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.

Rebates and Discounts: ~~Allowances~~ We accrue rebates for ~~rebates include~~ mandated discounts under the Medicaid Drug Rebate Program in the U.S. and mandated discounts in Europe in markets where government-sponsored healthcare systems are the primary payers for healthcare. ~~Rebate amounts~~These accruals are ~~based upon contractual agreements or legal requirements with public~~

55

~~Table of Contents~~

sector benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

59

Table of Contents

Chargebacks: Chargebacks are discounts that occur when certain contracted customers ~~which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule,~~ purchase directly from our ~~wholesalers. Contracted customers generally purchase the product~~wholesalers at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received, we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel. If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

Medicare Part D Coverage Gap: Medicare Part D prescription drug benefit mandates manufacturers to fund ~~50%~~70% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment. Additionally, beginning in January 2020, the amount of spending required by eligible patients in the Medicare Part D insurance coverage gap increased 30% due to the expiration of a provision in the Patient Protection and Affordable Care Act, which now results in a change in the True Out of Pocket (TrOOP) calculation methodology. The methodological change has resulted in an increase in required spending by patients and, in turn, an increase in manufacturers’ contributions on behalf of patients in the Medicare Part D insurance coverage gap.

Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.

Product Royalty Revenues

Royalty revenues on commercial sales for JAKAVI and TABRECTA by Novartis are estimated based on information provided by Novartis. Royalty revenues on commercial sales for OLUMIANT by Lilly are estimated based on information provided by Lilly. We exercise judgment in determining whether the information provided is sufficiently reliable for us to base our royalty revenue recognition thereon. If actual royalties vary from estimates, we may need to adjust the prior period, which would affect royalty revenue and receivable in the period of adjustment.

~~Cost of Product~~Milestone and Contract Revenues

Cost of product revenues includes all JAKAFI related product costs as well as ICLUSIG related product costs. The ICLUSIG inventories were recorded at fair value less costs to sell in connection with the Acquisition, which resulted in a higher cost of ICLUSIG product revenues over a one year period from the acquisition date. In addition, cost of product revenues include low single digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States. Subsequent to the Acquisition on June 1, 2016, cost of product revenues also includes the amortization of our licensed intellectual property for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years.

~~Contract and License Revenues~~

Under agreements involving multiple deliverables, services and/or rights to use assets that we entered into prior to January 1, 2011, the multiple elements are divided into separate units of accounting when certain criteria are met, including whether the delivered items have stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. When separate units of accounting exist, consideration is allocated

56

~~Table of Contents~~

among the separate elements based on their respective fair values. The determination of fair value of each element is based on objective evidence from historical sales of the individual elements by us to other customers. If such evidence of fair value for each undelivered element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value for each undelivered element does exist or until all elements of the arrangement are delivered. When elements are specifically tied to a separate earnings process, revenue is recognized when the specific performance obligation tied to the element is completed. When revenues for an element are not specifically tied to a separate earnings process, they are recognized ratably over the term of the agreement. We assess whether a substantive milestone exists atAt the inception of a contract, the transaction price reflects the amount of consideration we expect to be entitled to in exchange for transferring promised goods or services to our ~~agreements. For all milestones within~~collaborator. We review our ~~arrangements that are considered substantive, we recognize revenue upon the achievement~~estimate of the ~~associated milestone. If a milestone is not considered substantive, we would recognize the applicable milestone payment over the remaining~~transaction price each period, ~~of performance under the arrangement. As of September 30, 2017, all remaining potential milestones under our~~and make revisions to such estimates as necessary. Milestone and contract revenues from collaborative ~~arrangements are considered substantive.~~

~~On January 1, 2011, updated guidance on the recognition of revenues for~~ agreements with multiple ~~deliverables became effective~~performance obligations is determined based upon assessment of each distinct promised good or service’s estimated fair value and ~~applies to any agreements we may enter into on or after January 1, 2011. This updated guidance (i) relates to whether multiple deliverables exist, how~~recognized based upon the deliverables in a revenue arrangement should be separated and how the consideration should be allocated; (ii) requires companies to allocate revenues in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (iii) eliminates the usecompletion of the ~~residual method and requires companies~~promised good or service to allocate revenues using the relative selling price method. During the three and nine months ended September 30, 2017 and 2016, we did not enter into any agreements that are subject to this updated guidance. If we enter into an agreement with multiple deliverables after January 1, 2011 or amend existing agreements, this updated guidance could have a material effect on our ~~financial statements.~~collaborator.

Our ~~collaborations~~license agreements often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization ~~events. These three categories of milestone~~ events ~~reflect the three stages of the life-cycle~~outside of our ~~drugs, which we describe in more detail in the following paragraphs.~~

~~The~~control, such as regulatory ~~review and~~ approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the U.S. Food and Drug Administration (FDA) requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate’s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a ~~drug candidate in humans, we must submit an Investigational New Drug application (IND), which must~~compound, first patient dosing or achievement of sales-based thresholds. As such, milestones associated with our collaborations involve a substantial degree of uncertainty and risk that they may never be ~~reviewed by~~received. Given the ~~FDA.~~

The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (NDA) or biologics license application (BLA) to the FDA for review and FDA approval of the NDA or BLA.

Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially baseduncertainty associated with achieving these milestones, constraints on the ~~type, complexity and novelty of the product or the targeted disease.~~allocated consideration are assessed each reporting period. Revenues are recognized when achievement is probable, which may not be until achieved.

Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human

57

~~Table of Contents~~

subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase I, Phase II or Phase III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.

~~Research and Development Costs.~~ Our policy is to expense research and development costs as incurred. We often contract with clinical research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract.

These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period.

Under our clinical trial collaboration agreements, we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred.

Stock Compensation. Share-based payment transactions with employees, which include stock options, restricted stock units ~~(“RSUs”)~~(RSUs) and performance shares ~~(“PSUs”)~~(PSUs), are recognized as compensation expense over the requisite service period based on their estimated fair values at the date of grant as well as expected forfeiture ~~rates.~~rates based on actual experience. The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting. The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution

60

Table of Contents

method. The fair value of RSUs that are subject to cliff vesting are recognized as compensation expense over the requisite service period using the ~~straight line~~straight-line attribution method, and the fair value of RSUs that are subject to graded vesting are recognized as compensation expense over the requisite service period using the accelerated attribution method. The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement. We assess the probability of achievement of performance conditions, including projected product revenues and clinical development milestones, as of the end of each reporting period. Once a performance condition is considered probable, we record compensation expense based on the portion of the service period elapsed to date with respect to that award, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining requisite service period. We recorded $34.9 million and $99.3 million of stock compensation expense for the three and nine months ended September 30, 2017, respectively. We recorded $26.5 million and $68.6 million of stock compensation expense for the three and nine months ended September 30, 2016, respectively.

58

~~Table of Contents~~

~~Convertible Debt Accounting.~~ We perform an assessment of all embedded features of a debt instrument to determine if (1) such features should be bifurcated and separately accounted for, and (2) if bifurcation requirements are met, whether such features should be classified and accounted for as equity or liability instruments. If the embedded feature meets the requirements to be bifurcated and accounted for as a liability, the fair value of the embedded feature is measured initially, included as a liability on the condensed consolidated balance sheets, and re-measured to fair value at each reporting period. Any changes in fair value are recorded in the condensed consolidated statement of operations. We monitor, on an ongoing basis, whether events or circumstances could give rise to a change in our classification of embedded features.

We determined the embedded conversion options in the 0.375% convertible senior notes due 2018 (the 2018 Notes) and the 1.25% convertible senior notes due 2020 (the 2020 Notes) are not required to be separately accounted for as derivatives. However, since the 2018 Notes and the 2020 Notes can be settled in cash or common shares or a combination of cash and common shares at our option, we are required to separate the 2018 Notes and 2020 Notes into a liability and equity component. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated equity component. The carrying amount of the equity component representing the embedded conversion option is determined by deducting the fair value of the liability component from the initial proceeds. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of the 2018 Notes and 2020 Notesperiod using the ~~effective interest method. The equity component is not re-measured as long as it continues~~straight-line attribution method for PSUs that are subject to ~~meet the conditions for equity classification for contracts in an entity’s own equity.~~

~~The fair value of the liability component of the 2018 Notes was estimated at $299.4 million at issuance. Therefore, the difference between the $375.0 million face value of the 2018 Notes at issuance~~cliff vesting and ~~the $299.4 million estimated fair value of the liability component will be amortized to interest expense over the term of the 2018 Notes through November 15, 2018~~ using the ~~effective interest method.~~

The fair value of the liability component of the 2020 Notes was estimated at $274.8 million at issuance. Therefore, the difference between the $375.0 million face value of the 2020 Notes at issuance and the $274.8 million estimated fair value of the liability component will be amortized to interest expense over the term of the 2020 Notes through November 15, 2020 using the effective interest method.

~~The estimated fair value of the liability components at the date of issuance~~accelerated attribution method for ~~the 2018 Notes and 2020 Notes were determined using valuation models and~~PSUs that are ~~complex and~~ subject to judgment. Significant assumptions within the valuation models included an implied credit spread, the expected volatility and dividend yield of our common stock and the risk free interest rate for notes with a similar term.graded vesting.

Prior to May 14, 2014, the 2018 Notes and 2020 Notes were not convertible except in connection with a make-whole fundamental change, as defined in the respective indentures. Beginning on, and including, May 15, 2014, the 2018 Notes and 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2018 Notes or 2020 Notes, as applicable, on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of 2018 Notes or 2020 Notes, as applicable, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the 2018 Notes or 2020 Notes, as applicable, on each such trading day; or (3) upon the occurrence of specified corporate events. On or after May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, until the close of business on the second scheduled trading day immediately preceding the relevant maturity date, the Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.

59

~~Table of Contents~~

Upon an induced conversion, we allocate the fair value of the consideration transferred to the convertible debt holder to the liability component equal to the fair value of the liability immediately before extinguishment. The difference between the consideration allocated to the liability component and the net carrying amount of the liability component is recorded as expense related to senior note conversions.

On a quarterly basis, we perform an assessment in order to determine whether the 2018 Notes or 2020 Notes have become convertible at the option of the holder, based on meeting any of the conversion criteria described above. Should either the 2018 Notes or the 2020 Notes become convertible, we then assess our intent and ability to settle the 2018 Notes or the 2020 Notes in cash, shares of common stock, or a combination of cash and shares of common stock, in order to determine the appropriate classification of the 2018 Notes and the 2020 Notes at the balance sheet date. On October 1, 2017, the 2018 Notes and 2020 Notes became convertible through at least December 31, 2017, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended September 30, 2017 as described above. Management’s intent is to settle any conversions of 2018 Notes or 2020 Notes in common shares and, therefore, the 2018 and 2020 Notes are reflected in long term liabilities on the condensed consolidated balance sheet as of September 30, 2017.

Income Taxes. We account for income taxes using an asset and liability approach to financial accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which the basis differences are expected to reverse. We periodically assess the likelihood of the realization of deferred tax assets, and reduce the carrying amount of these deferred tax assets to an amount that is considered to be more-likely-than-not to be realizable. Our assessment considers recent cumulative earnings experience, projections of future taxable income (losses) and ongoing prudent and feasible tax planning strategies. When performing our assessment on projections of future taxable income (losses), we consider factors such as the likelihood of regulatory approval and commercial success of products currently under development, among other factors. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.

We ~~do not~~ recognize athe tax benefit ~~for~~from an uncertain tax position ~~unless~~only if it is more-likely-than-not that the position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any interest and penalties on uncertain tax positions are included within the tax provision.

~~Business combinations.~~ ~~Acquired businesses~~We record estimates and prepare and file tax returns in various jurisdictions across the U.S., Europe, and Asia based upon our interpretation of local tax laws and regulations. While we exercise significant judgment when applying complex tax laws and regulations in these various taxing jurisdictions, many of our tax returns are ~~accounted~~open to audit, and may be subject to future tax, interest, and penalty assessments.

We believe our estimates for ~~using~~ the ~~acquisition method~~valuation allowances against certain deferred tax assets and the amount of ~~accounting, which requires that assets acquired and liabilities assumed be recorded at fair value,~~benefits associated with ~~limited exceptions. Any excess~~uncertain tax positions recognized in our financial statements are appropriate based upon our assessment of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs are expensed as incurred. The operating results of the acquired business are reflected in our consolidated financial statements after the date of acquisition. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. When the related research and development is completed, the asset will be assigned a useful life and amortized. Acquired intellectual property rights are recognized at fair value and amortized over the estimated useful life.factors mentioned above.

The fair value of an IPR&D intangible asset acquired in the Acquisition was determined using an income approach. The assumptions used to estimate the cash flows of the IPR&D (which relates to the potential approval of ICLUSIG as a second line treatment) included a probability of technical success (“PTS”) of 25%, discount rate of 16%, estimated gross margins of 98%, income tax rates ranging from 7.8% in periods in which we have established tax holidays to 13.8% thereafter, and operating expenses consisting of direct costs based on the anticipated level of revenues as well as probability weighted milestone payments estimated for 2020 related to the clinical results and potential approval of ICLUSIG in second line.

The fair value of licensed intellectual property rights acquired in the Acquisition was determined using an income approach. The assumptions used to estimate the cash flows of the licensed intellectual property from the Acquisition included a discount rate of 15%, estimated gross margins of 98%, income tax rates ranging from 7.8% in periods in which

60

~~Table of Contents~~

we have established tax holidays to 13.8% thereafter, and operating expenses consisting of direct costs based on the anticipated level of revenues as well as the $7.0 million of research and development cost sharing payments we have agreed to fund in 2016 and 2017.

Indefinite-lived intangible assets, including IPR&D, are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value. Due to the discontinuation of the OPTIC-2L study, we considered our indefinite-lived IPR&D asset to be impaired and recorded $12.0 million of research and development expense on the condensed consolidated statements of operations during the three and nine months ended September 30, 2017.

Long-lived assets, including licensed intellectual property rights, with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. Our operations are currently comprised of a single, entity wide reporting unit.

Acquisition-related contingent consideration. Acquisition-related contingent consideration, which consists of our future royalty ~~and certain potential milestone~~ obligations to ~~ARIAD, is~~ARIAD/Takeda, was recorded on the acquisition date at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. The fair value ~~measurement is based on significant inputs that are unobservable in~~of the ~~market and thus represents a Level 3 measurement.~~

~~The preliminary fair value of~~ contingent consideration was determined using an income approach based on estimated ICLUSIG revenues in ~~our licensed territory for both~~ the approved third line treatment, as well as the second line treatment that until the three months ended September 30, 2017 was under development. The PTS of the second line indication was estimated at 25% based on the early stage of developmentEuropean Union and competitive market landscape, and the estimated future cash flows for the second line indication were probability weighted accordingly. The total projected cash flows of the third line and second line indications were estimated over 18 years, and discounted to present value using a discount rate of 10%. In addition, based on the believed limited effectiveness of ICLUSIG beyond the existing oncology indications, the fact that no development is currently ongoing for any new oncology or any non-oncology indications, and the lack of intention by us and ARIAD to develop ICLUSIG in additional oncology or non-oncology indications,other countries. As the fair value ~~of any cash flows for any new oncology or non-oncology was determined to be nil.~~ measurement is based on significant inputs that are unobservable in the market, this represents a Level 3 measurement.

The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. ~~Changes in~~The assumptions used to determine the fair value of the acquisition-related contingent consideration ~~can result from changes to one or multiple inputs including~~include projected ICLUSIG revenues and discount rates which, require significant judgement and the PTS of the second line indication for ICLUSIG, and a benefit of $24.0 million was recorded during the three and nine months ended September 30, 2017 related to the lack of expected future sales royalties payable due to the discontinued OPTIC-2L clinical trial for the second line indication for ICLUSIG. These inputs are analyzed on a quarterly ~~basis as changes~~basis. While we use the best available information to ~~the~~prepare our projected ICLUSIG revenues and discount rate assumptions, actual ICLUSIG revenues and/or market conditions could differ significantly. Changes to one or multiple inputs could have a material impact on the amount of acquisition-related contingent consideration expense recorded during the reporting period.

61

Table of Contents

Recent Accounting Pronouncements

In ~~May 2014,~~June 2016, the Financial Accounting Standards Board (“FASB”) issued ~~Accounting Standards Update (“ASU”)~~ASU No. ~~2014-09, “Revenue from Contracts with Customers,~~2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” ~~which will replace numerous requirements in U.S. GAAP, including industry-specific requirements.~~ This guidance ~~provides a five step model~~applies to all entities and impacts how entities account for credit losses for financial assets measured at amortized cost and available for sale debt securities. ASU 2016-13 requires financial assets measured at amortized cost to be ~~applied~~presented at the net amount expected to ~~all contracts with customers, with~~be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate expected credit losses over the lifetime of the asset. For available-for-sale debt securities, entities will be required to recognize an ~~underlying principle~~allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize ~~revenue~~any improvements in estimated credit losses on its available-for-sale debt securities immediately in earnings.

Upon adoption, we assessed each financial asset measured at amortized cost and each available-for-sale debt security held for the impact of the guidance as of January 1, 2020 and noted an insignificant impact due to ~~depict~~ the ~~transfer of goods or services~~minimal credit risk associated with our financial assets subject to

61

~~Table of Contents~~

~~customers at an amount~~ ASC 326. As such, it was concluded that a reserve for credit losses was de minimis on the ~~entity expects~~adoption date. Financial assets will continue to be ~~entitled~~assessed on a quarterly basis in future periods.

In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to ~~in exchange~~the Disclosure Requirements for ~~those goods or services. ASC No. 2014-09 requires extensive quantitative~~Fair Value Measurement,” which eliminates the required disclosure of the amount of and ~~qualitative disclosures covering~~reason for transfers between Level 1 and Level 2 of the ~~nature, amount, timing~~fair value hierarchy. The guidance also eliminates the required disclosure of the entity’s valuation process for Level 3 fair value measurements, however public entities are required to disclose the range and ~~uncertainty of revenue and cash flows arising from customer contracts, including disclosures on~~weighted average used to develop significant ~~judgments made when applying the guidance.~~unobservable inputs for Level 3 fair value measurements. This guidance is effective for ~~annual reporting periods~~fiscal years beginning after December 15, ~~2017~~2019. We adopted this guidance for the period beginning January 1, 2020 and ~~interim periods therein. An entity can elect~~enhanced our disclosures in Note 4 to ~~apply~~ the ~~guidance under one of the following two methods: (i) retrospectively~~condensed consolidated financial statements to ~~each prior reporting period presented – referred to as the full retrospective method or (ii) retrospectively~~comply with the ~~cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings – referred to as the modified retrospective method.~~

We have substantially completed an initial impact assessment of the potential changes from adopting ASU 2014-09. The impact assessment consisted of a review of a representative sample of contracts, discussions with key stakeholders, and a cataloging of potential impacts on our financial statements, accounting policies, financial controls, and operations. We currently do not anticipate a material impact on our revenue recognition practices for product and royalty revenues. We do anticipate that the adoption of ASU 2014-09 will have primarily two impacts on our contract revenues generated by our collaborative research and license agreements:

(i)Changes in the model for distinct licenses of functional intellectual property which may result in a timing difference of revenue recognition. Whereas revenue from these arrangements was previously recognized over a period of time pursuant to revenue recognition guidance that was in place for our arrangements at the time such arrangements commenced, revenue from these arrangements may now be recognized at point in time under the new guidance.

(ii)Assessments of milestone payments, which are linked to events that are in our control, will result in variable consideration that may be recognized at an earlier point in time under the new guidance, when it is probable that the milestone will be achieved without a significant future reversal of cumulative revenue expected.

We have not yet completed our final review of the impact of this guidance including the new disclosure requirements, as we are continuing to evaluate the impacts of adoption and the implementation approach to be used. We plan to adopt the new standard effective January 1, 2018 and are considering adopting using the modified retrospective method. We continue to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact our current conclusions.standard.

In ~~February 2016,~~August 2018, the FASB issued ASU No. ~~2016-02, “Leases,~~2018-14, “Compensation – Retirement Benefits – Defined Benefit Plans – General,” ~~that requires lessees~~an update to ~~recognize assets~~Subtopic ASC 715-20. The guidance amended year-end disclosure requirements related to defined benefit pension plans, and ~~liabilities on the balance sheet~~does not affect interim disclosures. The guidance is effective for ~~most leases including operating leases. Lessees now classify leases as either finance or operating leases~~fiscal years ending after December 15, 2020 and ~~lessors classify all leases as sales-type, direct financing or operating leases.~~is permitted for early adoption. The statement of operations presentation and expense recognition for lessees for finance leases is similar to that of capital leases under Accounting Standards Codification (“ASC”) 840 with separate interest and amortization expense with higher periodic expense in the earlier periods of a lease. For operating leases, the statement of operations presentation and expense recognition is similar to that of operating leases under ASC 840 with single lease cost recognized on a straight-line basis. This guidancestandard is to be applied ~~using~~on a ~~modified~~ retrospective ~~approach at the beginning of the earliest comparative period presented~~basis. Incyte sponsors defined benefit plans for employees located in ~~the financial statements and is effective for annual periods beginning after December 15, 2018 and interim periods therein. Early adoption is permitted.~~Europe. We are currently analyzing the impact of ASU No. ~~2016-02 and, at this time, are unable to determine~~2018-14 on the ~~impact of the new standard on our~~ condensed consolidated financial statements.

In ~~October 2016,~~August 2018, the FASB issued ASU No. ~~2016-16, “Intra-Entity Transfers of Assets~~2018-15, “Intangibles – Goodwill and Other ~~Than Inventory,~~– Internal-Use Software,” ~~which requires companies~~an update to account for the income tax effects of intercompany sales and transfers of assets other than inventory in the period in which the transfer occurs. The new standard is effective for public business entities for annual periods beginning after December 15, 2017 (i.e. 2018 for a calendar-year entity).Subtopic ASC 350-40. The guidance ~~will be applied~~directs accounting for ~~the annual period beginning January 1, 2018 using a modified retrospective approach with a cumulative catch-up adjustment~~service contracts for cloud computing arrangements to ~~opening retained earnings.~~

~~We have elected~~follow guidance within ASC 350-40 to ~~early adopt ASU No. 2016-16 as~~determine capitalization of ~~the first quarter of 2017, which requires us to reflect any adjustments as of January 1, 2017, the beginning of the annual period that includes the interim period of adoption.~~implementation costs. The ~~primary impact of adoption was the recognition of a deferred tax asset of $34.9 million related to the excess of the tax~~

62

~~Table of Contents~~

basis over the consolidated book value basis in the intellectual property rights that were licensed from the U.S. parent company to our wholly-owned subsidiary in Switzerland during 2015 and a $2.1 million reversal of long-term prepaid taxes. Under previous guidance companies were prohibited from recognizing an increase in tax basis and any income taxes incurred as a result of a sale or transfer of assets to companies that are part of a consolidated reporting entity. Given the full valuation allowance placed on the additional $34.9 million of deferred tax assets, the recognition upon adoption only required a $2.1 million adjustment to our retained earnings as of January 1, 2017 due to the adjustment of the prepaid tax asset.

In November 2016, the FASB issued ASU No. 2016-18, “Restricted Cash,” which requires entities to show the changes in total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions on the balance sheet. The reconciliation can either be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard is effective ~~for public business entities~~ for fiscal years beginning after December 15, ~~2017~~2019 and may be applied on either a retrospective or prospective basis. We adopted this guidance for the period beginning January 1, 2020 on a prospective basis. New contracts for development of internal-use software were assessed and no qualifying contracts were identified during the period. We will continue to assess contracts and will disclose material, qualifying contracts if identified in future periods.

In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.” The guidance clarifies the interactions between Topic 808 and Topic 606, including clarifications on revenue recognition, unit of account, and reporting disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 retrospectively to the date of our initial application of ASC 606, and noted that in assessment of our collaborative agreements, there was no material financial statement impact. Our collaborative arrangements and their associated accounting conclusions are described in detail within Note 9 to the condensed consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This guidance applies to all entities and aims to reduce the complexity of tax accounting standards

62

Table of Contents

while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods ~~therein and is to be applied retrospectively.~~therein. Early adoption is ~~permitted.~~permitted for any annual periods for which financial statements have not been issued and interim periods therein. We are currently analyzing the impact of ASU No. ~~2016-18~~2019-12 on ~~our~~the condensed consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles–Goodwill and Other,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Under the new standard, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The new standard is effective for public business entities that are SEC filers for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The standard is to be applied on a prospective basis. We are currently analyzing the impact of ASU No. 2017-04 on our condensed consolidated financial statements.

In March 2017, the FASB issued ASU No. 2017-07, “Compensation–Retirement Benefits,” which requires the presentation of the service cost component of the net periodic benefit cost in the same income statement line as other employee compensation costs arising from services rendered during the period. In addition, only the service cost component will be eligible for capitalization in assets. Disclosure of the line(s) used to present the other components of net periodic benefit cost, if the components are not presented separately in the income statement, is also required. The new standard is effective for public business entities for fiscal years beginning after December 15, 2017 and interim periods therein. The guidance on the presentation of the components of net periodic benefit cost in the income statement is to be applied retrospectively. The guidance limiting the capitalization of net periodic benefit cost in assets to the service cost component is to be applied prospectively. We are currently analyzing the impact of ASU No. 2017-07 on our condensed consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which requires inventory to be measured at the lower of cost and net realizable value rather than at the lower of cost or market value. The new standard is effective for public business entities for fiscal years beginning after December 15, 2016 and interim periods therein. The guidance is to be applied prospectively. We adopted ASU No. 2015-11 as of the first quarter of 2017 and the adoption had no impact on our condensed consolidated financial statements.

Results of Operations

We recorded net income of ~~$36.1 million and basic and diluted net income per share of $0.17 for the three months ended September 30, 2017, as compared to net income of $36.9~~$290.3 million and basic net income per share of ~~$0.20~~$1.33 and diluted net income per share of ~~$0.19~~$1.32 for the three months ended June 30, 2020, as compared to net income of $105.3 million and basic net income per share of $0.49 and diluted net income per share of $0.48 in the corresponding period in ~~2016.~~2019. We recorded net loss of ~~$163.5~~$430.3 million and basic and diluted net loss per share of ~~$0.81,~~$1.98 for the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020, as compared to net income of ~~$95.3~~$207.6 million and basic net income per share of ~~$0.51~~$0.97 and diluted net income per share of ~~$0.49~~$0.96 in the corresponding period in ~~2016.~~2019.

Revenues.


	For the Three Months Ended,				For the Six Months Ended,
	June 30,				June 30,
	2020		2019		2020		2019

	(in millions)				(in millions)
JAKAFI revenues, net	$	473.7	$	409.5	$	933.2	$	785.1
ICLUSIG revenues, net		22.8		24.4		50.0		45.0
PEMAZYRE revenues, net		3.8		—		3.8		—
Total product revenues, net		500.3		433.9		987.0		830.1
JAKAVI product royalty revenues		66.2		56.9		122.6		102.5
OLUMIANT product royalty revenues		25.8		19.1		51.3		35.2
TABRECTA product royalty revenues		0.7		—		0.7		—
Total product royalty revenues		92.7		76.0		174.6		137.7
Milestone and contract revenues		95.0		20.0		95.0		60.0
Total revenues	$	688.0	$	529.9	$	1,256.6	$	1,027.8

63

~~Table of Contents~~

~~Revenues.~~

For the Three Months Ended,

For the Nine Months Ended,

September 30,

September 30,


2017

2016

2017

2016


(in millions)

(in millions)

JAKAFI revenues, net

$
303.9

$
223.9

$
831.0

$
615.3

ICLUSIG revenues, net

18.1

12.7

47.5

16.7

Total product revenues, net

$
322.0

$
236.6

$
878.5

$
632.0

Product royalty revenues

44.5

29.6

108.5

77.5

Contract revenues

15.0

3.2

105.0

69.6

Other revenues

—

0.1

0.1

0.1

Total revenues

$
381.5

$
269.5

$
1,092.1

$
779.2

Our product revenues, net for the three and nine months ended September 30, 2017 were $322.0 million and $878.5 million, respectively. Our product revenues, net for the three and nine months ended September 30, 2016 were $236.6 million and $632.0 million, respectively. The increase in JAKAFI product revenues for the three months ended ~~September~~June 30, ~~2017~~2020 as compared to the corresponding period in ~~2016~~2019 was comprised of a volume increase of ~~$57.0~~$52.9 million and a price increase of ~~$23.0~~$11.3 million. The increase in JAKAFI product revenues for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 as compared to the corresponding period in ~~2016~~2019 was comprised of a volume increase of ~~$155.1~~$135.1 million and a price increase of ~~$60.6~~$13.0 million. ~~ICLUSIG~~Our product revenues ~~commenced~~may fluctuate from quarter to quarter due to our customers’ purchasing patterns over the course of the year, including as a result of increased inventory building by customers in ~~June 2016 following the Acquisition.~~advance of expected or announced price increases. Product revenues are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance. Our revenue recognition policies require estimates of the aforementioned sales allowances each period.

63

Table of Contents

The following table provides a summary of activity with respect to our sales allowances and ~~accruals:~~accruals (in thousands):


					Co-Pay
	Discounts and		Government		Assistance
	Distribution		Rebates and		and Other		Product
Nine Months Ended September 30, 2017	Fees		Chargebacks		Discounts		Returns		Total
Balance at January 1, 2017	$	2,818	$	22,412	$	199	$	1,211	$	26,640

															Co-Pay
											Discounts and		Government		Assistance
											Distribution		Rebates and		and Other		Product
Six Months Ended June 30, 2020											Fees		Chargebacks		Discounts		Returns		Total
Balance at January 1, 2020											$	6,530	$	54,762	$	703	$	1,660	$	63,655
Allowances for current period sales		23,936		106,331		3,401		668		134,336		28,144		167,522		8,731		662		205,059
Allowances for prior period sales		(59)		(971)		(10)		(353)		(1,393)		(160)		485		—		(596)		(271)
Credits/payments for current period sales		(21,759)		(82,363)		(3,225)		(34)		(107,381)		(21,898)		(127,476)		(7,513)		—		(156,887)
Credits/payments for prior period sales		(800)		(16,964)		(17)		(404)		(18,185)		(5,753)		(30,174)		(252)		(226)		(36,405)
Balance at September 30, 2017	$	4,136	$	28,445	$	348	$	1,088	$	34,017
Balance at June 30, 2020											$	6,863	$	65,119	$	1,669	$	1,500	$	75,151

Government rebates and chargebacks are the most significant component of our sales allowances. Increases in certain government reimbursement rates are limited to a measure of inflation, and when the price of a drug increases faster than this measure of inflation it will result in a penalty adjustment factor that causes a larger sales allowance to those government related entities. We expect government rebates and chargebacks as a percentage of our gross product sales will continue to increase in connection with any future ~~JAKAFI~~product price increases greater than the rate of inflation, and any such increase in these government rebates and chargebacks will have a negative impact on our reported product revenues, net. We adjust our estimates for government rebates and chargebacks based on new information regarding actual rebates as it becomes available. Claims by third-party payors for rebates and chargebacks are frequently submitted after the period in which the related sales occurred, which may result in adjustments to prior period accrual balances in the period in which the new information becomes available. We also adjust our allowance for product returns based on new information regarding actual returns as it becomes available.

We expect our sales allowances to fluctuate from quarter to quarter as a result of the Medicare Part D Coverage Gap, the volume of purchases eligible for government mandated discounts and rebates as well as changes in discount percentages which are impacted by potential future price increases, rate of inflation, and other factors.

64

~~Table of Contents~~

Product royalty revenues on commercial sales of JAKAVI and TABRECTA by Novartis are based on net sales of licensed products in licensed territories as provided by Novartis. Our JAKAVI product royalty revenues for the three and nine months ended September 30, 2017 were $41.3 million and $104.0 million, respectively. Our JAKAVI product royalty revenues for the three and nine months ended September 30, 2016 were $29.6 million and $77.5 million, respectively. Product royalty revenues on commercial sales of OLUMIANT by Lilly are based on net sales of licensed products in licensed territories as provided by Lilly.

Our ~~OLUMIANT product royalty~~milestone and contract revenues for the ~~three and nine~~six months ended ~~September~~June 30, ~~2017 were $3.2 million and $4.5 million, respectively.~~

Our contract revenues were $15.0 million and $105.0 million for the three and nine months ended September 30, 2017, respectively. Our contract revenues were $3.2 million and $69.6 million for the three and nine months ended September 30, 2016, respectively. For the nine months ended September 30, 2017, contract revenues2020, were derived from a $5.0 million milestone ~~payments from Lilly~~under the Innovent research collaboration and licensing agreement and $90.0 million in milestones under the Novartis ~~earned during~~collaboration and license agreement. Our milestone and contract revenues for the ~~period. For the nine~~six months ended ~~September~~June 30, ~~2016, contract revenues~~2019, were derived from ~~the straight line recognition of revenue associated with the Lilly~~a $40.0 million upfront fees over the estimated performance period as well as milestone payments from Lilly and Novartis earned during the period. During the nine months ended September 30, 2017, under the Lilly agreement, we recognized a $15.0 million regulatory milestone payment for the approval of baricitinib for the treatment of rheumatoid arthritis by Japan’s Ministry of Health, Labor and Welfare and a $65.0 million regulatory milestone payment for the approval of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patient by the European Commission and under the Novartis agreement, we recognized a $25.0 million development milestone payment based on the formal initiation by Novartis of a Phase III clinical trial evaluating ruxolitinib in the GVHD field. During the nine months ended September 30, 2016, under the Novartis agreement, we recognized a $5.0 million payment for the development and commercialization of ruxolitinib in GVHD outside of the United States and under the Lilly agreement, we recognized a $35.0 million regulatory milestone payment for the submission of a new drug application to the U.S. Food and Drug Administration for the approval of oral once-daily baricitinib for the treatment of moderate-to-severe rheumatoid arthritis and a $20.0 million ~~regulatory~~ milestone ~~for~~under the ~~submission of a Marketing Authorization Application to the European Medicines Agency for the approval of oral once-daily baricitinib for the treatment of moderate-to-severe rheumatoid arthritis.~~Innovent research collaboration and licensing agreement.

Cost of Product Revenues.


									For the Three Months Ended,				For the Six Months Ended,
									June 30,				June 30,
									2020		2019		2020		2019

	For the Three Months Ended,				For the Nine Months Ended,
	September 30,				September 30,
	2017		2016		2017		2016
	(in millions)				(in millions)
									(in millions)				(in millions)
Product costs	$	1.7	$	3.8	$	5.2	$	6.3	$	3.7	$	3.1	$	6.9	$	6.0
Salary and benefits related										0.9		0.6		1.8		1.3
Stock compensation										0.2		0.2		0.5		0.4
Royalty expense		14.9		11.0		35.7		25.1		23.2		20.1		40.7		33.5
Amortization of definite-lived intangible assets		5.4		5.4		16.2		7.2		5.4		5.4		10.8		10.8
Total cost of product revenues	$	22.0	$	20.2	$	57.1	$	38.6	$	33.4	$	29.4	$	60.7	$	52.0

Cost of product revenues includes all JAKAFI, ICLUSIG and PEMAZYRE related product costs, ~~all ICLUSIG related product~~employee personnel costs, ~~and~~including stock compensation, for those employees dedicated to the production of our commercial

64

Table of Contents

products, low ~~single digit~~single-digit royalties to Novartis on all sales of JAKAFI in the United States. The ICLUSIG inventories were recorded at fair value less costs to sell in connection with the Acquisition, which resulted in a higher cost of ICLUSIG product revenues over a one year period from the acquisition date. Subsequent to the acquisition on June 1, 2016, cost of product revenues also includes theStates and amortization of our licensed intellectual property rights for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years.

Cost of product revenues was $22.0 million and $57.1 million for the three and nine months ended September 30, 2017, respectively. Cost of product revenues was $20.2 million and $38.6 million for the three and nine months ended September 30, 2016, respectively. The increase in cost of product revenues for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 as compared to the ~~same~~corresponding periods in ~~2016 is~~2019 was due primarily to increased royalties to Novartis on all JAKAFI sales in the United ~~States and amortization of our licensed intellectual property acquired on June 1, 2016.~~States.

65

~~Table of Contents~~

Operating Expenses.

Research and development expenses.


									For the Three Months Ended,				For the Six Months Ended,
									June 30,				June 30,
									2020		2019		2020		2019

	For the Three Months Ended,				For the Nine Months Ended,
	September 30,				September 30,
	2017		2016		2017		2016
	(in millions)				(in millions)
									(in millions)				(in millions)
Salary and benefits related	$	51.4	$	36.7	$	141.6	$	101.5	$	64.9	$	57.7	$	133.0	$	120.7
Stock compensation		23.4		16.2		67.8		42.8		32.5		27.6		61.2		55.0
Clinical research and outside services		173.9		76.1		612.6		235.7		165.5		177.4		1,129.1		331.2
Occupancy and all other costs		20.9		14.2		57.4		40.3		23.7		26.7		48.6		53.0
Total research and development expenses	$	269.6	$	143.2	$	879.4	$	420.3	$	286.6	$	289.4	$	1,371.9	$	559.9

We ~~currently~~ account for research and development costs by natural expense line and not costs by project. ~~Salary~~The increase in salary and benefits related expense ~~increased from~~for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016~~2020 as compared to the ~~three and nine months ended September 30, 2017~~corresponding periods in 2019 was due primarily to increased development headcount to sustain our development pipeline. Stock compensation expense may fluctuate from period to period based on the number of awards granted, stock price volatility and expected award lives, as well as expected award forfeiture rates which are used to value equity-based compensation.

The increase in clinical research and outside services expense ~~from~~for the ~~three and nine~~six months ended ~~September~~June 30, ~~2016~~2020 as compared to the ~~three and nine months ended September 30, 2017~~corresponding period in 2019 was primarily due to upfront consideration related to our collaborative agreement with MorphoSys recorded during 2020. Research and development expenses include upfront and milestone expenses related to our collaborative agreements ~~as well as an overall increase in development costs to advance our clinical pipeline. Specifically, we recorded charges~~of $3.5 million and $809.0 million, respectively, for the ~~new Calithera~~three and ~~Merus agreements, and the amended Agenus agreement, during the nine~~six months ended ~~September~~June 30, ~~2017. The total charges recorded for these agreements was $209.1 million during the nine months ended September 30, 2017. In addition, research~~2020. Research and development expenses include upfront and milestone expenses related to our collaborative agreements of $25.0 million and $25.3 million, respectively, for the ~~nine~~three and six months ended ~~September~~June 30, ~~2017 includes expense related to Incyte Biosciences Luxembourg S.à.r.l. resulting from the Acquisition on June 1, 2016.~~2019. Research and development expenses for the ~~nine~~three and six months ended ~~September~~June 30, ~~2017~~2020 and ~~2016~~2019 were net of $3.2 million, ~~$12.3~~$4.9 million, ~~$3.7~~$2.4 million and ~~$11.0~~$6.4 million, respectively, of costs reimbursed by our collaborative partners. ~~Research~~

In addition to one-time expenses resulting from upfront fees in connection with the entry into any new or amended collaboration agreements and payment of milestones under those agreements, research and development expenses may fluctuate from period to period depending upon the stage of certain projects and the level of ~~pre‑clinical~~pre-clinical and clinical trial related activities. Many factors can affect the cost and timing of our clinical trials, including requests by regulatory agencies for more information, inconclusive results requiring additional clinical trials, slow patient enrollment, adverse side effects among patients, insufficient supplies for our clinical trials and real or perceived lack of effectiveness or safety of our investigational drugs in our clinical trials. In addition, the development of all of our products will be subject to extensive governmental regulation. These factors make it difficult for us to predict the timing and costs of the further development and approval of our products.

In July 2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and we are responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval. In January 2017, we exercised our co-development option in psoriatic arthritis to fund 30% of future global development costs through regulatory approval, including post-launch studies required by a regulatory authority. We also exercised our co-development options in both atopic dermatitis and axial spondyloarthritis, should Lilly decide to progress into a pivotal program in these indications. Research and development expenses recorded under the Lilly agreement representing 30% of the global development costs for baricitinib for the treatment of rheumatoid arthritis, psoriatic arthritis and atopic dermatitis were $9.1 million and $27.2 million for the three and nine months ended September 30, 2017, respectively. Research and development expenses recorded under the Lilly agreement representing 30% of the global development costs for baricitinib for the treatment of rheumatoid arthritis were $10.6 million and $21.0 million for the three and nine months ended September 30, 2016, respectively. We have retained certain mechanisms to give us cost protection as baricitinib advances in clinical development. We can defer our portion of co-development study costs by indication if they exceed a predetermined level. This deferment would be credited against future milestones or royalties and we would still be eligible for the full incremental royalties related to the co-development option. In addition, even if we have started co-development funding for any indication, we can at any time opt out, which will stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-

6665

Table of Contents

~~rated royalty commensurate with our contribution to the total co-development cost for those indications for which we contributed funding.~~

Selling, general and administrative expenses.


									For the Three Months Ended,				For the Six Months Ended,
									June 30,				June 30,
									2020		2019		2020		2019

	For the Three Months Ended,				For the Nine Months Ended,
	September 30,				September 30,
	2017		2016		2017		2016
	(in millions)				(in millions)
									(in millions)				(in millions)
Salary and benefits related	$	27.4	$	23.2	$	76.9	$	58.7	$	34.9	$	31.4	$	71.0	$	62.8
Stock compensation		11.5		10.3		31.5		25.8		13.6		12.8		27.1		25.8
Other contract services and outside costs		52.4		42.3		160.2		122.7		69.5		61.7		131.0		141.3
Total selling, general and administrative expenses	$	91.3	$	75.8	$	268.6	$	207.2	$	118.0	$	105.9	$	229.1	$	229.9

~~Salary~~The increase in salary and benefits related expense ~~increased from~~for the ~~three and nine~~six months ended ~~September~~June 30, ~~2016~~2020 as compared to the ~~three and nine months ended September 30, 2017~~corresponding period in 2019 was due primarily to increased headcount. This increased headcount was due primarily to the ongoing commercialization efforts related to JAKAFI for intermediate or ~~high‑risk~~high-risk myelofibrosis, ~~and~~ uncontrolled polycythemia vera and GVHD as well as increased headcount related to our European operations. The decrease in other contract services and outside costs for the ~~Acquisition on~~six months ended June ~~1, 2016.~~30, 2020 as compared to the corresponding period in 2019 was due primarily to a decrease in donations to independent non-profit patient assistance organizations in the United States. Stock compensation expense may fluctuate from period to period based on the number of awards granted, stock price volatility and expected award lives, as well as expected award forfeiture rates which are used to value ~~equity‑based~~equity-based compensation. The increase in other contract services and outside costs was primarily the result of marketing activities for JAKAFI for intermediate or high‑risk myelofibrosis and uncontrolled polycythemia vera in addition to an increase in donations to independent non-profit patient assistance organizations in the United States.

Change in fair value of acquisition-related contingent consideration

Acquisition-related contingent consideration, which consists of our future royalty ~~and certain potential milestone~~ obligations to ~~ARIAD,~~Takeda, was recorded on the acquisition date, June 1, 2016, at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured ~~quarterly, resulting~~quarterly. The change in ~~a benefit~~fair value of ~~$16.3 million and $1.9 million~~the acquisition-related contingent consideration for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020 was $6.1 million and $12.7 million, respectively, which is recorded in change in fair value of acquisition-related contingent consideration on the condensed consolidated statements of operations. The change in fair value of the acquisition-related contingent consideration for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016~~2019 was ~~expense of $8.0~~$6.6 million and ~~$10.3~~$13.3 million, respectively, which is recorded in change in fair value of acquisition-related contingent consideration on the condensed consolidated statements of operations. The change in fair value ~~of the contingent consideration~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017 is~~2020 and 2019 was due primarily to the passage of time ~~and a benefit of $24.0 million recorded~~as there were no other significant changes in the key assumptions during the ~~third quarter related to~~periods.

Collaboration loss sharing

Under the ~~lack~~collaboration and license agreement with MorphoSys, which was executed in March 2020, we and MorphoSys are both responsible for the commercialization efforts of ~~expected future sales royalties payable due to~~tafasitamab in the ~~discontinued OPTIC-2L clinical trial.~~United States and will share equally the profits and losses from the co-commercialization efforts. For the three and six months ended June 30, 2020, our 50% share of the costs for tafasitamab was $13.3 million and $15.4 million, respectively, as recorded in collaboration loss sharing on the condensed consolidated statement of operations.

Other income (expense).

~~Interest and other~~Other income (expense), net. ~~Interest and other~~Other income (expense), net for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 was ~~$5.6~~$4.8 million and ~~$10.9~~$13.5 million, respectively. ~~Interest and other~~Other income (expense), net for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016~~2019 was ~~and $1.2~~$15.0 million and ~~$3.8~~$24.4 million, respectively. The decrease in other income (expense), net for the six months ended June 30, 2020 primarily relates to a decrease in interest income.

Interest expense. Interest expense for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 was ~~$0.2~~$0.6 million and ~~$6.5~~$1.2 million, ~~respectively, as compared to $9.5 million and $29.3 million, respectively,~~respectively. Interest expense for ~~the same periods in 2016. The decrease in interest expense during~~ the three and ~~nine~~six months ended ~~September~~June 30, ~~2017 relates to the conversion of senior notes during the period.~~2019 was $0.3 million and $0.7 million, respectively. Included in interest expense for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 was ~~$0.3~~$0.2 million and ~~$5.8~~$0.4 million, respectively, of non-cash charges to amortize the ~~discounts~~discount on the ~~2018~~2020 Notes and ~~the 2020 Notes.~~approximately $0.3 million

66

Table of Contents

and $0.6 million, respectively, of interest expense on our finance lease liabilities. Included in interest expense for the three and ~~nine~~six months ended ~~September~~June 30, ~~2016~~2019 was ~~$7.9~~$0.2 million and ~~$23.6~~$0.4 million, respectively, of non-cash charges to amortize the ~~discounts~~discount on the ~~2018 Notes and the~~ 2020 Notes.

Unrealized gain (loss) on long term investments. Unrealized gains ~~(losses)~~and losses on long term investments will fluctuate from period to period, based on the change in fair value of the securities we hold in our publicly held collaboration partners.

67

~~Table~~ The following table provides a summary of ~~Contents~~

~~With respect to our long term investment in Agenus, the~~those unrealized ~~gain on investment~~gains and (losses):


	For the Three Months Ended,				For the Six Months Ended,
	June 30,				June 30,
	2020		2019		2020		2019

	(in millions)				(in millions)
Agenus	$	26.2	$	0.5	$	(2.7)	$	11.0
Calithera		1.5		(4.9)		(0.7)		(0.2)
Merus		12.7		(0.4)		6.4		2.1
MorphoSys		27.5		—		17.6		—
Syros		4.4		0.2		3.5		3.5
Total unrealized gain (loss) on long term investments	$	72.3	$	(4.6)	$	24.1	$	16.4

Provision for income taxes. The provision for income taxes for the three and ~~nine~~six months ended ~~September 31, 2017~~June 30, 2020 and was ~~$10.2~~$17.0 million and ~~$6.8~~$33.5 million, ~~respectively, as compared to the unrealized gain of $24.3 million and $20.5 million, respectively,~~respectively. The provision for the same periods in 2016. The unrealized gain on our long term investment in Merus for the three months ended September 30, 2017 was $12.9 million and the unrealized loss for the nine months ended September 30, 2017 was $9.2 million.

~~Expense related to senior note conversions.~~ ~~Expense related to senior note conversions~~income taxes for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2019 and was ~~$0.0~~$3.4 million and ~~$54.9~~$5.1 million, ~~respectively, on~~respectively. The increase in provision for income taxes for the ~~conversions of our 2018 Notes~~three and six months ended June 30, 2020 ~~Notes.~~primarily relates to federal and state tax liabilities that are not fully sheltered by net operating losses or research and development tax credit carryforwards. The increase was also driven by reduced tax benefits for stock-based compensation in the current period.

Liquidity and Capital Resources

Due to historical net losses, we had an accumulated deficit of ~~$1.8~~$1.9 billion as of ~~September~~June 30, ~~2017.~~2020. We have funded our research and development operations through sales of equity securities, the issuance of convertible notes, cash received from customers, and collaborative arrangements. At ~~September~~June 30, ~~2017,~~2020, we had available cash, cash equivalents and marketable securities of ~~$1.3~~$1.6 billion. Our cash and marketable securities balances are held in a variety of interest-bearing instruments, including money market accounts, ~~corporate debt securities~~ and U.S. government debt securities. Available cash is invested in accordance with our investment policy’s primary objectives of liquidity, safety of principal and diversity of investments.

Net cash used byin operating activities ~~was $3.7 million~~ for the ~~nine~~six months ended ~~September~~June 30, ~~2017, compared to $210.4~~2020 was $414.0 million and net cash provided by operating activities for the ~~nine~~six months ended ~~September~~June 30, ~~2016.~~2019 was $308.6 million. The ~~$214.1~~$722.6 million decrease in cash provided by operating activities was due primarily to ~~the payments made to our collaborative partners for new or amended arrangements during the first quarter of 2017, expense~~cash outflows in March 2020 related to our ~~senior note conversions~~collaboration and license agreement with MorphoSys and changes in working ~~capital during the 2017 period.~~capital.

Our investing activities, other than purchases, sales and maturities of marketable securities, have consisted predominantly of capital expenditures and purchases of long term investments. Net cash used by investing activities was ~~$207.0~~$151.8 million for the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020, which represented purchases of marketable securities of ~~$131.9~~$287.4 million, capital expenditures of ~~$85.8~~$83.1 million and purchases of long term equity investments of ~~$123.9~~$95.5 million, offset in part by the sale of long term investment of $4.5 million and the sale and maturity of marketable securities of $309.7 million. Net cash used in investing activities was $69.7 million for the six months ended June 30, 2019, which represented purchases of marketable securities of $104.0 million and capital expenditures of $65.6 million, offset in part by the sale and maturity of marketable securities of $134.6 million. Net cash used in investing activities was $196.5 million for the nine months ended September 30, 2016, which represented purchases of marketable securities of $26.9 million, capital expenditures of $104.4 million and acquisition of ARIAD Pharmaceuticals (Luxembourg) S.a.r.l. for net cash of $143.0 million, offset in part by the sale and maturity of marketable securities of $77.8$99.8 million. In the future, net cash used by investing activities may fluctuate significantly from period to period due to the timing of strategic equity investments, acquisitions, and capital expenditures and maturities/sales and purchases of marketable securities.

Net cash provided by financing activities was ~~$686.4~~$58.9 million and ~~$44.8~~$13.5 million, respectively, for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 and ~~2016, respectively,~~2019, primarily representing ~~proceeds from the issuance of common stock in our September 2017 public offering and, to a lesser extent,~~ proceeds from the issuance of common stock under our stock plans, ~~and employee stock purchase plan,~~ offset in part by cash paid to ~~ARIAD~~ARIAD/Takeda for contingent ~~consideration and cash paid in connection with senior note conversions.~~

consideration.

6867

Table of Contents

The following summarizes our significant contractual obligations as of ~~September~~June 30, ~~2017~~2020 and the effect those obligations are expected to have on our liquidity and cash flow in future periods (in millions):


			Less Than		Years		Years		Over
	Total		1 Year		2 - 3		4 - 5		5 Years

													Less Than		Years		Years		Over
											Total		1 Year		2 - 3		4 - 5		5 Years
Contractual Obligations:
Principal on convertible senior debt	$	26.8	$	—	$	7.7	$	19.1	$	—	$	18.9	$	18.9	$	—	$	—	$	—
Interest on convertible senior debt		0.9		0.3		0.5		0.1		—		0.1		0.1		—		—		—
Non-cancelable lease obligations		28.8		12.4		12.5		2.3		1.6
Finance lease liabilities												44.0		1.9		5.9		5.6		30.6
Operating lease liabilities												27.4		11.0		9.9		2.1		4.4
Other non-cancelable obligations												3.2		1.6		1.5		0.1		—
Total contractual obligations	$	56.5	$	12.7	$	20.7	$	21.5	$	1.6	$	93.6	$	33.5	$	17.3	$	7.8	$	35.0

We have entered into and may in the future seek to license additional rights relating to technologies or drug development candidates in connection with our drug discovery and development programs. Under these licenses, we may be required to pay upfront fees, milestone payments, and royalties on sales of future products, which are not reflected in the table above.

In October 2019, we entered into an agreement with Wilmington Friends School Inc., to purchase property for $50.0 million to expand our global headquarters. Under that agreement, closing of the purchase is subject to certain standard closing conditions, including an initial diligence period and a subsequent approval period.

We believe that our cash flow from operations, together with our cash, cash equivalents and marketable securities, will be adequate to satisfy our capital needs for ~~at least~~ the ~~next twelve months.~~foreseeable future. Our cash requirements depend on numerous factors, including our expenditures in connection with our drug discovery and development programs and commercialization operations; expenditures in connection with litigation or other legal proceedings; ~~competing technological and market developments; the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;~~ costs for future facility requirements; our receipt of any milestone or other payments under any collaborative agreements we may enter into, including the agreements with Novartis, Lilly, Innovent and ~~Lilly; expenditures in connection with potential exchanges of our outstanding convertible senior notes;~~Zai Lab; and expenditures in connection with strategic relationships and license agreements, including our agreements with Agenus, ~~ARIAD,~~ARIAD/Takeda, Calithera, ~~Hengrui,~~ Lilly, MacroGenics, MorphoSys, Merus and ~~Merus,~~Syros, strategic equity investments or potential acquisitions. Changes in our research and development or commercialization plans or other changes affecting our operating expenses may result in changes in the timing and amount of expenditures of our capital resources. To the extent we seek to augment our existing cash resources and cash flow from operations to satisfy our cash requirements for future acquisitions or other strategic purposes, we expect that additional funding can be obtained ~~primarily~~ through ~~public~~equity or ~~private equity offerings,~~ debt financings ~~borrowings~~ or ~~strategic collaborations.~~from other sources. The sale of equity or additional convertible debt securities in the future may be dilutive to our stockholders, and may provide for rights, preferences or privileges senior to those of our holders of common stock. Debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to incur further indebtedness.

Off Balance Sheet Arrangements

We have no off-balance sheet arrangements other than those that are discussed above.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our investments in marketable securities, which are composed primarily of ~~corporate debt securities and~~ U.S. government debt securities, are subject to default, changes in credit rating and changes in market value. These investments are also subject to interest rate risk and will decrease in value if market ~~rate~~ interest rates increase. As of ~~September~~June 30, ~~2017,~~2020, marketable securities were ~~$153.3~~$262.8 million. Due to the nature of these investments, if market interest rates were to increase immediately and uniformly by 10% from levels as of ~~September~~June 30, ~~2017,~~2020, the decline in fair value would not be material.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures. We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and

68

Table of Contents

forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing

69

~~Table of Contents~~

and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in internal control over financial reporting. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the ~~nine~~three months ended ~~September~~June 30, ~~2017,~~2020, that materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II:OTHER INFORMATION

Item 1A.Risk Factors

RISKS RELATING TO COMMERCIALIZATION OF OUR PRODUCTS

We depend heavily on our lead product, JAKAFI (ruxolitinib), which is marketed as JAKAVI outside the United States. If we are unable to successfully commercialize JAKAFI in its approved indications or to successfully obtain regulatory approval for and commercialize ruxolitinib for the treatment of additional indications, or if we are significantly delayed or limited in doing so, our business may be materially harmed.

JAKAFI is our first ~~and, currently, only~~ product marketed by us that is approved for sale in the United States. ItJAKAFI was approved by the U.S. Food and Drug Administration, or FDA, in November 2011 for the treatment of patients with intermediate or ~~high‑risk~~high-risk myelofibrosis, ~~and~~ in December 2014 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, which we refer to as uncontrolled polycythemia ~~vera.~~vera, and in May 2019 for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. Although we have received regulatory approval for these indications, such approval does not guarantee future revenues. While we ~~recently acquired exclusive rights to develop and commercialize~~also sell ICLUSIG in the European Union, or EU, and other countries for the treatment of certain types of leukemia, and PEMAZYRE in the United States for the treatment of specified cholangiocarcinoma indications and our exclusive licensees sell OLUMIANT (baricitinib), for the treatment of specified rheumatoid arthritis indications and TABRECTA for the treatment of a certain type of non small-cell lung cancer, and have recently commenced sales efforts for MONJUVI for the treatment of certain lymphoma indications, we anticipate that JAKAFI product sales will continue to contribute a significant percentage of our total revenues over the next several years.

The commercial success of JAKAFI and our ability to generate and maintain revenues from the sale of JAKAFI will depend on a number of factors, including:

·

●

the number of patients with intermediate or ~~high‑risk~~high-risk myelofibrosis, or uncontrolled polycythemia vera or steroid-refractory acute graft-versus-host disease who are diagnosed with the ~~disease~~diseases and the number of such patients that may be treated with JAKAFI;

·

●

the acceptance of JAKAFI by patients and the healthcare community;

·

●

whether physicians, patients and healthcare payors view JAKAFI as therapeutically effective and safe relative to cost and any alternative therapies;

69

Table of Contents

·

●

the ability to obtain and maintain sufficient coverage or reimbursement by ~~third‑party payors;~~

third-party payors and pricing;

·

●

the ability of our ~~third‑party~~third-party manufacturers to manufacture JAKAFI in sufficient quantities ~~with acceptable quality;~~

that meet all applicable quality standards;

70

~~Table of Contents~~

·

●

the ability of our company and our ~~third‑party~~third-party providers to provide marketing and distribution support for JAKAFI;

·

●

the effects of the COVID-19 Pandemic, any associated quarantine, travel restriction, stay-at-home or shutdown orders, guidelines or practices, and any disruption in our supply chain for JAKAFI on our ability to provide marketing and distribution support for JAKAFI, our ability to produce sufficient quantities of JAKAFI that meet all applicable quality standards, patient demand (including new patient prescriptions) and other risks detailed further below under “—Other Risks Relating to our Business—Public health epidemics, such as the COVID-19 Pandemic, could adversely affect our business, results of operations, and financial condition”;

●

the label and promotional claims allowed by the FDA;

·

●

the maintenance of regulatory approval for the approved indications in the United States; and

·

●

our ability to develop, obtain regulatory approval for and commercialize ruxolitinib in the United States for additional indications.

If we are not ~~successful in commercializing~~able to maintain revenues from JAKAFI in the United States, or ~~are significantly delayed or limited in doing so,~~our revenues from JAKAFI decrease, our business may be materially harmed and we may need to delay other drug discovery, development and ~~development~~commercialization initiatives or even significantly curtail ~~operations.~~operations, and our ability to license or acquire new products to diversify our revenue base could be limited.

In addition, our receipt of royalties under our collaboration ~~agreement~~agreements with Novartis for sales of JAKAVI outside the United States and TABRECTA globally and with Eli Lilly and Company for worldwide sales of OLUMIANT will depend on factors similar to those listed above, ~~for~~with similar regulatory, pricing and reimbursement issues driven by applicable regulatory authorities and governmental and third-party payors affecting jurisdictions outside the United States.

If we are unable to obtain, or maintain at anticipated levels, reimbursement for our products from government health administration authorities, private health insurers and other organizations, our pricing may be affected or our product sales, results of operations or financial condition could be harmed.

We may not be able to sell our products on a profitable basis or our profitability may be reduced if we are required to sell our products at lower than anticipated prices or reimbursement is unavailable or limited in scope or amount. The costs of JAKAFI, ICLUSIG and ~~ICLUSIG~~PEMAZYRE are ~~expensive~~not insignificant and the cost of MONJUVI is similarly expected not to be insignificant and almost all patients will require some form of ~~third party~~third-party coverage to afford their cost. Our future revenues and profitability will be adversely affected if we cannot depend on government and other ~~third‑party~~third-party payors to defray the cost of our products to the patient. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. Reimbursement in the EU must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries, we expect that it may exceed 12 months. Risks related to pricing and reimbursement are described below under “—Other Risks Relating to our Business—Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators’ products and drug candidates. Our ability to generate revenues will be diminished if we or our collaborators are unable to obtain an adequate level of reimbursement from private insurers, government insurance programs or other third party payors of health care costs, which could be affected by current and potential healthcare reform ~~legislation.~~legislation, and diminished revenues will harm our operating results and financial condition and could adversely affect our ability to conduct our research and

70

Table of Contents

development operations.” If government and other ~~third‑party~~third-party payors refuse to provide coverage and reimbursement with respect to our products, determine to provide a lower level of coverage and reimbursement than anticipated, or reduce previously approved levels of coverage and reimbursement, or delay reimbursement payments due to budgetary constraints relating to the COVID-19 Pandemic, then our pricing or reimbursement for our products may be affected and our product sales, results of operations or financial condition could be harmed.

We depend upon a limited number of specialty pharmacies and wholesalers for a significant portion of any revenues from JAKAFI, and the loss of, or significant reduction in sales to, any one of these specialty pharmacies or wholesalers could adversely affect our operations and financial condition.

We sell JAKAFI primarily to specialty pharmacies and wholesalers. Specialty pharmacies dispense JAKAFI to patients in fulfillment of prescriptions and wholesalers sell JAKAFI to hospitals and physician offices. We do not promote JAKAFI to specialty pharmacies or wholesalers, and they do not set or determine demand for JAKAFI. Our ability to successfully commercialize JAKAFI will depend, in part, on the extent to which we are able to provide adequate distribution of JAKAFI to patients. Although we have contracted with a number of specialty pharmacies and wholesalers, they are expected generally to carry a very limited inventory and may be reluctant to be part of our distribution network in the future if demand for the product does not increase. Further, it is possible that these specialty pharmacies and wholesalers could decide to change their policies or fees, or both, at some time in the future. This could result in their refusal to carry smaller volume products such as JAKAFI, or lower margins or the need to find alternative methods of distributing our product. Although we believe we can find alternative channels to distribute JAKAFI on relatively short notice, our revenue

71

~~Table of Contents~~

during that period of time may suffer and we may incur additional costs to replace any such specialty pharmacy or wholesaler. The loss of any large specialty pharmacy or wholesaler as part of our distribution network, a significant reduction in sales we make to specialty pharmacies or wholesalers, or any failure to pay for the products we have shipped to them could materially and adversely affect our results of operations and financial condition.

If we are unable to establish and maintain effective sales, marketing and distribution capabilities, or to enter into agreements with third parties to do so, we will not be able to successfully commercialize our products.

Prior to our commercialization of JAKAFI, we had no experience selling and marketing drug products and with pricing and obtaining adequate third‑party reimbursement for drug products. Under our collaboration and license agreement with Novartis, we have retained commercialization rights to JAKAFI in the United States. We have established commercial capabilities in the United States and outside of the United States, but cannot guarantee that we will be able to enter into and maintain any marketing, distribution or ~~third‑party~~third-party logistics agreements with ~~third‑party~~third-party providers on acceptable terms, if at all. In connection with our recent acquisition from ARIAD Pharmaceuticals, Inc. we licensed rights to develop and commercialize ICLUSIG in certain countries and we acquired the European sales, marketing and distribution operations of ARIAD. We may not be able to maintain those operations or retain their personnel or distribution arrangements. We may not be able to correctly judge the size and experience of the sales and marketing force and the scale of distribution capabilities necessary to successfully market and sell ~~our~~any new products. Establishing and maintaining sales, marketing and distribution capabilities are expensive and ~~time‑consuming.~~time-consuming. Competition for personnel with experience in sales and marketing can be high. Our expenses associated with building and maintaining the sales force and distribution capabilities may be disproportional compared to the revenues we may be able to generate on sales of our products.

To the extent that we are able to obtain marketing approval for ruxolitinib cream for dermatology indications such as atopic dermatitis and vitiligo, we will have to establish and maintain sales, marketing and distribution capabilities that will generally be separate from our existing capabilities for oncology indications, and we have no prior experience in commercializing products for dermatology indications. Successful commercialization of our drug candidates for dermatology indications, if approved, will require us to establish new physician and payor relationships, reimbursement strategies and governmental interactions. Our inability to commercialize successfully products in indications outside of oncology could harm our business and operating results.

If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity.

We cannot guarantee that we will be able to maintain regulatory approval to market our products in the jurisdictions in which they are currently marketed. If we do not maintain our regulatory approval to market our products, in particular JAKAFI, our results of operations will be materially harmed. We and our collaborators, ~~third‑party~~third-party manufacturers and suppliers are subject to rigorous and extensive regulation by the FDA and other federal and state agencies as well as foreign governmental agencies. These regulations continue to apply after product marketing approval,

71

Table of Contents

and cover, among other things, testing, manufacturing, quality control and assurance, labeling, advertising, promotion, risk mitigation, and adverse event reporting requirements.

The commercialization of our products is subject to ~~post‑regulatory~~post-regulatory approval product surveillance, and our products may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing for our products, and our products may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity. For example, from late 2013 through 2014, ICLUSIG was subject to review by the European Medicines Agency, or EMA, of the benefits and risks of ICLUSIG to better understand the nature, frequency and severity of events obstructing the arteries or veins, the potential mechanism that leads to these side effects and whether there needed to be a revision in the dosing recommendation, patient monitoring and a risk management plan for ICLUSIG. This review was completed in January 2015, with additional warnings in the product information but without any change in the approved indications. The EMA could take additional actions in the future that reduce the commercial potential of ICLUSIG.

Failure to comply with the laws and regulations administered by the FDA or other agencies could result in:

·

●

administrative and judicial sanctions, including warning letters;

·

●

fines and other civil penalties;

·

●

suspension or withdrawal of regulatory approval to market or manufacture our products;

·

●

interruption of production;

72

~~Table of Contents~~

·

●

operating restrictions;

·

●

product recall or seizure;

·

●

injunctions; and

·

●

criminal prosecution.

The occurrence of any such event may have a material adverse effect on our business.

If the use of our products harms patients, or is perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims.

The testing of JAKAFI, ICLUSIG, PEMAZYRE and ~~ICLUSIG,~~MONJUVI, the manufacturing, marketing and sale of JAKAFI and PEMAZYRE and the marketing and sale of ICLUSIG and MONJUVI expose us to product liability and other risks. Side effects and other problems experienced by patients from the use of our productscould:

·

●

lessen the frequency with which physicians decide to prescribe our products;

·

●

encourage physicians to stop prescribing our products to their patients who previously had been prescribed our products;

·

●

cause serious harm to patients that may give rise to product liability claims against us; and

·

●

result in our need to withdraw or recall our products from the marketplace.

72

Table of Contents

If our products are used by a wide patient population, new risks and side effects may be discovered, the rate of known risks or side effects may increase, and risks previously viewed as less significant could be determined to be significant.

Previously unknown risks and adverse effects of our products may also be discovered in connection with unapproved, or ~~off‑label,~~off-label, uses of our products. We are prohibited by law from promoting or in any way supporting or encouraging the promotion of our products for ~~off‑label~~off-label uses, but physicians are permitted to use products for ~~off‑label~~off-label purposes. In addition, we are studying and expect to continue to study JAKAFI in diseases for potential additional indications in controlled clinical settings, and independent investigators are doing so as well. In the event of any new risks or adverse effects discovered as new patients are treated for intermediate or ~~high‑risk~~high-risk myelofibrosis, or uncontrolled polycythemia vera or acute graft-versus-host disease and as JAKAFI is studied in or used by patients for ~~off‑label~~off-label indications, regulatory authorities may delay or revoke their approvals, we may be required to conduct additional clinical trials, make changes in labeling of JAKAFI, reformulate JAKAFI or make changes and obtain new approvals. We may also experience a significant drop in the sales of JAKAFI, experience harm to our reputation and the reputation of JAKAFI in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent sales of JAKAFI or substantially increase the costs and expenses of commercializing JAKAFI. Similar results could occur with respect to our commercialization of ~~ICLUSIG.~~ICLUSIG, PEMAZYRE and MONJUVI.

Patients who have been enrolled in our clinical trials or who may use our products in the future often have severe and advanced stages of disease and known as well as unknown significant ~~pre‑existing~~pre-existing and potentially ~~life‑threatening~~life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our products. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time

73

~~Table of Contents~~

consuming or inconclusive. These investigations may interrupt our sales efforts, impact and limit the type of regulatory approvals our products receive or maintain, or delay the regulatory approval process in other countries.

Factors similar to those listed above also apply to our ~~collaboration partner~~collaborator Novartis for jurisdictions in which it has development and commercialization rights, to ICLUSIG for jurisdictions outside the United ~~States.~~States, to our collaborator Lilly for all jurisdictions and to our collaborator Innovent for PEMAZYRE in the jurisdictions in which it has development and commercialization rights.

If we market our products in a manner that violates various laws and regulations, we may be subject to civil or criminal penalties.

In addition to FDA and related regulatory requirements, we are subject to health care “fraud and abuse” laws, such as the federal False Claims Act, the ~~anti‑kickback~~anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. Federal and state ~~anti‑kickback~~anti-kickback laws prohibit, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid, or other ~~federally‑~~federally- or ~~state‑financed~~state-financed health care programs. Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities.

Although physicians are permitted, based on their medical judgment, to prescribe products for indications other than those approved by the FDA, manufacturers are prohibited from promoting their products for such ~~off‑label~~off-label uses. We market JAKAFI for intermediate or ~~high‑risk~~high-risk myelofibrosis, ~~and~~ uncontrolled polycythemia vera and acute graft-versus-host disease and provide promotional materials to physicians regarding the use of JAKAFI for these indications. Although we believe that our promotional materials for physicians do not constitute ~~off‑label~~improper promotion of JAKAFI, the FDA or other agencies may disagree. If the FDA or another agency determines that our promotional materials or other activities constitute ~~off‑label~~improper promotion of JAKAFI, it could request that we modify our promotional materials or other activities or subject us to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, civil fine and

73

Table of Contents

criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is later determined we are not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our position and have to divert significant management resources from other matters. Similar risks will exist for our marketing of PEMAZYRE and our and our collaborator MorphoSys’s marketing of MONJUVI.

The European Union and member countries, as well as governmental authorities in other countries, impose similar strict restrictions on the promotion and marketing of drug products. The off-label promotion of medicinal products is prohibited in the EU and in other ~~territories.~~territories, and the EU also maintains strict controls on advertising and promotional materials. The promotion of medicinal products that are not subject to a marketing authorization is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU and in other territories could be penalized by administrative measures, fines and imprisonment.

The majority of states also have statutes or regulations similar to the federal ~~anti‑kickback~~anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. ~~In recent years, several~~Numerous states and localities ~~including California, Connecticut, the District of Columbia, Massachusetts, Minnesota, Nevada, New Mexico, Texas, Vermont, and West Virginia,~~ have enacted or are considering enacting legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports ~~with the state~~ or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. ~~Similar legislation is being considered in other states.~~ Additionally, as part of the Patient Protection and Affordable Care Act, the federal government has enacted the Physician Payment Sunshine provisions. The Sunshine provisions and similar laws and regulations in other jurisdictions where we do business require manufacturers to publicly report certain payments or other transfers of value made to physicians and teaching hospitals. Many of these requirements are new and uncertain, and the penalties for failure to comply with these requirements are unclear. Nonetheless, if we are found not to be in full compliance with these laws, we could face enforcement action and fines and other penalties, which could be significant in amount or result in exclusion from federal healthcare programs such as Medicare and Medicaid. Any action initiated against us for violation of these laws, even if we successfully defend against it, could ~~receive adverse publicity.~~require the expenditure of significant resources and generate negative publicity, which could harm our business and operating results. See also “—Other Risks Relating to our Business—If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business” below.

74

~~Table of Contents~~

Competition for our products could harm our business and result in a decrease in our revenue.

Present and potential competitors for JAKAFI could include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms. For example, ~~Gilead Sciences, Inc. has~~in August 2019, Celgene Corporation, now a ~~drug candidate in Phase III clinical trials~~subsidiary of Bristol-Myers Squibb Company, announced that the FDA had approved INREBIC (fedratinib) for the treatment of myelofibrosis. See “—Other Risks Relating to our Business— We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated” for a description of risks relating to this type of competition. In addition, JAKAFI could face competition from generic products. As a result of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the United States, generic manufacturers may seek approval of a generic version of an innovative pharmaceutical by filing with the FDA an Abbreviated New Drug Application, or ANDA. The Hatch-Waxman Act provides significant incentives to generic manufacturers to challenge U.S. patents on successful innovative pharmaceutical products. In February 2016, we received a notice letter regarding an ANDA that requested approval to market a generic version of JAKAFI and purported to challenge patents covering ruxolitinib phosphate and its use that expire in 2028. The notice letter does not challenge the ruxolitinib composition of matter patent, which expires in December 2027. To date, to our knowledge, the FDA has taken no action with respect to this ANDA. Separately, in January 2018 the Patent Trial and Appeal Board (PTAB) of United States Patent and Trademark Office denied a petition challenging our patent covering deuterated ruxolitinib analogs and the PTAB subsequently denied the petitioner’s request for rehearing in May 2018. Nevertheless, the petitioner still has the right separately to challenge the validity of our patent in federal court. There can be no assurance that our patents will be upheld or that any litigation in which we might engage with any such generic

74

Table of Contents

manufacturer would be successful in protecting JAKAFI’s exclusivity. The entry of a generic version of JAKAFI could result in a decrease in JAKAFI sales and materially harm our business, operating results and financial condition.

ICLUSIG currently competes with existing therapies that are approved for the treatment of patients with chronic myeloid leukemia, or CML, who are resistant or intolerant to prior tyrosine kinase inhibitor, or TKI, therapies, on the basis of, among other things, efficacy, cost, breadth of approved use and the safety and side-effect profile. In addition, a generic ~~version~~versions of imatinib ~~was launched in the United States in February 2016,~~are available and, ~~generic versions are expected to be launched in other markets. Although~~while we currently believe that generic versions of imatinib will not materially impact our commercialization of ICLUSIG, given ICLUSIG’s various indication statements globally that are currently focused on resistant or intolerant CML, we cannot be certain how physicians, payors, patients, regulatory authorities and other market participants will respond to the availability of generic versions of imatinib.

Present and potential competitors for PEMAZYRE and MONJUVI could include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms.

OTHER RISKS RELATING TO OUR BUSINESS

Public health epidemics, such as the COVID-19 Pandemic, could adversely affect our business, results of operations, and financial condition.

Our global operations expose us to risks associated with public health epidemics, such as the COVID-19 Pandemic that has spread globally. The extent to which the COVID-19 Pandemic and the measures taken to limit COVID-19’s spread impact our operations and those of our suppliers, collaborators, service providers and healthcare organizations serving patients, as well as demand for our drug products, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and any future resurgence of the outbreak, additional or modified government actions, including any further restrictions or reopening of local, state or national social or economic activity, new information that may emerge concerning the severity of COVID-19 and the actions taken to contain COVID-19 or treat its impact, among others.

As a result of the COVID-19 Pandemic, we may experience disruptions that could severely impact our business, results of operations and financial condition, including the following:

●

To protect the health of our employees and their families, and our communities, in accordance with – and in some cases in advance or - direction from state and local government authorities, we currently have limited access to certain of our facilities and instituted additional precautions in our facilities that have reopened , and a significant percentage of our personnel continue to work remotely a significant portion of their time. In the event that governmental authorities were to modify current restrictions or re-establish greater restrictions, our employees conducting research and development activities may not be able to access our laboratory space, and our research and development activities may be significantly limited or curtailed, possibly for an extended period of time. These research and development activities could include completing Investigational New Drug (IND)/Clinical Trial Application (CTA)-enabling studies, our ability to select future development candidates, and initiation of additional clinical trials for our development programs. Having a significant portion of our employees work from home can strain our information technology infrastructure, which may affect our ability to operate effectively, may make us more susceptible to communications disruptions, and expose us to greater cybersecurity risks.

●

Our sales and marketing activities, including our interactions with healthcare professionals, have been limited and made more difficult by the work from home orders and travel restrictions, and we cannot predict the effects on patient demand or future sales if there are prolonged quarantines, work from home orders or travel restrictions.

●

Our clinical trials have been and may in the future be affected by delays in site initiation, patient screening, patient enrollment, and monitoring and data collection as a result of prioritization of hospital resources for the COVID-19 Pandemic, travel restrictions, and the inability to access sites for initiation and monitoring. In addition, some patients may be unable to comply with clinical trial protocols if quarantines or stay at home orders impede patient movement or interrupt health services, we may be unable to obtain blood samples for testing, and we may not be able to provide the trial drug candidate to patients.

75

Table of Contents

●

Health regulatory agencies globally have experienced disruptions in their operations as a result of the coronavirus pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be materially delayed. If any of these disruptions occur or continue to occur, we cannot predict how long they may last. Our drug candidate application reviews and potential approvals could be impacted or delayed by these disruptions, if they occur or continue to occur.

●

The outbreak and measures taken to limit the spread of the outbreak, especially if prolonged, could also disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products and product candidates, which could adversely affect our revenues and clinical trial timelines. Currently, our supply chain for our drug products and product candidates depends on operations by us and by other companies in multiple countries around the world, and the effects of the COVID-19 Pandemic or any or all of these countries is uncertain and unpredictable and potential disruption is possible. And, for JAKAFI, while our strategy is to maintain a 24 month stock of active pharmaceutical ingredient, or API, inclusive of finished product, ruxolitinib phosphate might be used by us either to make JAKAFI or for ruxolitinib drug candidates in clinical trials.

●

The deterioration of worldwide credit and financial markets could result in losses on our holdings of cash and investments due to failures of financial institutions and other parties, and interruptions and delays in our ability to collect, or potential losses on, our accounts receivable.

Our collaborators could be affected by similar factors as those that have or could affect our business. The ultimate impact of the COVID-19 Pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential impacts or delays on our or our collaborators’ businesses, our revenues, including milestone and royalty revenues from our collaborators, our and our collaborators’ clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on our business, results of operations, and financial condition.

We may be unsuccessful in our efforts to discover and develop drug candidates and commercialize drug products.

~~None~~Our long-term success, revenue growth and diversification of revenues depends on our ability to obtain regulatory approval for new drug ~~candidates, other than JAKAFI/JAKAVI, has received regulatory approval.~~products and new indications for our existing drug products. Our ability to discover and develop drug candidates and to commercialize additional drug products and indications will depend on our ability to:

·

●

hire and retain key employees;

·

●

identify high quality therapeutic targets;

·

●

identify potential drug candidates;

·

●

develop products internally or license drug candidates from others;

·

●

identify and enroll suitable human subjects, either in the United States or abroad, for our clinical trials;

·

●

complete laboratory testing;

·

●

commence, conduct and complete safe and effective clinical trials on humans;

·

●

obtain and maintain necessary intellectual property rights to our products;

·

●

obtain and maintain necessary regulatory approvals for our products, both in the United States and abroad;

·

●

enter into arrangements with third parties to provide services or to manufacture our products on our behalf;

7576

Table of Contents

·

●

deploy sales, marketing, distribution and ~~marketing~~manufacturing resources effectively or enter into arrangements with third parties to provide these functions in compliance with all applicable laws;

·

●

obtain appropriate coverage and reimbursement levels for the cost of our products from governmental authorities, private health insurers and other ~~third‑party~~third-party payors;

·

●

lease facilities at reasonable rates to support our growth; and

·

●

enter into arrangements with third parties to license and commercialize our products.

We ~~have limited experience with many of the activities listed above and~~ may not be successful in discovering, developing, or commercializing additional drug ~~products.~~products or our existing drug products in new indications. Discovery and development of drug candidates are expensive, uncertain and ~~time‑consuming,~~time-consuming, and we do not know if our efforts will lead to discovery of any drug candidates that can be successfully developed and marketed. Of the compounds or biologics that we identify as potential drug products or that we may ~~in‑license~~in-license from other companies, including potential products for which we are conducting clinical trials, only a few, if any, are likely to lead to successful drug development programs and commercialized drug products.

We depend heavily on the success of our most advanced drug candidates. We might not be able to commercialize any of our drug candidates successfully, and we may spend significant time and money attempting to do so.

We have invested significant resources in the development of our most advanced drug candidates. We and our collaborator MorphoSys have submitted a European Marketing Authorization Application with the EMA for tafasitamab in combination with lenalidomide for the treatment of patients with a specified type of lymphoma. Ruxolitinib ~~recently entered into a pivotal~~is in Phase IIIII clinical ~~trial~~trials for the treatment of patients with steroid-refractory ~~acute~~ graft-versus-host disease and patients with COVID-19 and is in other clinical trials. ~~Epacadostat commenced~~Ruxolitinib cream is in Phase III clinical trials for the treatment of patients with atopic dermatitis and vitiligo. Itacitinib is in ~~late 2016.~~Phase III clinical trials for the treatment of patients with chronic graft-versus-host disease. Further, we have a number of drug candidates in Phase I and Phase II clinical trials. Our ability to generate product revenues will depend on the successful development and eventual commercialization of our most advanced drug candidates. We, or our collaborators or licensees, may decide to discontinue development of any or all of our drug candidates at any time for commercial, scientific or other reasons. For ~~example,~~example: in early 2016, we decided to discontinue the ~~studies~~clinical trials of ruxolitinib in pancreatic cancer and solid tumors and ~~INCB39110~~itacitinib in pancreatic ~~cancer.~~cancer; and, in April 2018, we along with Merck stopped the ECHO-301 study with epacadostat, and we also significantly downsized the epacadostat development program. In addition, in January 2020 we announced that itacitinib did not meet the primary endpoint in the Phase III clinical trial for the treatment of patients with acute graft-versus-host disease. If a product is developed but not approved or marketed, we may have spent significant amounts of time and money on it, which could adversely affect our operating results and financial condition as well as our business plans.

If we or our collaborators are unable to obtain regulatory approval for our drug candidates in the United States and foreign jurisdictions, we or our collaborators will not be permitted to commercialize products resulting from our research.

In order to commercialize drug products in the United States, drug candidates will have to obtain regulatory approval from the FDA. Satisfaction of regulatory requirements typically takes many years. To obtain regulatory approval, we or our collaborators, as the case may be, must first show that our or our collaborators’ drug candidates are safe and effective for target indications through preclinical testing (animal testing) and clinical trials (human testing). Preclinical testing and clinical development are long, expensive and uncertain processes, and we do not know whether the FDA will allow us or our collaborators to undertake clinical trials of any drug candidates in addition to our or our collaborators’ compounds currently in clinical trials. If regulatory approval of a product is granted, this approval will be limited to those disease states and conditions for which the product is demonstrated through clinical trials to be safe and effective.

Completion of clinical trials may take several years and failure may occur at any stage of testing. The length of time required varies substantially according to the type, complexity, novelty and intended use of the drug candidate. Interim results of a preclinical test or clinical trial do not necessarily predict final results, and acceptable results in early clinical trials may not be repeated in later clinical trials. For example, a drug candidate that is successful at the preclinical level

77

Table of Contents

may cause harmful or dangerous side effects when tested at the clinical level. Our rate of commencement and completion of clinical trials may be delayed, and existing clinical trials with our or our collaborators’ drug candidates may be stopped, due to many potential factors, including:

·

●

the high degree of risk and uncertainty associated with drug development;

76

~~Table of Contents~~

·

●

our inability to formulate or manufacture sufficient quantities of materials for use in clinical trials;

·

●

variability in the number and types of patients available for each study;

·

●

difficulty in maintaining contact with patients after treatment, resulting in incomplete data;

·

●

unforeseen safety issues or side effects;

·

●

poor or unanticipated effectiveness of drug candidates during the clinical trials; or

·

●

government or regulatory delays.

Data obtained from clinical trials are susceptible to varying interpretation, which may delay, limit or prevent regulatory approval. Many companies in the pharmaceutical and biopharmaceutical industry, including our company, have suffered significant setbacks in advanced clinical trials, even after achieving promising results in earlier clinical trials. In addition, regulatory authorities may refuse or delay approval as a result of other factors, such as changes in regulatory policy during the period of product development and regulatory agency review. For example, the FDA has in the past required, and could in the future require, that we or our collaborators conduct additional trials of any of our drug candidates, which would result in delays. In April 2017, we and our collaborator Lilly announced that the FDA had issued a complete response letter for the New Drug Application, ~~(NDA)~~or NDA, of OLUMIANT ~~(baricitinib)~~ as a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis. The letter ~~indicates that the FDA is unable to approve the application in its current form. Specifically, the FDA~~ indicated that additional clinical data ~~are~~were needed to determine the most appropriate ~~doses. The FDA also stated that additional data are necessary~~doses and to further characterize safety concerns across treatment arms. In ~~July 2017, we and Lilly announced that~~June 2018, after a resubmission toof the NDA, the FDA approved the 2mg dose of OLUMIANT for the ~~NDA for baricitinib will be delayed for~~treatment of adults with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor inhibitor therapies. The FDA did not at that time approve any higher dose of OLUMIANT and required a ~~period anticipated to be a minimum of 18 months and that the FDA had requested an additional clinical study.~~warning label in connection with its approval.

Compounds or biologics developed by us or with or by our collaborators and licensees may not prove to be safe and effective in clinical trials and may not meet all of the applicable regulatory requirements needed to receive marketing approval. For example, in January 2016, a Phase II trial that was evaluating ruxolitinib in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer and high C-reactive protein was stopped early after a planned analysis of interim efficacy data determined that the likelihood of the trial meeting its efficacy endpoint was insufficient. In addition, in February 2016, we made a decision to discontinue our JANUS 1 study, our JANUS 2 study, our other studies of ruxolitinib in colorectal, breast and lung cancer, and our study of INCB39110 in pancreatic cancer after a planned analysis of interim efficacy data of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation. Also, in April 2018, we along with Merck announced that the ECHO-301 study had been stopped and we also significantly downsized the epacadostat development program and in January 2020 we stopped our Phase III trial of itacitinib for the treatment of acute graft-versus-host-disease. If clinical trials of any of our or our collaborators’ compounds or biologics are stopped for safety, efficacy or other reasons or fail to meet their respective endpoints, our overall development plans, business, prospects, expected operating results and financial condition could be materially harmed and the value of our company could be negatively affected.

Outside the United States, our and our collaborators’ ability to market a product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities. This foreign regulatory approval process typically includes all of the risks associated with the FDA approval process described above and may also include additional risks. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country and may require us to perform additional testing and expend additional resources. Approval by the FDA

78

Table of Contents

does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA.

Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators’ products and drug candidates. Our ability to generate revenues will be diminished if we or our collaborators are unable to obtain an adequate level of reimbursement from private insurers, government insurance programs or other ~~third‑party~~third-party payors of health care costs, which could be affected by current and potential healthcare reform ~~legislation.~~legislation, and diminished revenues will harm our operating results and financial condition and could adversely affect our ability to conduct our research and development operations.

Our ability to commercialize our current and any future approved products successfully will depend in part on the prices we are able to charge for our approved products and the extent to which adequate reimbursement levels for the cost of our products and related treatment are obtained from

77

~~Table of Contents~~

~~third‑party~~ third-party payors, such as private insurers, government insurance programs, including Medicare and Medicaid, health maintenance organizations (HMOs) and other health care related ~~organizations.~~organizations in the U.S. and abroad.

In recent years, through legislative and regulatory actions and executive orders, the U.S. federal government has made substantial changes to various payment systems under the Medicare and other federal health care programs. Comprehensive reforms to the U.S. healthcare system were enacted, including changes to the methods for, and amounts of, Medicare reimbursement. While there is currently significant uncertainty regarding the implementation of some of these reforms or the scope of amended or additional reforms, the implementation of reforms could significantly reduce payments from Medicare and Medicaid. Reforms or other changes to these payment systems may change the availability, methods and rates of reimbursements from Medicare, private insurers and other third-party payors for our current and any future approved products. Some of these changes and proposed changes could result in reduced reimbursement rates or in eliminating dual sources of payment, which could reduce the price that we or any of our collaborators or licensees receive for any products in the future, and which would adversely affect our business strategy, operations and financial results. ~~Further~~

In addition, there has been an increasing legislative and enforcement interest in the United States with respect to drug pricing practices. This has resulted in several recent federal and state proposals, including executive orders issued by the Trump Administration in July 2020, to regulate prices of pharmaceutical products and other health care reforms, ~~are possible,~~any of which could limit the prices that we can ~~be charged~~charge for ~~any of~~ our products and may further limit the commercial viability of our products and drug candidates. Specifically, there have been several federal congressional inquiries and proposed and enacted federal and state legislation and the July 2020 executive orders designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, reform government program reimbursement methodologies for prescription drugs, allow importation of drugs into the U.S. from other countries and limit allowable prices for drugs to a function of an average international reference price that may be substantially lower than what we currently or would otherwise charge. In certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control. We expect that the health care reform measures that have been adopted in the United States and in foreign markets, and further reforms that may be adopted in the future, could result in more rigorous coverage criteria and additional downward pressure on the prices that we may receive for our approved products. If reimbursement for our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially ~~harmed.~~harmed, including by our revenue potentially being materially adversely affected and our research and development efforts potentially being materially curtailed or, in some cases, ceasing. There may be future changes that result in reductions in current prices, coverage and reimbursement levels for our current or any future approved products, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.

~~Third‑party~~The consequences of the COVID-19 Pandemic, including the economic effect on government budgets in the U.S. and elsewhere, may accelerate any of the healthcare reform efforts described above or result in future reform efforts, any of which could have adverse effects on our business, including higher costs for us, lower reimbursement rates for our products and lower demand for our products.

If third parties institute high co-payment amounts or other benefit limits for our products, the demand for our products and, accordingly, our revenues and results of operations, could be adversely affected. Our patient assistance

79

Table of Contents

programs have provided support for non-profit organizations that provide financial assistance to eligible patients or in some cases have provided our products without charge to patients who have no or limited insurance coverage through these charitable organizations. Substantial support in this manner could harm our profitability in the future. Further, those organizations’ ability to provide assistance to patients is dependent on funding from external sources, and we cannot guarantee that such funding will be provided at adequate levels, or at all.

Further, if we become the subject of any governmental or other regulatory hearing or investigation with respect to the pricing of our products or other business practices, we could incur significant expenses and could be distracted from the operation of our business and execution of our business strategy. Any such hearing or investigation could also result in significant negative publicity and harm to our reputation, reduced market acceptance and demand, which could adversely affect our financial results and growth prospects.

Third-party payors are increasingly challenging the prices charged for medical products and services. Also, the trend toward managed health care in the United States, the organizations for which could control or significantly influence the purchase of health care services and products, as well as legislative and regulatory proposals to reform health care or reduce government insurance programs, may all result in lower prices for or rejection of our products. Adoption of our products by the medical community may be limited without adequate reimbursement for those products. Cost control initiatives may decrease coverage and payment levels for our products and, in turn, the price that we will be able to charge for any product. Our products may not be considered ~~cost‑effective,~~cost-effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our products on a profitable basis. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payors to our current and any future approved products.

The continuing efforts of legislatures, health agencies and ~~third‑party~~third-party payors to contain or reduce the costs of health care, any denial of private or government payor coverage or inadequate reimbursement for our drug candidates could materially and adversely affect our business strategy, operations, future revenues and profitability, and the future revenues and profitability of our potential customers, suppliers, collaborators and licensees and the availability of capital. The same risks apply to our compounds developed and marketed by our collaborators, and our future potential milestone and royalty revenues could be affected in a similar manner.

We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business.

We have licensed to Novartis rights to ruxolitinib outside of the United States and worldwide rights to our c‑MET inhibitor compounds, including TABRECTA, and licensed to Lilly worldwide rights to baricitinib. WeIn addition, we have ~~also~~ licensed to ~~Pfizer~~Innovent and to Zai Lab certain Asian rights to some of our ~~portfolio of CCR2 antagonist~~clinical stage compounds. Under the terms of our agreements with these collaborators, we have no or limited control over the further clinical development of these drug candidates in the relevant territories and any revenues we may receive if these drug candidates receive regulatory approval and are commercialized in the relevant territories will depend primarily on the development and commercialization efforts of others. While OLUMIANT ~~(baricitinib)~~ was approved by the European Commission in February 2017 for the treatment of moderate-to-severe rheumatoid arthritis in adult patients and by Japan’s Ministry of Health, Labor and Welfare in July 2017 for the treatment of rheumatoid arthritis in patients with inadequate response to standard-of-care therapies, if the ~~New Drug Application~~NDA for ~~baricitinib~~OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis ~~does not receive FDA approval, we will not receive future milestone payments or royalties related to that indication~~was approved in June 2018, and only in the ~~United States under our agreement~~lower dosage tablet and with ~~Lilly. In addition, even if baricitinib is approved~~a warning label. Delays in any marketing approval by the FDA, ~~in this indication, delays in any~~

78

~~Table of Contents~~

~~such approval,~~European or other regulatory authorities, or any label modifications or restrictions in connection with any such approval, ~~by the FDA, European or other regulatory authorities,~~ or the existence of other risks relating to approved drug products, including those described under “Risks Relating to Commercialization of Our Products,” could delay the receipt of and reduce resulting potential royalty and milestone revenue from ~~baricitinib.~~baricitinib or any of our other out-licensed drug candidates.

Conflicts may arise with our collaborators and licensees if they pursue alternative technologies or develop alternative products either on their own or in collaboration with others as a means for developing treatments for the diseases that we have targeted. Competing products and product opportunities may lead our collaborators and licensees to withdraw their support for our drug candidates. Any failure of our collaborators and licensees to perform their obligations under our

80

Table of Contents

agreements with them or otherwise to support our drug candidates could negatively impact the development of our drug candidates, lead to our loss of potential revenues from product sales and milestones and delay our achievement, if any, of profitability. Additionally, conflicts may arise if, among other things, there is a dispute about the achievement and payment of a milestone amount or the ownership of intellectual property that is developed during the course of a collaborative relationship.

Our existing collaborative and license agreements can be terminated by our collaborators and licensees for convenience, among other circumstances. If any of our collaborators or licensees terminates its agreement with us, or terminates its rights with respect to certain indications or drug candidates, we may not be able to find a new collaborator for them, and our business could be adversely affected. Should an agreement be terminated before we have realized the benefits of the collaboration or license, our reputation could be harmed, we may not obtain revenues that we anticipated receiving, and our business could be adversely affected.

The success of our drug discovery and development efforts may depend on our ability to find suitable collaborators to fully exploit our capabilities. If we are unable to establish collaborations or if these future collaborations are unsuccessful in the development and commercialization of our drug candidates, our research, development and commercialization efforts may be unsuccessful, which could adversely affect our results of operations and financial condition.

An ~~important~~ element of our business strategy is to enter into collaborative or license arrangements with other parties, under which we license our drug candidates to those parties for development and commercialization or under which we study our drug candidates in combination with other parties’ compounds or biologics. For example, in addition to our Novartis, Lilly, Innovent and ~~Pfizer~~Zai Lab collaborations, we have entered into clinical study relationships with respect to several of our programs, including epacadostat, and are evaluating strategic relationships with respect to several of our other programs. However, because collaboration and license arrangements are complex to negotiate, we may not be successful in our attempts to establish these arrangements. Also, we may not have drug candidates that are desirable to other parties, or we may be unwilling to license a drug candidate to a particular party because such party interested in it is a competitor or for other reasons. The terms of any such arrangements that we establish may not be favorable to us. Alternatively, potential collaborators may decide against entering into an agreement with us because of our financial, regulatory or intellectual property position or for scientific, commercial or other reasons. If we are not able to establish collaboration or license arrangements, we may not be able to develop and commercialize a drug product, which could adversely affect our business and our revenues.

We will likely not be able to control the amount and timing of resources that our collaborators or licensees devote to our programs or drug candidates. If our collaborators or licensees prove difficult to work with, are less skilled than we originally expected, do not devote adequate resources to the program, are unable to obtain regulatory approval of our drug candidates, pursue alternative technologies or develop alternative products, or do not agree with our approach to development or manufacturing of the drug candidate, the relationship could be unsuccessful. Our collaborations with respect to epacadostat ~~involve~~involved the study of our collaborators’ drugs used in combination with epacadostat on a number of indications or tumor types, many of which ~~are~~were the same across multiple collaborations. We cannot assure you that potential conflicts will not arise or be alleged among these collaborations. If a business combination involving a collaborator or licensee and a ~~third party~~third-party were to occur, the effect could be to terminate or cause delays in development of a drug candidate.

If we fail to enter into additional licensing agreements or if these arrangements are unsuccessful, our business and operations might be adversely affected.

79

~~Table of Contents~~

In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties’ compounds or biologics, we may explore opportunities to develop our clinical pipeline by in-licensing drug candidates or therapeutics targets that fit within our focus on oncology, such as our collaborations with Agenus Inc., Calithera Biosciences, Inc., MacroGenics, Inc., Merus N.V., MorphoSys, and ~~Jiangsu Hengrui Medicine Co., Ltd.~~Syros Pharmaceuticals, Inc., or explore additional opportunities to further develop and commercialize existing drug candidates in specific jurisdictions, such as our ~~recent~~June 2016 acquisition of the development and commercialization rights to ICLUSIG in certain countries. We may be

81

Table of Contents

unable to enter into any additional in-licensing agreements because suitable drug candidates that are within our expertise may not be available to us on terms that are acceptable to us or because competitors with greater resources seek to in-license the same drug candidates. Drug candidates that we would like to develop or commercialize may not be available to us because they are controlled by competitors who are unwilling to license the rights to the drug candidate to us. In addition, we may enter into license agreements that are unsuccessful and our business and operations might be adversely affected if we are unable to realize the expected economic benefits of a collaboration or other licensing arrangement, by the termination of a drug candidate and termination and winding down of the related license agreement, or due to other business or regulatory issues, including financial difficulties, that may adversely affect a licensor’s ability to continue to perform its obligations under an in-license agreement. For example, we may make or incur contractual obligations to make significant upfront payments in connection with licenses for late-stage drug candidates, as we did in March 2020 in connection with the effectiveness of our collaboration agreement with MorphoSys, and if any of those drug candidates do not receive marketing approval or commercial sales as anticipated or we have to fund additional clinical trials before marketing approval can be obtained, we will have expended significant funds that might otherwise be applied for other uses or have to expend funds that were not otherwise budgeted or anticipated in connection with the collaboration, and such developments could have a material adverse effect on our stock price and our ability to pursue other transactions. As discussed above under “We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business,” conflicts or other issues may arise with our licensors. Those conflicts could result in delays in our plans to develop drug candidates or result in the expenditure of additional funds to resolve those conflicts that could have an adverse effect on our results of operations. We may also need to license drug delivery or other technology in order to continue to develop our drug candidates. If we are unable to enter into additional agreements to license drug candidates, drug delivery technology or other technology or if these arrangements are unsuccessful, our research and development efforts could be adversely affected.

Even if a drug candidate that we develop receives regulatory approval, we may decide not to commercialize it if we determine that commercialization of that product would require more money and time than we are willing to invest.

Even if any of our drug candidates receives regulatory approval, it could be subject to ~~post‑regulatory~~post-regulatory surveillance, and may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing, and the drug product may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity. As a result, we may not continue to commercialize a product even though it has obtained regulatory approval. Further, we may decide not to continue to commercialize a product if the market does not accept the product because it is too expensive or because third parties such as insurance companies or Medicare, have not approved it for substantial reimbursement. In addition, we may decide not to continue to commercialize a product if competitors develop and commercialize similar or superior products or have proprietary rights that preclude us from ultimately marketing our products.

Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community.

Even if we or our collaborators are successful in gaining regulatory approval of any of our or our collaborators’ drug candidates in addition to JAKAFI, OLUMIANT, PEMAZYRE and MONJUVI or acquire rights to approved drug products in addition to ICLUSIG, we may not generate significant product revenues ~~and we may not become profitable~~ if these drug products do not achieve an adequate level of acceptance. Physicians may not recommend our or our collaborators’ drug products until ~~longer‑term~~longer-term clinical data or other factors demonstrate the safety and efficacy of our or our collaborators’ drug products as compared to other alternative treatments. Even if the clinical safety and efficacy of our or our collaborators’ drug products is established, physicians may elect not to prescribe these drug products for a variety of reasons, including the reimbursement policies of government and other ~~third‑party~~third-party payors and the effectiveness of our or our collaborators’ competitors in marketing their products.

82

Table of Contents

Market acceptance of our drug products, if approved for commercial sale, will depend on a number of factors, ~~including:~~including the following, and market acceptance of our collaborators’ drug products will depend on similar factors:

·

●

the willingness and ability of patients and the healthcare community to use our drug products;

80

~~Table of Contents~~

·

●

the ability to manufacture our drug products in sufficient quantities ~~with acceptable~~that meet all applicable quality standards and to offer our drug products for sale at competitive prices;

·

●

the perception of patients and the healthcare community, including ~~third‑party~~third-party payors, regarding the safety, efficacy and benefits of our drug products compared to those of competing products or therapies;

·

●

the label and promotional claims allowed by the FDA;

·

●

the pricing and reimbursement of our drug products relative to existing treatments; and

·

●

marketing and distribution support for our drug products.

We have limited capacity to conduct preclinical testing and clinical trials, and our resulting dependence on other parties could result in delays in and additional costs for our drug development efforts.

We have limited internal resources and capacity to perform preclinical testing and clinical trials. As part of our development strategy, we often hire clinical research organizations, or CROs, to perform preclinical testing and clinical trials for drug candidates. If the CROs that we hire to perform our preclinical testing and clinical trials do not meet deadlines, do not follow proper procedures, or a conflict arises between us and our CROs, our preclinical testing and clinical trials may take longer than expected, may cost more, may be delayed or may be terminated. If we were forced to find a replacement entity to perform any of our preclinical testing or clinical trials, we may not be able to find a suitable entity on favorable terms, or at all. Even if we were able to find another company to perform a preclinical test or clinical trial, the delay in the test or trial may result in significant additional expenditures. Events such as these may result in delays in our obtaining regulatory approval for our drug candidates or our ability to commercialize our products and could result in increased expenditures that would adversely affect our operating results.

We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated.

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our drug discovery and development efforts may target diseases and conditions that are already subject to existing therapies or that are being developed by our competitors, many of which have substantially greater resources, larger research and development staffs and facilities, more experience in completing preclinical testing and clinical trials, and formulation, marketing and manufacturing capabilities. As a result of these resources, our competitors may develop drug products that render our products obsolete or noncompetitive by developing more effective drugs, developing their products more efficiently or pricing their products more competitively. Our ability to develop competitive products would be limited if our competitors succeeded in obtaining regulatory approvals for drug candidates more rapidly than we were able to or in obtaining patent protection or other intellectual property rights that limited our drug development efforts. Any drug products resulting from our research and development efforts, or from our joint efforts with collaborators or licensees, might not be able to compete successfully with our competitors’ existing and future products, or obtain regulatory approval in the United States or elsewhere. The development of products or processes by our competitors with significant advantages over those that we are developing could harm our future revenues and profitability.

83

Table of Contents

Our reliance on other parties to manufacture our drug products and drug candidates could result in a short supply of the drugs, delays in clinical trials or drug development, increased costs, and withdrawal or denial of a regulatory authority’s approval.

We do not currently operate manufacturing facilities for clinical or commercial production of JAKAFI, PEMAZYRE and our other drug candidates or for ~~ICLUSIG.~~ICLUSIG or MONJUVI. We currently hire third parties to manufacture the raw materials, ~~active pharmaceutical ingredient, or~~ API and finished drug product of JAKAFI, ICLUSIG, PEMAZYRE and our other drug candidates for clinical ~~trials. Under~~trials and our ~~license agreement with ARIAD, we receive our supply~~collaborator MorphoSys is currently responsible for sourcing manufacturing of ~~ICLUSIG from ARIAD.~~MONJUVI. In addition, we expect to continue to rely on third parties for the manufacture of commercial supplies of raw materials, API and finished drug product for any drugs that we successfully develop. We also hire third parties to package and label the finished product. The FDA requires that the raw materials, API and finished product for drug products such as JAKAFI and PEMAZYRE and our other drug candidates be manufactured

81

~~Table of Contents~~

according to its current Good Manufacturing Practices regulations and regulatory authorities in other countries have similar requirements. There are only a limited number of manufacturers that comply with these requirements. Failure to comply with current Good Manufacturing Practices and the applicable regulatory requirements of other countries in the manufacture of our drug candidates and products could result in the FDA or a foreign regulatory authority halting our clinical trials, withdrawing or denying regulatory approval of our drug product, enforcing product recalls or other enforcement actions, which could have a material adverse effect on our business.

We may not be able to obtain sufficient quantities of our drug candidates or any drug products we may develop if our designated manufacturers do not have the capacity or capability to manufacture them according to our schedule and specifications. Manufacturers of pharmaceutical products often encounter difficulties in production, especially in scaling up initial production. These problems include difficulties with production costs and yields, quality control and assurance and shortages of qualified personnel. To the extent our supply chain involves parties in China or materials originating in areas of China that are or could be affected by disease outbreaks such as the COVID-19 Pandemic in 2020, we could see disruptions to our supply chain. Currently, our supply chain for our drug products and product candidates depends on operations by us and by other companies in multiple countries around the world, and the effects of the COVID-19 Pandemic or any or all of these countries is uncertain and unpredictable and potential disruption is possible. And, for JAKAFI, while our strategy is to maintain a 24 months stock of API, inclusive of finished product, ruxolitinib phosphate might be used by us either to make JAKAFI or for ruxolitinib drug candidates in clinical trials. In addition, we may not be able to arrange for our drug candidates or any drug products that we may develop to be manufactured by one of these parties on reasonable terms, if at all. We generally have a single source or a limited number of suppliers that are qualified to supply each of the API and finished product of ~~JAKAFI~~our drug products and our other drug candidates and, in the case of JAKAFI, we only have a single source for its raw materials. If any of these suppliers were to become unable or unwilling to supply us with raw materials, API or finished product that complies with applicable regulatory requirements, we could incur significant delays in our clinical trials or interruption of commercial supply that could have a material adverse effect on our business. If we have promised delivery of a drug candidate or drug product and are unable to meet the delivery requirement due to manufacturing difficulties, our development programs could be delayed, we may have to expend additional sums in order to ensure that manufacturing capacity is available when we need it even if we do not use all of the manufacturing capacity, and our business and operating results could be harmed.

We may not be able to adequately manage and oversee the manufacturers we choose, they may not perform as agreed or they may terminate their agreements with us. Foreign manufacturing approval processes typically include all of the risks associated with the FDA approval process for manufacturing and may also include additional risks.

~~Two~~A number of our collaborations involve the manufacture of antibodies. ~~Under~~Either we or our collaboration with Agenus, Agenus had primary responsibility for manufacturing activities, including selecting and monitoring third-party manufacturers. Under the February 2017 amendment to our collaboration agreement, we assumed primary responsibility for manufacturing activities, including selecting and monitoring third party manufacturers, of all products from royalty-bearing programs under the collaboration. Under our collaboration with Hengrui, Hengrui currently hascollaborators have primary responsibility for manufacturing activities, and we are ~~in the process of transferring manufacturing activities to a third party~~currently using third-party contract manufacturing ~~organization.~~organizations. Manufacturing antibodies and products containing antibodies is a more complex process than manufacturing small molecule drugs and subject to additional risks. The process of manufacturing antibodies and products containing antibodies is highly susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling up the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are

84

Table of Contents

discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.

If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.

Our activities, and the activities of our collaborators, partners and ~~third‑party~~third-party providers, are subject to extensive government regulation and oversight both in the United States and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. States increasingly have been placing greater restrictions on the marketing practices of healthcare ~~companies.~~companies and have instituted pricing disclosure and other requirements for companies selling pharmaceuticals. In addition, pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulations, including claims asserting submission of incorrect pricing information, ~~impermissible off‑label~~improper promotion of pharmaceutical products, payments intended to

82

~~Table of Contents~~

influence the referral of federal or state healthcare business, submission of false claims for government reimbursement, antitrust violations, violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar ~~anti‑bribery~~anti-bribery or ~~anti‑corruption~~anti-corruption laws, or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. In December 2018, we received a civil investigative demand from the U.S. Department of Justice for documents and information relating to our speaker programs and patient assistance programs, including our support of non-profit organizations that provide financial assistance to eligible patients. Violations of governmental regulation by us, our vendors or donation recipients may be punishable by criminal and civil sanctions, including damages, fines and ~~civil monetary~~ penalties and exclusion from participation in government programs, including Medicare and Medicaid. In addition to damages, fines and penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. Actions taken by federal or local governments, legislative bodies and enforcement agencies with respect to these legal and regulatory compliance matters could also result in reduced demand for our products, reduced coverage of our products by health care payors, or both. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or ~~third‑party~~third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which due to different product distribution methods, marketing programs or patient assistance programs may result in additional regulatory burdens and obligations.

The illegal distribution and sale by third parties of counterfeit or unfit versions of our or our collaborators’ products or stolen products could harm our business and reputation.

We are aware that counterfeit versions of our products have been distributed or sold by entities not authorized by us using product packaging suggesting that the product was provided by us. If unauthorized third parties illegally distribute and sell counterfeit versions of our or our collaborators’ products, those products may not meet our or our collaborators’ rigorous manufacturing, distribution and handling standards. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, may not meet our or our collaborators’ distribution and handling standards. A patient who receives a counterfeit or unfit drug may suffer dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name and could result in lost sales for us and decreased revenues. If counterfeit or unfit drugs are sold under our or our collaborators’ brand names, our reputation and business could suffer harm and we could experience decreased royalty revenues.

85

Table of Contents

As most of our drug discovery and development operations are conducted at our headquarters in Wilmington, Delaware, the loss of access to this facility would negatively impact our business.

Our facility in Wilmington, Delaware is our headquarters and is also where we conduct ~~all~~most of our drug discovery, research, development and marketing activities. In addition, natural disasters, the effects of or measures taken to limit the effects of health epidemics such as the COVID-19 Pandemic, or actions of activists opposed to aspects of pharmaceutical research may disrupt our experiments or our ability to access or use our facility. The loss of access to or use of our Wilmington, Delaware facility, either on a temporary or permanent basis, would result in an interruption of our business and, consequently, would adversely affect our overall business.

We depend on key employees in a competitive market for skilled personnel, and the loss of the services of any of our key employees or our inability to attract and retain additional personnel would affect our ability to expand our drug discovery and development programs and achieve our objectives.

We are highly dependent on the members of our executive management team and principal members of our commercial, development, medical, operations and scientific staff. We experience intense competition for qualified personnel. Our future success also depends in part on the continued service of our executive management team and key personnel and our ability to recruit, train and retain essential personnel for our drug discovery and development programs, and for our medical affairs and commercialization activities. If we lose the services of any of these people or if we are unable to recruit sufficient qualified personnel, our research and product development goals, and our commercialization efforts could be delayed or curtailed. We do not maintain “key person” insurance on any of our employees.

If we fail to manage our growth effectively, our ability to develop and commercialize products could suffer.

We expect that if our drug discovery efforts continue to generate drug candidates, our clinical drug candidates continue to progress in development, and we continue to build our development, medical and commercial organizations, we will require significant additional investment in personnel, management and resources. Our ability to achieve our research, development and commercialization objectives depends on our ability to respond effectively to these demands and expand our internal organization, systems, controls and facilities to accommodate additional anticipated growth. If we are unable to manage our growth effectively, our business could be harmed and our ability to execute our business strategy could suffer.

We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management’s attention and harm our operating results and prospects.

83

~~Table of Contents~~

As part of our business strategy, we may pursue additional acquisitions of what we believe to be complementary businesses or assets or seek to enter into joint ventures. We also may pursue strategic alliances in an effort to leverage our existing infrastructure and industry experience to expand our product offerings or distribution, or make investments in other companies. For example, in June 2016, we completed the acquisition of the European operations of ~~ARIAD and obtained the exclusive license to develop and commercialize ICLUSIG in Europe and other countries.~~ARIAD. The success of our acquisitions, joint ventures, strategic alliances and investments will depend on our ability to identify, negotiate, complete and, in the case of acquisitions, integrate those transactions and, if necessary, obtain satisfactory debt or equity financing to fund those transactions. We may not realize the anticipated benefits of any acquisition, joint venture, strategic alliance or investment. We may not be able to integrate acquisitions successfully into our existing business, achieve planned synergies or cost savings, maintain the key business relationships of businesses we acquire, or retain key personnel of an acquired business, and we could assume unknown or contingent liabilities or incur unanticipated expenses. Integration of acquired companies or businesses also may require management resources that otherwise would be available for ongoing development of our existing business. Any acquisitions or investments made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. For example, inas recently as the ~~years~~three months ended ~~December~~March 31, ~~2016 and December 31, 2015,~~2020, we recorded unrealized losses related to all of our ~~investment~~investments in ~~Agenus Inc.,~~ our collaboration partners,and we may in the future experience additional losses related to our investments. In addition, if we choose to issue shares of our stock as consideration for any acquisition, dilution to our stockholders could result.

86

Table of Contents

Risks associated with ~~the expansion of~~ our operations outside of the United States could adversely affect our business.

Our acquisition of ARIAD’s European operations significantly expanded our operations in Europe, and we plan to continue to expand our operations and conduct certain development activities outside of the United States. ~~We have limited experience with conducting~~For example, as part of our plans to expand our activities outside of the United ~~States.~~States, we now conduct some of our drug development activities in Japan and are in the process of opening an office in China. International operations and business expansion plans are subject to numerous additional risks, including:

·

●

multiple, conflicting and changing laws and regulations such as tax laws, privacy regulations, tariffs, export and import restrictions, employment, immigration and labor laws, regulatory requirements, and other governmental approvals, permits and ~~licenses;~~

licenses, compliance with which can increase in complexity as we enter into additional jurisdictions;

·

●

difficulties in staffing and managing ~~foreign~~ operations in diverse countries and difficulties in connection with assimilating and integrating ~~the ARIAD operations and personnel, and~~ any ~~other~~ operations and personnel we might acquire into our company;

·

●

risks associated with obtaining and maintaining, or the failure to obtain or maintain, regulatory approvals for the sale or use of our products in various countries;

·

●

complexities associated with managing government payor systems, multiple ~~payor‑reimbursement~~payor-reimbursement regimes or patient ~~self‑pay~~self-pay systems;

·

●

financial risks, such as longer payment cycles, difficulty obtaining financing in foreign markets, difficulty enforcing contracts and intellectual property rights, difficulty collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;

·

●

general political and economic conditions in the countries in which we operate, including terrorism and political unrest, curtailment of trade and other business restrictions, and uncertainties associated with the future relationship between the United Kingdom and the European Union; ~~and~~

·

●

public health risks, such as the spread globally of COVID-19 in 2020, and related effects on supply chain, travel and employee health and availability; and

●

regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its ~~anti‑bribery~~anti-bribery provisions, or similar ~~anti‑bribery~~anti-bribery or ~~anti‑corruption~~anti-corruption laws and ~~regulations.~~

regulations in other countries, such as the U.K. Anti-Bribery Act and the U.K. Criminal Finances Act, which may have similarly broad extraterritorial reach.

84

~~Table of Contents~~

~~Although we conducted~~In addition, our revenues are subject to foreign currency exchange rate fluctuations due ~~diligence of ARIAD’s European operations prior~~ to the ~~acquisition, we may discover or identify deficiencies or non-compliance with such laws and regulations as we complete~~global nature of our operations. To the ~~integration~~extent that our non-U.S. source revenues represent a more significant portion of ~~the ARIAD business and conduct~~ our ~~European operations.~~total revenues, these fluctuations could materially affect our operating results. Any of the risks described above, if encountered, could significantly increase our costs of operating internationally, prevent us from operating in certain jurisdictions, or otherwise significantly harm our future international expansion and operations, which could have a material adverse effect on our business, financial condition and results of operations.

If product liability lawsuits are brought against us, we could face substantial liabilities and may be required to limit commercialization of our products and our results of operations could be harmed.

In addition to the risks described above under “—Risks Relating to Commercialization of Our Products—If the use of our products harms patients, or is perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims,” the conduct of clinical trials of medical products that are intended for human use entails an

87

Table of Contents

inherent risk of product liability. If any product that we or any of our collaborators or licensees develops causes or is alleged to cause injury during clinical trials or commercialization, we may be held liable. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities, including substantial damages to be paid to the plaintiffs and legal costs, or we may be required to limit further development and commercialization of our products. Additionally, any product liability lawsuit could cause injury to our reputation, participants and investigators to withdraw from clinical trials, and potential collaborators or licensees to seek other partners, any of which could impact our results of operations.

Our product liability insurance policy may not fully cover our potential liabilities. In addition, we may determine that we should increase our coverage, and this insurance may be prohibitively expensive to us or our collaborators or licensees and may not fully cover our potential liabilities. Since December 30, 2017, we elected to self-insure a portion of our exposure to product liability risks through our wholly-owned captive insurance subsidiary, in tandem with third-party insurance policies. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the development or commercialization of our drug candidates and ~~products.~~products, and if our liabilities from any such claims exceed our third-party insurance limits and self-insurance reserves, our results of operations, cash flows and financial condition could be adversely impacted.

Because our activities involve the use of hazardous materials, we may be subject to claims relating to improper handling, storage or disposal of these materials that could be time consuming and costly.

We are subject to various environmental, health and safety laws and regulations governing, among other things, the use, handling, storage and disposal of regulated substances and the health and safety of our employees. Our research and development processes involve the controlled use of hazardous and radioactive materials and biological waste resulting in the production of hazardous waste products. We cannot completely eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. If any injury or contamination results from our use or the use by our collaborators or licensees of these materials, we may be sued and our liability may exceed our insurance coverage and our total assets. Further, we may be required to indemnify our collaborators or licensees against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations or licenses. Compliance with the applicable environmental and workplace laws and regulations is expensive. Future changes to environmental, health, workplace and safety laws could cause us to incur additional expense or may restrict our operations or impair our research, development and production efforts.

RISKS RELATING TO OUR FINANCIAL RESULTS

We may incur losses in the future, and we expect to continue to incur significant expenses to discover and develop drugs, which may ~~not~~make it difficult for us to achieve sustained profitability on a quarterly or ~~maintain profitability~~annual basis in the future.

Due to historical net losses, we had an accumulated deficit of ~~$1.8~~$1.9 billion as of ~~September~~June 30, ~~2017.~~2020. We intend to continue to spend significant amounts on our efforts to discover and develop drugs. As a result, we may incur losses ~~for the year ending December 31, 2017 and~~ in future periods as well. Our revenues, expenses and net income (loss) may fluctuate, even significantly, due to the risks described in these “Risk Factors” and factors discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as the timing of charges and expenses that we may take, including those relating to transactions such as acquisitions and the entry into collaborative agreements.

We anticipate that our drug discovery and development efforts and related expenditures will increase as we focus on the studies, including preclinical tests and clinical trials prior to seeking regulatory approval, that are required before we can sell a drug product.

85

~~Table of Contents~~

The development of drug products will require us to spend significant funds on research, development, testing, obtaining regulatory approvals, manufacturing and marketing. To date, we do not have any drug products that have generated significant revenues other than from sales of JAKAFI and we cannot assure you that we will generate significant revenues from the drug candidates that we license or develop, including ICLUSIG, PEMAZYRE and MONJUVI, for several years, if ever.

88

Table of Contents

We cannot be certain whether or when we will achieve sustained or increased profitability on a quarterly or annual basis because of the factors discussed above and the significant uncertainties relating to our ability to generate commercially successful drug products. Even if we are successful in obtaining regulatory approvals for manufacturing and commercializing drug products in addition to JAKAFI, ICLUSIG, PEMAZYRE and ~~ICLUSIG,~~MONJUVI, we may incur losses if our drug products do not generate significant revenues. ~~If we achieve profitability, we may not be able to sustain or increase profitability.~~

We may need additional capital in the future. If we are unable to generate sufficient funds from operations, the capital markets may not permit us to raise additional capital at the time that we require it, which could result in limitations on our research and development or commercialization efforts or the loss of certain of our rights in our technologies or drug candidates.

Our future funding requirements will depend on many factors and we anticipate that we may need to raise additional capital to fund our business plan and research and development efforts ~~going‑forward and to repay our indebtedness.~~going-forward.

Additional factors that may affect our future funding requirements include:

·

●

the amount of revenues generated from our business activities;

·

●

any changes in the breadth of our research and development programs;

·

●

the results of research and development, preclinical testing and clinical trials conducted by us or our current or future collaborators or licensees, if any;

·

●

our exercise of any ~~co‑development~~co-development options with collaborators that may require us to fund future development;

·

●

the acquisition of businesses, technologies, or drug candidates, or the licensing of technologies or drug candidates, if any;

·

●

costs for future facility requirements;

·

●

our ability to maintain and establish new corporate relationships and research collaborations;

·

●

competing technological and market developments;

·

●

the time and costs involved in filing, prosecuting, defending and enforcing patent and intellectual property claims;

·

●

the receipt of contingent licensing or milestone fees or royalties on product sales from our current or future collaborative and license arrangements, if established; and

·

●

the timing of regulatory approvals, if any.

If we require additional capital at a time when investment in companies such as ours, or in the marketplace generally, is limited due to the then prevailing market or other conditions, we may have to scale back our operations, eliminate one or more of our research or development programs, or attempt to obtain funds by entering into an agreement with a collaborator or licensee that would result in terms that are not favorable to us or relinquishing our rights in certain

86

~~Table of Contents~~

of our proprietary technologies or drug candidates. If we are unable to raise funds at the time that we desire or at any time thereafter on acceptable terms, we may not be able to continue to develop our drug candidates. The sale of equity or ~~additional convertible debt~~equity-linked securities in the future may be dilutive to our stockholders and may provide for rights, preferences or privileges senior to those of our holders of common stock, and debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to pay dividends or other distributions on our common stock or incur further indebtedness.

89

Table of Contents

Our marketable securities and long term investments are subject to risks that could adversely affect our overall financial position.

We invest our cash in accordance with an established internal policy and customarily in instruments, ~~corporate bonds and~~ money market funds, U.S. government backed-funds and Treasury assets, which historically have been highly liquid and carried relatively low risk. In recent periods, similar types of investments and money market funds have experienced losses in value or liquidity issues that differ from their historical pattern.

Should a portion of our cash or marketable securities lose value or have their liquidity impaired, it could adversely affect our overall financial position by imperiling our ability to fund our operations and forcing us to seek additional financing sooner than we would otherwise. Such financing, if available, may not be available on commercially attractive terms.

As discussed under “Other Risks Relating to Our Business— We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management’s attention and harm our operating results and prospects,” any investments that we may make in companies with which we have strategic alliances, such as Agenus and Merus, could result in our recognition of losses on those investments. In addition, to the extent we may seek to sell or otherwise monetize those investments, we may not be able to do so at our desired price or valuation levels, or at all, due to the limited liquidity of some or all of those investments.

Any loss in value of our long term investments could adversely affect our financial position on the consolidated balance sheets and consolidated statements of operations.

~~Our current~~We derive a substantial portion of our revenues ~~are derived~~ from ~~JAKAFI~~royalties, milestone payments and ~~ICLUSIG product sales, JAKAVI product royalties, collaborations and from licensing~~other payments under our ~~intellectual property.~~collaboration agreements. If we are unable to achieve milestones, develop ~~products~~product candidates to license or renew or enter into new collaborations, our revenues may decrease, and future milestone and royalty payments may not contribute significantly to revenues for several years, and may never result in revenues.

We derived ~~substantially all~~a substantial portion of our revenues for the ~~three and nine~~six months ended ~~September~~June 30, ~~2017~~2020 from ~~JAKAFI~~JAKAVI and ~~ICLUSIGproduct revenues, JAKAVI~~OLUMIANT product royalties and from milestone payments under our ~~collaborations and licensing our intellectual property to others.~~collaboration agreements. Future revenues from research and development collaborations depend upon continuation of the collaborations, the achievement of milestones and royalties we earn from any future products developed from our research. If we are unable to successfully achieve milestones or our collaborators fail to develop successful products, we will not earn the future revenues contemplated under our collaborative agreements. For example, delays in or other limitations with respect to the approval of baricitinib in the United States for the treatment of moderate-to-severe rheumatoid arthritis, or the failure to obtain such approval, as discussed under “—We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business.” would affect potential future royalty and milestone and contract revenue.

RISKS RELATING TO INTELLECTUAL PROPERTY AND LEGAL MATTERS

If we are subject to arbitration, litigation and infringement claims, they could be costly and disrupt our drug discovery and development efforts.

The technology that we use to make and develop our drug products, the technology that we incorporate in our products, and the products we are developing may be subject to claims that they infringe the patents or proprietary rights of others. The success of our drug discovery and development efforts will also depend on our ability to develop new

87

~~Table of Contents~~

compounds, drugs and technologies without infringing or misappropriating the proprietary rights of others. We are aware of patents and patent applications filed in certain countries claiming intellectual property relating to some of our drug discovery targets and drug candidates. While the validity of issued patents, patentability of pending patent applications and applicability of any of them to our programs are uncertain, if any of these patents are asserted against us or if we choose to license any of these patents, our ability to commercialize our products could be harmed or the potential return to us from any product that may be successfully commercialized could be diminished.

90

Table of Contents

From time to time we have received, and we may in the future receive, notices from third parties offering licenses to technology or alleging patent, trademark, or copyright infringement, claims regarding trade secrets or other contract claims. Receipt of these notices could result in significant costs as a result of the diversion of the attention of management from our drug discovery and development efforts. Parties sending these notices may have brought and in the future may bring litigation against us or seek arbitration relating to contract claims.

We may be involved in future lawsuits or other legal proceedings alleging patent infringement or other intellectual property rights or contract violations. In addition, litigation or other legal proceedings may be necessary to:

·

●

assert claims of infringement;

·

●

enforce our patents or trademarks;

·

●

protect our trade secrets or ~~know‑how;~~know-how; or

·

●

determine the enforceability, scope and validity of the proprietary rights of others.

We may be unsuccessful in defending or pursuing these lawsuits, claims or other legal proceedings. Regardless of the outcome, litigation or other legal proceedings can be very costly and can divert management’s efforts. An adverse determination may subject us to significant liabilities or require us or our collaborators or licensees to seek licenses to other parties’ patents or proprietary rights. We or our collaborators or licensees may also be restricted or prevented from manufacturing or selling a drug or other product that we or they develop. Further, we or our future collaborators or licensees may not be able to obtain any necessary licenses on acceptable terms, if at all. If we are unable to develop ~~non‑infringing~~non-infringing technology or license technology on a timely basis or on reasonable terms, our business could be harmed.

We may be unable to adequately protect or enforce our proprietary information, which may result in its unauthorized use, a loss of revenue under a collaboration agreement or loss of sales to generic versions of our products or otherwise reduce our ability to compete in developing and commercializing products.

Our business and competitive position depends in significant part upon our ability to protect our proprietary technology, including any drug products that we create. Despite our efforts to protect this information, unauthorized parties may attempt to obtain and use information that we regard as proprietary. For example, one of our collaborators may disclose proprietary information pertaining to our drug discovery efforts. In addition, while we have filed numerous patent applications with respect to ruxolitinib and our drug candidates in the United States and in foreign countries, our patent applications may fail to result in issued patents. In addition, because patent applications can take several years to issue as patents, there may be pending patent applications of others that may later issue as patents that cover some aspect of ruxolitinib and our drug candidates. Our existing patents and any future patents we may obtain may not be broad enough to protect our products or all of the potential uses of our products, or otherwise prevent others from developing competing products or technologies. In addition, our patents may be challenged and invalidated or may fail to provide us with any competitive advantages if, for example, others were first to invent or first to file a patent application for the technologies and products covered by our patents. As noted above under “—Risks Relating to Commercialization of Our Products—Competition for our products could potentially harm our business and result in a decrease in our revenue,” a potential generic drug company competitor has challenged certain patents relating to JAKAFI.

Additionally, when we do not control the prosecution, maintenance and enforcement of certain important intellectual property, such as a drug candidate ~~in‑licensed~~in-licensed to us or subject to a collaboration with a ~~third party,~~third-party, the protection of the intellectual property rights may not be in our hands. If we do not control the intellectual property rights ~~in‑licensed~~

88

~~Table of Contents~~

in-licensed to us with respect to a drug candidate and the entity that controls the intellectual property rights does not adequately protect those rights, our rights may be impaired, which may impact our ability to develop, market and commercialize the ~~in‑licensed~~in-licensed drug candidate.

Our means of protecting our proprietary rights may not be adequate, and our competitors may:

·

●

independently develop substantially equivalent proprietary information, products and techniques;

91

Table of Contents

·

●

otherwise gain access to our proprietary information; or

·

●

design around patents issued to us or our other intellectual property.

We pursue a policy of having our employees, consultants and advisors execute proprietary information and invention agreements when they begin working for us. However, these agreements may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure. If we fail to maintain trade secret and patent protection, our potential future revenues may be decreased.

If the effective term of our patents is decreased due to changes in the United States patent laws or if we need to refile some of our patent applications, the value of our patent portfolio and the revenues we derive from it may be decreased.

The value of our patents depends, in part, on their duration. A shorter period of patent protection could lessen the value of our rights under any patents that we obtain and may decrease the revenues we derive from our patents. The United States patent laws ~~were amended in 1995 to change the~~provide a term of patent protection ~~from 17 years from patent issuance to~~of 20 years from the earliest effective filing date of the patent application. Because the time from filing to issuance of biotechnology applications may be more than three years depending on the subject matter, a ~~20‑year~~20-year patent term from the filing date may result in substantially shorter patent protection.

Additionally, United States patent laws were amended in 2011 with the enactment of the America Invents Act and third parties are now able to challenge the validity of issued U.S. patents through various review proceedings; thus rendering the validity of U.S. patents more uncertain. We may be obligated to participate in review proceedings to determine the validity of our U.S. patents. We cannot predict the ultimate outcome of these proceedings, the conduct of which could result in substantial costs and diversion of our efforts and resources. If we are unsuccessful in these proceedings some or all of our claims in the patents may be narrowed or invalidated and the patent protection for our products and drug candidates in the United States could be substantially shortened. Further, if all of the patents covering one of our products are invalidated, the FDA could approve requests to manufacture a generic version of that product prior to the expiration date of those patents.

Other changes in the United States patent laws or changes in the interpretation of patent laws could diminish the value of our patents or narrow the scope of our patent protection. For example, the Supreme Court of the United States recently ruled that isolated DNA sequences cannot be patented. Although we no longer receive significant revenues generated from our former information products business, the majority of our gene patent portfolio from that business consists of patents on isolated DNA sequences, and this ruling limits our ability to derive additional revenues from our gene patent portfolio. Additionally, the Supreme Court recently resolved a split among the circuit courts of appeals regarding antitrust challenges to settlements of patent infringement lawsuits under the ~~Hatch‑Waxman~~Hatch-Waxman Act between ~~brand‑name~~brand-name drug companies and generic drug companies. The Court rejected the “scope of the patent” test and ruled that settlements involving “reverse payments” from ~~brand‑name~~brand-name drug companies to generic drug companies should be analyzed under the rule of reason. This ruling may create uncertainty and make it more difficult to settle patent litigation if a company seeking to manufacture a generic version of one of our products challenges the patents covering that product prior to the expiration date of those patents.

89

~~Table of Contents~~

International patent protection is particularly uncertain and costly, and our involvement in opposition proceedings in foreign countries may result in the expenditure of substantial sums and management resources.

Biotechnology and pharmaceutical patent law outside the United States is even more uncertain and costly than in the United States and is currently undergoing review and revision in many countries. Further, the laws of some foreign countries may not protect our intellectual property rights to the same extent as United States laws. For example, certain countries do not grant patent claims that are directed to the treatment of humans. We have participated, and may in the future participate, in opposition proceedings to determine the validity of our foreign patents or our competitors’ foreign patents, which could result in substantial costs and diversion of our efforts. For example, there is a patent opposition proceeding in India against our Indian patent that covers the composition of matter and use of certain Janus Kinase inhibitors, including ruxolitinib phosphate, for the treatment of myeloid proliferative disorders, cancer, immune‑related diseases, skin disorders, and other diseases. Successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and allow third parties to use our proprietary technologies without a license from us or our collaborators, which may also result in loss of future royalty payments. In addition, successful challenges may jeopardize or delay our ability to enter into new collaborations or commercialize potential products, which could harm our business and results of operations.

92

Table of Contents

RISKS RELATING TO INFORMATION TECHNOLOGY AND DATA PRIVACY

Significant disruptions of information technology systems, breaches of data security, or unauthorized disclosures of sensitive data or personally identifiable information or individually identifiable health information could adversely affect our business,and couldsubject us to liability or reputational damage.

Our business is increasingly dependent on critical, complex, and interdependent information technology (IT) systems, including Internet-based systems, some of which are managed or hosted by third parties, to support business processes as well as internal and external communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion, and computer viruses, which may result in the impairment of our ability to operate our business effectively. In addition, having a significant portion of our employees work remotely due to the COVID-19 Pandemic can strain our information technology infrastructure, which may affect our ability to operate effectively, may make us more susceptible to communications disruptions, and expose us to greater cybersecurity risks.

We are continuously evaluating and, where appropriate, enhancing our IT systems to address our planned growth, including to support our planned manufacturing operations. There are inherent costs and risks associated with implementing the enhancements to our IT systems, including potential delays in access to, or errors in, critical business and financial information, substantial capital expenditures, additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced systems, demands on management time, and costs of delays or difficulties in transitioning to the enhanced systems, any of which could harm our business and results of operations. In addition, the implementation of enhancements to our IT systems may not result in productivity improvements at a level that outweighs the costs of implementation, or at all. In addition, our systems and the systems of our third-party providers and collaborators are potentially vulnerable to data security breaches which may expose sensitive data to unauthorized persons or to the public. Such data security breaches could lead to the loss of confidential information, trade secrets or other intellectual property, or could lead to the public exposure of personal information (including personally identifiable information or individually identifiable health information) of our employees, clinical trial patients, customers, business partners, and ~~others.~~others, could lead to potential identity theft, or could lead to reputational harm. Data security breaches could also result in loss of clinical trial data or damage to the integrity of that data. In addition, the increased use of social media by our employees and contractors could result in inadvertent disclosure of sensitive data or personal information, including but not limited to, confidential information, trade secrets and other intellectual property.

Any such disruption or security breach, as well as any action by us or our employees or contractors that might be inconsistent with the rapidly evolving data privacy and security laws and regulations applicable within the United States and elsewhere where we conduct business, could result in enforcement actions by U.S. states, the U.S. Federal government or foreign governments, liability or sanctions under data privacy laws, including healthcare laws such as HIPAA, that protect ~~personally identifiable~~certain types of sensitive information, regulatory penalties, other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to our development programs, business operations and collaborations, diversion of management efforts and damage to our reputation, which could harm our business and operations. Because of the rapidly moving nature of technology and the increasing sophistication of cybersecurity threats, our measures to prevent, respond to and minimize such risks may be unsuccessful.

In addition, the European Parliament and the Council of the European Union has adopted a comprehensive general data privacy regulation, known as the GDPR, which governs the collection and use of personal data in the European Union. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to €20 million or 4% of the annual global revenues of the infringer, whichever is greater. Moreover, the European Court of Justice in July 2020 invalidated the Privacy Shield framework that had been in place between the EU and the U.S., which invalidation has created uncertainty about how data can now be shared in a compliant manner. Additionally, the California Consumer Privacy Act (CCPA), effective January 1, 2020, requires, among other things, provision of new disclosures to California consumers, gives such consumers new abilities to opt-out of certain sales of personal information,

9093

Table of Contents

and affords a private right of action to such consumers if certain data breaches result in the loss or theft of their personal information. The GDPR, CCPAand other similar laws or regulations enacted in the United States or other jurisdictions associated with the enhanced protection of certain types of sensitive data, including healthcare data or other personal information, may increase our costs of doing business, and the differing requirements of these laws and regulations can complicate our compliance efforts.

Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.

We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.

9194

Table of Contents

Item 6.Exhibits


Exhibit Number		Description of Document
Exhibit Number10.1†*		~~Description~~Letter agreement, dated May 13, 2020, between the Company and Eli Lilly and Company, together with related Letter of ~~Document~~Understanding, dated March 5, 2020, between the Company and Eli Lilly and Company, each relating to License, Development and Commercialization Agreement entered into as of December 18, 2009 by and between the Company and Eli Lilly and Company.

31.1*		Rule 13a-14(a) Certification of Chief Executive Officer

31.2*		Rule 13a-14(a) Certification of Chief Financial Officer

32.1**		Statement of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

32.2**		Statement of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

101		XBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Presentation Linkbase Document

101.DEF*		XBRL Taxonomy Definition Linkbase Document


104		Cover Page Interactive Data File (embedded within the Inline XBRL document).


*		Filed herewith.

**		In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.
†	Portions of this exhibit have been omitted pursuant to Item 601(b)(10(iv) of Regulation S-K.

9295

Table of Contents

SIGNATURES

~~SIGNATURES~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	INCYTE CORPORATION

Dated: ~~October 31, 2017~~August 4, 2020	By:	/s/ HERVÉ HOPPENOT
		Hervé Hoppenot
		Chairman, President, and Chief Executive Officer
		(Principal Executive Officer)

Dated: ~~October 31, 2017~~August 4, 2020	By:	/s/ ~~DAVID W. GRYSKA~~CHRISTIANA STAMOULIS
		~~David W. Gryska~~Christiana Stamoulis
		Chief Financial Officer
		(Principal Financial Officer)

9396


Delaware		94-3136539
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

1801 Augustine Cut-Off Wilmington, DE 19803		19803
(Address of principal executive offices)		(Zip Code)



Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, $.001 par value per share	INCY	The Nasdaq Stock Market LLC


Large accelerated filer ☒		Accelerated filer ☐

Non-accelerated filer ☐		Smaller reporting company ☐
~~(Do not check if a smaller reporting company)~~
		Emerging growth company ☐

0
PART I: FINANCIAL INFORMATION			3

~~PART I~~: ~~FINANCIAL INFORMATION~~Item 1.		3
Financial Statements			3
~~Item 1.~~	~~Financial Statements~~		3

	Condensed Consolidated Balance Sheets		3
			3

	Condensed Consolidated Statements of Operations		4
			4

	Condensed Consolidated Statements of Comprehensive Income (Loss)		5
			5

	Condensed Consolidated Statements of Stockholders’ Equity		6

	Condensed Consolidated Statements of Cash Flows		6
			7

	Notes to Condensed Consolidated Financial Statements		7 8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		38 39

Item 3.	Quantitative and Qualitative Disclosures about Market Risk		69 68

Item 4.	Controls and Procedures		69 68

PART II: OTHER INFORMATION

Item 1A.	Risk Factors		70 69

Item 6.	Exhibits		92
			95

	Signatures		93 96


	September 30,		December 31,
	2017		2016*
		(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	1,128,046	$	652,343
Marketable securities—available-for-sale		153,343		156,203
Accounts receivable		198,345		148,758
Inventory		3,261		4,106
Prepaid expenses and other current assets		58,327		32,768
Total current assets		1,541,322		994,178

Restricted cash and investments		926		886
Long term investments		169,020		31,987
Inventory		11,297		15,193
Property and equipment, net		246,825		167,679
Other intangible assets, net		242,285		258,437
In-process research and development		—		12,000
Goodwill		155,593		155,593
Other assets, net		7,033		2,644
Total assets	$	2,374,301	$	1,638,597

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	69,933	$	75,599
Accrued compensation		61,274		50,904
Interest payable		100		762
Accrued and other current liabilities		164,298		126,697
Acquisition-related contingent consideration		24,330		19,539
Total current liabilities		319,935		273,501

Convertible senior notes		23,711		651,481
Acquisition-related contingent consideration		259,670		281,461
Other liabilities		13,235		12,687
Total liabilities		616,551		1,219,130

Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of September 30, 2017 and December 31, 2016		—		—
Common stock, $0.001 par value; 400,000,000 shares authorized; 211,019,366 and 188,848,752 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively		211		189
Additional paid-in capital		3,585,403		2,096,929
Accumulated other comprehensive income (loss)		12,512		(2,886)
Accumulated deficit		(1,840,376)		(1,674,765)
Total stockholders’ equity		1,757,750		419,467
Total liabilities and stockholders’ equity	$	2,374,301	$	1,638,597


	Acquisition
(in thousands)	Fair Values
Current assets	$	21,363
Property and equipment		850
Restricted cash		432
Intangible assets(a)		283,000
Total identifiable assets		305,645
Current liabilities		(15,538)
Other long term liabilities		(5,226)
Total liabilities assumed		(20,764)
Goodwill(b)		155,593
Total fair value of consideration transferred	$	440,474


	Level 3
Balance at January 1, 2017	$	301,000
Contingent consideration earned during the period but not yet paid		(5,657)
Payments made during the period		(9,429)
Change in fair value of contingent consideration		(1,914)
Balance at September 30, 2017	$	284,000


			Net		Net
	Amortized		Unrealized		Unrealized		Estimated
	Cost		Gains		Losses		Fair Value
	(in thousands)
September 30, 2017
Debt securities (corporate and government)	$	153,650	$	—	$	(307)	$	153,343

December 31, 2016
Debt securities (corporate and government)	$	156,330	$	—	$	(127)	$	156,203


	Percentage of Total				Percentage of Total
	Contract Revenues for the				Contract Revenues for the
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Collaboration Partner A	—	%	—	%	24	%	7	%
Collaboration Partner B	100	%	100	%	76	%	93	%


	Weighted-	Gross				Net
	Average Useful	Carrying		Accumulated		Carrying
	Lives (Years)	Amount		Amortization		Amount
Finite-lived intangible assets:
Licensed IP(1)	12.5	$	271,000	$	28,715	$	242,285
Indefinite-lived intangible assets:
Acquired IPR&D(1)	N/A		—		—		—
		$	271,000	$	28,715	$	242,285


		Remainder of
		2017		2018		2019		2020		2021		Thereafter
Amortization expense	$	5,384	$	21,536	$	21,536	$	21,536	$	21,536	$	150,757